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Mercury (Hg) is a global pollutant that affects the health of both humans and ecosystems. Wildlife
and humans are exposed to Hg primarily through diet in the form of methylmercury (MeHg) because
MeHg bioaccumulates and biomagnifies in the food web. Among Hg species, MeHg toxicity is
significantly more damaging to the nervous system in early developmental stages because it leads to
alterations in both structure and function. Even at low doses, prenatal exposure to MeHg can disrupt
fetal brain development leading to long-term effects even in adulthood.
This Special Issue collected three review papers and six research articles that report the latest
findings on the mechanisms of MeHg toxicology and its impacts on environmental health. Despite
well-described neurobehavioral effects, the mechanisms of MeHg-induced toxicity are not completely
understood. Antunes dos Santos et al. [1] reviewed the latest evidence indicating oxidative stress to be
an important molecular mechanism in MeHg-induced intoxication. They have also highlighted the role
of the PI3K/Akt signalling pathway and the nuclear transcription factor NF-E2-related factor 2 (Nrf2)
in MeHg-induced redox imbalance. These results are important for future research in identifying the
adverse outcome pathway for MeHg. In addition to its neurotoxicity, MeHg exposure has also been
reported to affect heart health; however, evidence remains inconsistent. Karita et al. [2] reviewed the
latest evidence on the association between MeHg and heart rate variability (HRV). They identified 13
studies examining the effect of MeHg exposure on HRV in human populations in the Faroe Islands,
Seychelles, and other countries. They found that eight studies showed significant associations and
five studies did not show any significant association. They concluded that the effects of MeHg might
differ for prenatal and postnatal exposures and the HRV parameters calculated by frequency domain
analysis were more sensitive than those by time domain analysis. These results suggest that HRV
should be included in the risk characterization of MeHg. The third review by Sakamoto et al. [3]
reported valuable lessons learned from the MeHg pollution in Minamata and the significance is
discussed below.
Takahashi et al. [4] investigated the relationship between a chemokine, C-C motif Chemokine
Ligand 4 (CCL4) expression and MeHg toxicity. Using both in vivo and in vitro approaches, they found
that induction of CCL4 expression occurred prior to cytotoxicity caused by MeHg. They also showed
that CCL4 is a protective factor against MeHg toxicity. Lee et al. [5] investigated the roles of a
metal-binding protein metallothionein-III (MT-III) in chemokine gene expression changes in response
to MeHg and Hg mercury vapour in the cerebrum and cerebellum in wild-type and MT-III knockout
mice. They showed that the expression of Ccl12 and Cxcl12 was increased in the cerebrum by MeHg
exposure in the wild-type mice only. Their results confirmed that MT-III plays a role in the expression
of some chemokine genes in response to MeHg. The new understanding of these two studies on
the protective roles of chemokines against the MeHg toxicity in the brain is important for the future
development of treatments.
The mechanisms responsible for MeHg-induced changes in adult neuronal function,
when exposure occurs primarily during fetal development, are not yet understood. Yuan et al. [6]
dosed primary cortical precursor cells obtained from mice embryo with MeHg and found the cortical
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precursor exposed to extremely low dose (0.25 nM) of MeHg increased neuronal differentiation;
while its proliferation was inhibited. In comparison, reduced neuronal differentiation was observed
in the higher dose groups. These results suggest that sub-nanomolar MeHg exposure may deplete
the pool of neural precursors by increasing premature neuronal differentiation. This can lead to
long-term neurological effects in adulthood as neural precursors are important for adult neurogenesis.
In contrast, the higher MeHg doses cause more immediate toxicity during infant development leading
to neurobehaviour effects observed in infants and children. These results may explain the long delay
effects of MeHg reported in Minamata, Japan as reported by Takaoka et al. [7]. In 2009, Takaoka et
al. performed health surveys on 973 residents in the polluted area and 142 residents from a control
area. Their results show that Minamata disease had spread outside of the central area and could still
be observed almost 50 years after the Chisso Company’s factory halted the dumping of Hg-polluted
waste water in 1968. Results presented in this paper provide invaluable information on the long-term
effects of MeHg, particularly on the wide range of clinical symptoms observed in adults who had
no reported symptoms at younger age. Sakamoto et al. [3] reported a comprehensive review of the
exposure and health effects which result from the MeHg pollution in Minamata. Information acquired
during this review included the use of preserved umbilical cords to study the extent of pre-natal
exposure, the higher sensitivity of male than female newborns to MeHg, and the neuropathology and
kinetics of MeHg in fetuses. The sex-specific results were also confirmed by the results of a cohort study
conducted by Tatsuta et al. [8]. To clarify the effects of MeHg on child development, a longitudinal
prospective birth cohort study was conducted by the Tohoku Study of Child Development (TSCD) in
Japan. Tatsuta et al. [8] reported the latest findings of the TSCD, showing that prenatal MeHg exposure
affected psychomotor development in 18-month-olds, especially in males. The results of these studies
provide important new information on the comparative use of different biomarkers, such as maternal
blood or hair, for the dose-response assessment for MeHg on fetuses and child development.
Many toxic trace metals including Hg have been shown to induce immunotoxicity. However,
there is a lack of specific biomarkers in peripheral blood samples for the effects of different chemical
exposure. Monastero et al. [9] conducted a pilot study to correlate the blood levels of three metals,
including cadmium, lead and mercury, with differences in the expression of 98 genes associated with
stress, toxicity, inflammation, and autoimmunity in 24 participants from the Long Island Study of
Seafood Consumption. They found that the expression of three genes (IL1RAP, CXCR1, and ITGB2) was
negatively associated with Hg. This preliminary result suggests the possibility of using gene expression
in blood samples to study the effects of MeHg on immune functions in future population studies.
In summary, this collection of papers on the toxicology and risk assessment provides useful new
information on the mechanisms of MeHg toxicity and methods of improving risk assessment of MeHg.
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Abstract: Methylmercury (MeHg) is a hazardous environmental pollutant, which elicits significant
toxicity in humans. The accumulation of MeHg through the daily consumption of large predatory
fish poses potential health risks, and the central nervous system (CNS) is the primary target of
toxicity. Despite well-described neurobehavioral effects (i.e., motor impairment), the mechanisms of
MeHg-induced toxicity are not completely understood. However, several lines of evidence point out
the oxidative stress as an important molecular mechanism in MeHg-induced intoxication. Indeed,
MeHg is a soft electrophile that preferentially interacts with nucleophilic groups (mainly thiols
and selenols) from proteins and low-molecular-weight molecules. Such interaction contributes to
the occurrence of oxidative stress, which can produce damage by several interacting mechanisms,
impairing the function of various molecules (i.e., proteins, lipids, and nucleic acids), potentially
resulting in modulation of different cellular signal transduction pathways. This review summarizes
the general aspects regarding the interaction between MeHg with regulators of the antioxidant
response system that are rich in thiol and selenol groups such as glutathione (GSH), and the
selenoenzymes thioredoxin reductase (TrxR) and glutathione peroxidase (Gpx). A particular attention
is directed towards the role of the PI3K/Akt signaling pathway and the nuclear transcription factor
NF-E2-related factor 2 (Nrf2) in MeHg-induced redox imbalance.
Keywords: methylmercury; oxidative stress; molecular mechanisms
1. Introduction
Mercury (Hg) is a global pollutant ubiquitously present in the environment with a potential toxic
effect in humans. Hg can be emitted to the atmosphere by natural sources (volcanoes and forest fire)
or by anthropogenic sources (industrial activities, mining, and coal combustion), and deposits into
aquatic systems, where it is primarily found [1]. The inorganic mercury in the aquatic environment can
Toxics 2018, 6, 47; doi:10.3390/toxics6030047 www.mdpi.com/journal/toxics4
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be biomethylated by aquatic sulfate-reducing bacteria forming methylmercury (MeHg) [2]. MeHg has
a significant biomagnification potential and accumulates along the food chain by more than seven
orders of magnitude, reaching higher concentrations in large predatory fish [3]. Therefore, fish
consumption is the main source of MeHg exposure in humans [4,5]. After ingestion, MeHg is absorbed
from the gastrointestinal tract (around 90–95%) and is distributed to all organs and systems, however,
the central nervous system (CNS) is the most sensitive organ to MeHg-induced toxicity [6–11]. In this
regard, it has been demonstrated that the developing CNS is particularly vulnerable to MeHg when
compared to adults (i.e., the mature CNS) [12,13]. Several epidemiologic studies have shown that MeHg
is able to produce severe cognitive deficits after prenatal and postnatal exposures [14–16]. Indeed,
deficits in neurons and glia including abnormal migration, differentiation, and growth have been
associated with prolonged pre- and/or perinatal exposure to MeHg, even at moderate doses [17,18].
In addition, studies with animals have shown the effects of developmental exposure to MeHg on
animal behavior, such as reduced motor activity [19], decrease in memory [20–22] and learning [23],
among others. Furthermore, there is evidence of a correlation between heavy metals’ (including Hg)
exposure and several skeletal deformities in fish larvae [24].
In addition, behavioral deficits in locomotor activity and motor performance were demonstrated in
adult mice exposed to MeHg [25–27]. Indeed, the symptoms of MeHg poisoning in adults are frequently
associated with loss of neuronal cells in the visual cortex and the cerebellum [28]. Even though
the relationship between MeHg-induced motor deficit and cerebellar damage is a well-described
phenomenon [29], the cellular mechanisms mediating MeHg-induced neurotoxicity have yet to be
fully understood. In this regard, it is well documented that the electrophilic abilities of MeHg allow
this toxicant to bind to soft nucleophilic groups, such as thiol (-SH) and selenol groups [1,12,30],
disrupting the structure and activity of a large number of proteins and lead to disruption of various
intracellular functions. Furthermore, a number of mechanisms have been identified as critical
factors in MeHg-induced cell damage, including induction of oxidative stress via overproduction
of reactive oxygen species (ROS) or reduction of antioxidant defenses and disruption of glutamate
and calcium (Ca2+) homeostasis [1,31–33]. The impairment of astrocytic glutamate transport by
MeHg can lead to an overproduction of ROS, since increased glutamate concentrations in the
synaptic cleft can cause hyperactivation of N-methyl D-aspartate (NMDA) type glutamate receptors,
leading to an increase in intracellular Na+ and Ca2+ [34], which is associated with generation of
ROS [35]. In fact, inhibition of MeHg-induced ROS production was demonstrated in neurons treated
with N-methyl-D-aspartate (NMDA) receptor antagonists [36]. Moreover, decreased antioxidant
enzyme activity, such as glutathione peroxidase (Gpx), thioredoxin (Trx), and thioredoxin reductase
(TrxR) [1,37–39], has been associated with increased ROS generation after exposures to MeHg, as well
as the MeHg-induced mitochondrial dysfunction. MeHg can target specific thiol-containing proteins
in the mitochondria, including respiratory chain complexes, leading to mitochondrial membrane
potential loss and generation of ROS [40,41].
To summarize the current state of pertinent literature: (1) thiol and selenol groups have critical
roles in governing MeHg pharmacokinetics; (2) the oxidative stress has a pivotal role in mediating
MeHg-induced toxicity; (3) the nuclear factor erythroid 2–related factor 2 (Nrf2) can regulate the
cellular response for attenuation of oxidative stress elicited by environmental toxicants [42]; (4) the
phosphatidylinositol 3 (PI3) kinase/Akt pathway is essential for cell survival and can regulate
Nrf2-mediated antioxidant and detoxification reactions [43,44]; this review summarizes the current
knowledge regarding the molecular mechanisms involved in MeHg-induced oxidative stress and
cell toxicity. Considerable attention has been directed towards the role of thiols and selenols in
MeHg-induced redox imbalance, as well as the regulation/modulation induced by this metal of the
transcription factor Nrf2 and PI3K/Akt signaling pathway.
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2. Thiols and Selenols Play Fundamental Roles in MeHg-Induced Toxicity
Hg compounds react specifically with sulfhydryls (-SH) groups of cellular proteins and nonprotein
molecules, forming stable complexes with defined stoichiometry, -S-Hg-R. MeHg’s affinity for the
anionic form of thiol (-SH) groups is extremely high and responsible for most of its toxicological
effects [45]. Indeed, in biological media, MeHg is always complexed to -SH-containing ligands [46–50]
and the therapeutic agents effective in reducing its body-burden contain -SH groups [51]. In this
regard, it is noteworthy that the MeHg distribution to the different organs, as well as its excretion and,
consequently, toxicity are likely related to its interaction with -SH groups on various biomolecules.
MeHg interacts with the -SH group from non-protein molecules like glutathione (GSH), and also binds
to L-cysteine forming the MeHg-L-cysteine complex, which is taken up by cells from different tissues
by molecular mimicry as a surrogate of methionine [52]. Particularly important, MeHg-L-cysteine
conjugates serve as a substrate for the neutral amino acid transporter, LAT-1, which transports MeHg
(complexed with L-cysteine) across membranes [53]. Complexes of MeHg-cysteine and MeHg-GSH
have been identified in blood [46,47], and complexes with MeHg-GSH in brain [48], liver [49],
and bile [50].
Selenium (Se) is an essential trace element that is an integrant part of several enzymes
(selenoenzymes) in the form of selenocysteine (Sec) [54]. Selenoenzymes play critical roles in the
maintenance of cellular homeostasis since the reactivity of the selenol group (-SeH) in Sec is high [55,56].
Since selenols chemically resemble thiols (-SH) it also serves as a soft ligand for complexation with
soft metals [57]. Given that under physiological conditions, selenols have a lower pKa (around 5.3)
when compared to thiols, the fully ionized isoform (selenolates, -Se−) are predominant and also more
susceptible to electrophilic reactions by mercurials [58]. Five glutathione peroxidases (GPx) and three
thioredoxin reductases (TrxR) are among the well-known redox-active selenoenzymes, with a selenol
group in their redox active sites [55,56].
As previously mentioned, MeHg’s affinity for sulfhydryls and selenols interferes with several
important regulators of the antioxidant response that are rich in thiol and selenol groups. In this
regard, the thioredoxin (Trx) and glutathione GSH systems play important roles in maintaining the
redox balance in the brain, a tissue that is prone to oxidative stress due to its high-energy demand [59].
Taking it into account, the following sections address the predominant molecules targeted by MeHg
in biological systems, as well as the effects of MeHg on the regulation/modulation of the PI3K/Akt
signaling pathway and Nrf2 transcription factor
2.1. Glutathione (GSH)
GSH is the most abundant low molecular weight thiol compound synthesized in cells, reaching
the concentrations of 1–10 mM, and it is the major antioxidant and redox buffer in human cells. In fact,
GSH serves as a reducing agent for ROS and other unstable molecules, in the reaction catalyzed
by GPx [60]. Several aspects of MeHg-induced neurotoxicity have been ascribed to GSH depletion.
MeHg is able to interact with GSH, leading to the formation of an excretable GS–MeHg complex [61].
This interaction decreases the levels of GSH and, consequently, the GSH:GSSG (disulfide-oxidized)
ratio, which contributes to the occurrence of oxidative stress [33]. It is worth mentioning that the pKa
of GSH is high at physiological pH conditions and little GSH is ionized. However, at physiological pH
values, glutathione S-transferase (GST) effectively lowers the pKa of the cysteine thiol of GSH from
~9.3 in solution to 6.5–7.4 at the active site of various GSTs, resulting in formation of the catalytically
active nucleophilic thiolate anion (GS−) [62,63].
MeHg has been shown to bind GSH, both in animal models and cell culture systems [64,65].
Indeed, several in vitro [66,67] and in vivo [12,68] evidences have shown that MeHg exposure causes
GSH depletion. In addition, GSH and enzymes related to its synthesis are known important targets of
MeHg-induced developmental neurotoxicity. For example, Stringari et al. have shown that prenatal
exposure to MeHg disrupts the postnatal development of the GSH antioxidant system (GSH levels,
GPx and glutathione reductase (GR) activities) in mouse brain. Furthermore, the authors demonstrated
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that the biochemical alterations endured even when mercury tissue levels decreased and became
indistinguishable from those noted in pups born to control dams [68].
Epidemiological and animal studies have shown that MeHg causes loss of neuronal cells in specific
brain regions including the visual cortex and the cerebellum [28], with massive loss of cerebellar granule
cells (CGC) [69]. Interestingly, the increased sensitivity of CGC has been attributed to the relatively
low GSH content of these cells, although it is not the only factor recognized [70–72]. In this regard,
decreased GSH levels have been reported in the cerebral and cerebellar cortices of MeHg-exposed
animals whose cortical mercury levels were in the low micromolar range [12,68]. In the mammalian
cerebrum and cerebellum, the intracellular GSH concentrations are in the millimolar (mM) range,
therefore the generation of ROS induced by MeHg might be related to GSH-independent mechanisms
as well, in addition to its direct interaction with GSH [66,73].
GSH is synthesized by the sequential addition of cysteine to glutamate followed by the addition
of glycine. In this sense, MeHg selectively inhibits astrocytic uptake systems for cystine and cysteine
transport [74,75], compromising GSH synthesis and the CNS redox potential [76]. The MeHg-induced
inhibition of cystine transport and astrocytic GSH production would ultimately lead to decreased
neuronal GSH levels and increased glutamate toxicity. It is worth mentioning that one of the major
mechanisms involved in MeHg-induced neurotoxicity is glutamate dyshomeostasis. Indeed, inhibition
of vesicular glutamate uptake, increase in spontaneous release of glutamate from presynaptic terminals,
and inhibition of glutamate uptake by astrocytes are crucial phenomena related to MeHg-mediated
neurotoxicity [31,77,78].
Furthermore, studies on the toxicological relevance of MeHg–GSH interaction have demonstrated
that strategies able to raise GSH levels are protective against MeHg-induced neurotoxicity [79,80].
For instance, increased ROS formation and depleted mono- and disulfide GSH were observed in
neuronal, glial, and mixed cultures, and supplementation with exogenous GSH protected against the
MeHg-induced neuronal death [81].
2.2. Selenoenzymes
Selenium plays a crucial role in antioxidant defense, as one Se atom is absolutely required
at the active site of all selenoenzymes, such as GPx and TrxR, in the form of selenocystein [82].
GPx is an antioxidant enzyme that, in the presence of tripeptide GSH, adds two electrons to reduce
H2O2 and lipid peroxides to water and lipid alcohols, respectively, while simultaneously oxidizing
GSH to glutathione disulfide. The GPx/GSH system is thought to be a major defense in low-level
oxidative stress, and decreased GPx activity or GHS levels may lead to the absence of adequate
H2O2 and lipid peroxides detoxification, which may be converted to OH-radicals and lipid peroxyl
radicals, respectively, by transition metals (Fe2+) [83]. Thioredoxin (Trx) is essential for maintaining
intracellular redox status. The expression of this small (12 kDa) ubiquitous thiol-active protein is
induced by ROS and an elevated serum level may indicate a state of oxidative stress. In this regard,
TrxR, a NADPH-dependent lipid hydroperoxide reductase, uses NADPH to maintain the levels of
reduced Trx via a mechanism similar to that used by GR to maintain GSH levels, contributing to the
maintenance of thiol redox homeostasis in proteins. Importantly, the inhibition of TrxR impairs the
cyclical regeneration of Trx activity, as Trx remains in the oxidized state [84,85].
The activity of selenoenzymes, such as GPx, may be negatively affected by MeHg [38,41].
In addition, TxrR may be particularly sensitive to mercury compounds after both in vitro [86,87]
and in vivo exposure [39,88]. Glutathione peroxidase isoform 1 (GPx1) is an initial molecular target in
CGC exposed to nanomolar concentrations of MeHg (300 nM) for 4 days in vitro [37]. Interestingly,
the authors have shown that GPx-1 inhibition occurred before any changes on potential targets that are
normally affected by high-dose MeHg exposures. Moreover, Gpx1 overexpression was able to prevent
MeHg-induced neuronal death in these cells [37], suggesting that selenoproteins may help to prevent
oxidative stress induced when MeHg directly disrupts proteins involved in cellular redox system
pathways. Of particular toxicological significance, the results obtained by Farina et al. 2009 [37] indicate
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the potential role of Gpx1 as a primary target of MeHg. In agreement, another study has demonstrated
that MeHg decreased GPx activity in three different models: (a) in mouse brain after treatment with
MeHg (40 mg/L in drinking water), (b) in mouse brain mitochondrial-enriched fractions isolated from
MeHg-treated animals, and (c) in cultured human neuroblastoma SH-SY5Y cells [38]. The authors
have concluded that the inhibition of this antioxidant enzyme may cause a significant increase of
MeHg-induced impairment of cell viability and oxidative stress. Ruszkiewicz et al., 2016 have
demonstrated that MeHg affects the antioxidant Trx and GSH systems in a sex-and structure-specific
manner, and that these changes are not associated with altered mRNA expression, but rather
posttranscriptional mechanisms [89]. Although the direct interaction of MeHg with the selenol group
of the selenoproteins is an important molecular mechanism involved in the MeHg-induced cytotoxicity
and decreased protein function [37,90], posttranscriptional events concerning mercury–selenium
interaction seem to be also involved in the decreased activity of these selenoproteins [91,92].
Se deficiency has been reported to exacerbate the neurodevelopmental effects induced by
MeHg [93,94]. In fact, maternal exposure to MeHg decreased Se concentration and impaired GPx
activity in the neural tissue of the offspring, but not in the maternal neural tissue. In addition,
MeHg exposure of Se-deficient perinatal mice resulted in retarded neurobehavioral development [94].
A relatively recent study corroborates the hypothesis that Se deficiency is a contributing factor to
MeHg-induced toxicity. The authors have shown that selenoprotein genes from antioxidant pathways,
such as members of the GPx and TrxR families, were exclusively downregulated by MeHg in whole
zebrafish (Danio rerio) embryos, and then rescued by elevated Se levels [91]. These results suggest
that Se can reduce the toxicity of MeHg, although the mechanisms behind this interaction have yet
to be fully clarified. In addition, it has been shown that the selenocompounds diphenyl diselenide
(PhSe)2 and ebselen possess thiol peroxidase-like activity, and neuroprotective properties against
MeHg-induced neurotoxicity in vivo and in vitro [95–98]. Using an in vitro experimental model of
cultured human neuroblastoma cells (SH-SY5Y), a recent study has shown that MeHg was able to
inhibit the activity of Gpx and TrxR, while coexposure to (PhSe)2 and MeHg showed a protective effect
on both the activity and expression of TrxR [99]. The authors have speculated that a direct interaction
of MeHg with the selenol groups of these enzymes and/or a reduction in enzyme synthesis may
possibly be related to the inhibition of TrxR and GPx activities [33].
3. MeHg and PI3K/Akt Signaling Pathway
The phosphoinositide-3 kinase (PI3K)/Akt signaling pathway has been extensively reviewed by
several authors [100–102]. Briefly, activation of receptor tyrosine kinases (RTK) or G-protein-coupled
receptors (GPCR) lead the recruitment of PI3K in the plasma membrane. Following its recruitment, PI3K
is activated and phosphorylates phosphatidylinositol (4,5) biphosphate (PIP2) to phosphatidylinositol
(3,4 5)-triphosphate (PIP3). PIP3 recruits Akt to the plasmatic membrane, allowing its activation
through phosphorylation on threonine 308 and serine 473 by phospho-inositide-dependent kinase-1
(PDK1) [103] and mammalian target of rapamycin complex 2 (mTORC2) [104], respectively. In addition,
negative regulation of the pathway is mediated by phosphatase and tensin homolog (PTEN), which
dephosphorylates PIP3 to PIP2 [105]. It is well known that the PI3K/Akt signaling pathway plays a key
role in multiple cellular processes, including metabolism, cell survival, proliferation, and motility [102],
to name a few. In this regard, the activation of the PI3K/Akt signaling pathway can culminate in the
inhibition of apoptosis in several cellular models [106–108], whereas the inhibition of this pathway
could be associated with decreased cell viability [109]. Furthermore, it has been shown that ROS
can activate the PI3K/Akt signaling pathway and inhibit PTEN [110,111], thus, inducing the Akt
activation, as shown in several cultured cell models, such as fibroblasts [112], vascular smooth muscle
cells [113], and mesanglial cells [114]. Sonoda et al., 1999 have demonstrated that the activation of Akt
by hydrogen peroxide (H2O2) in a glioblastoma cell line was blocked by wortmannin, a PI3K inhibitor,
culminating in increased cell death [115].
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Moreover, MeHg can also modulate the PI3K/Akt signaling pathway. Indeed, exposure
to 100 nM MeHg for 24 h induced apoptosis in differentiating PC12 cells, and decreased Akt
phosphorylation [116]. Corroborating these findings, Pierozan et al., 2017 have also demonstrated that
MeHg reduced neuronal viability and induced caspase 3-dependent apoptosis with downregulated
PI3K/Akt pathway in primary cortical neurons treated with 1 μM MeHg for 24 h. In this
study, the authors noted increased oxidative damage, suggesting that MeHg downregulated Akt
phosphorylation despite the noted increase in ROS production [117]. A recent in vivo study using
30-day-old pups from pregnant rats treated with 2 mg/kg MeHg from gestational day 5 until
parturition, has shown that the pups prenatally exposed to MeHg failed to increase hippocampal
oxidative stress, while the levels of Akt phosphorylation were decreased. These results suggest that
MeHg may regulate the Akt signaling pathway by a mechanism independent of ROS generation [9].
On the other hand, a submicromolar MeHg exposure (1 μmol/L) induced Akt activation,
probably secondary to increased ROS production (in pancreatic β cell—derived HIT-T15 cells).
Moreover, the antioxidant N-acetyl-L-cysteine (NAC) prevented MeHg-induced upregulation of Akt
phosphorylation but did not reverse PI3K activity in these cells [118]. Similar results were obtained
in isolated mouse pancreatic islets [118], suggesting that MeHg-induced oxidative stress may be
involved in the regulation of Akt phosphorylation independently of PI3K in pancreatic cells. The same
authors have shown similar results in mice treated for 2–4 weeks with 20 μg/kg MeHg, demonstrating
an increase in oxidative stress parameters and upregulation of Akt phosphorylation in pancreatic
islets [118]. Furthermore, a low-dose MeHg exposure (up to 2 μM) increased Akt phosphorylation,
presumably by inactivation of PTEN through S-mercuration (in neuroblastoma SH-SY5Y cell line).
Pretreatment with the PI3K/Akt inhibitor, wortmannin, enhanced MeHg-induced cytotoxicity [119].
In this study, the authors have suggested that low-dose MeHg exposures might be associated with
activation of cell survival responses [120].
4. MeHg Regulation of Nrf2 Activity
As mentioned before, the increase in ROS generation and the disruption of the antioxidant defense
system are primary mechanisms related to MeHg-induced cell toxicity and neurodegeneration [1,33].
In this sense, a recent body of evidence has suggested that MeHg can modulate the Nrf2,
the transcription factor involved in the regulation of the antioxidant defense system. Nrf2 is
a transcription factor that belongs to cap ‘n’ collar (CNC) family, with a basic leucine zipper in
its structure. This protein is an important regulator of the antioxidant cell response, regulating
the expression of around 1055 genes involved not only in the antioxidant defenses, but also in cell
proliferation, metabolism, and immune and detoxifying responses. Once activated, Nrf2 is translocated
to the cell nucleus and forms heterodimers with other transcript such as c-Jun and small Maf proteins,
binding to the antioxidant response element (ARE: 5′-GTGACNNNGC-3′), favoring the transcription
of Nfr2-related genes [121–123]. The main regulator of Nrf2 activity is the Kelch-like ECH-associated
protein 1 (Keap1) protein [123]. In basal conditions, Keap-1 is associated to Nrf2 inducing Nrf2
ubiquitination by E3 ubiquitin ligase, and consequent degradation through 26S proteasome. The Keap-1
structure contain some reactive cysteine residues (Cys151, Cys273, Cys288 and Cys297), which
can be modified under oxidative stress conditions or by electrophilic compounds, promoting the
disruption of the Keap-1/Nrf2 association and Nrf2 translocation to the cell nucleus, and consequent
gene expression [121,123,124]. In addition, besides the negative regulation of Keap-1 on Nrf2
activity, the modulation of this protein by other signaling pathways has also been described. In fact,
nuclear translocation of Nrf2 may involve the PKC and AMPK-dependent phosphorylation [125,126].
An association between PI3K/Akt activation and Nrf2 up-regulation has also been reported [127–130].
Once activated, Akt promotes the inhibition of GSK-3β through phosphorylation on ser-9. GSK-3β can
induce Nrf2 phosphorylation, creating a degradation domain that is recognized by the ubiquitin ligase,
targeting Nrf2 for proteasomal degradation [131–134]. GSK-3β can also phosphorylate a member of
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the src-kinase family named Fyn, which can phosphorylate Nrf2, favoring its export from the cell
nucleus [130,135].
Since MeHg is a potent oxidative stress inducer and an electrophilic agent, the activation and
up-regulation of Nrf2 have been described upon exposure to this metal. This hypothesis is supported
by numerous data showing an increase in the Nrf2-related gene expression (such as: ho-1, nqo-1,
cglc and Nrf2), and also an increase in the Nrf2 nuclear translocation, after exposures to MeHg
in vitro [67,71,120,136] and in vivo [137]. Furthermore, it has been demonstrated that Nrf2 genetic
knockdown can increase the susceptibility to MeHg toxicity, and treatment with compounds that are
able to increase Nrf2 activity ameliorate some consequences of MeHg-induced toxicity [136,138]. In this
sense, it seems that MeHg-induced Nrf2 activation is associated with a cellular defense mechanism in
response to this metal exposure.
MeHg is able to disrupt the Nrf2/Keap-1 association, which may be associated with an increase
in the Nrf2 activation [136,139]. It has been shown a direct interaction between MeHg and the
cysteine residues in Keap-1 structure (Cys151, Cys368, and Cys489) [136,139,140]. As mentioned
previously, MeHg can react with GSH to form a MeHg-SG adduct that is transferred to extracellular
space by the multidrug-resistance associated protein (MRP) [1]. This GSH adduct readily undergoes
S-transmercuration with cellular proteins, inducing the mercuration of Cys319 residue in the Keap-1
structure [141]. Cys151 residue is essential to electrophile-mediated disassociation of Keap1 from
Nrf2, and The Cys319 residue is critical to the ubiquitin E3 ligase activity and consequent Nrf2
degradation [136,142,143]. In this sense, it is possible to speculate that the MeHg-induced modifications
in these cysteine residues, through direct interaction with Cys151 and Cys319 or by ROS-mediated
modifications, could disrupt the inhibitory effect of Keap-1 in Nrf2 activation, allowing its translocation
to the cell nucleus. It is noteworthy that the cysteine residues in Keap-1 are also potential targets for
oxidation mediated by ROS [124,130]. However, further studies are necessary to elucidate the role of
ROS in MeHg-induced Nrf2 activation.
MeHg can induce the modulation of PI3k/Akt, and the inhibition of this signaling pathway was
able to attenuate the MeHg-induced Nrf2 activation [71]. An increase in GSK-3β phosphorylation was
also observed 6 h after an in vitro MeHg exposure in primary cortical astrocytes. MeHg decreased
the expression of Fyn and Sp1 (the transcription factor associated to fyn expression), and Fyn nuclear
localization, which may possibly suggest a Fyn downregulation in these cells [120]. Thus, it is
speculated that MeHg promotes Akt activation and consequent inhibitory phosphorylation of GSK-3β.
In these conditions, the downregulation of Fyn phosphorylation may inhibit the Fyn-mediated Nrf2
nuclear export, enhancing the Nrf2 nuclear localization. These authors have also shown that the
increase in the Nrf2-related genes was followed by downregulation of Sp1-related genes (such as
fyn and tgf-β1) [120]. This finding corroborates the idea that Sp1 can interact with Nrf2 at promoter
sequences, suppressing the expression of Sp1 specific target genes [144].
5. Conclusions
MeHg is a hazardous environmental pollutant of great concern to public health because of its
neurotoxic effects. Due to its electrophilic nature, MeHg can react with nucleophiles such as sulfhydryl-
and selenol-containing proteins and low-molecular-weight molecules in biological systems. MeHg’s
affinity for the anionic form of thiol and selenol groups is extremely high and responsible for most of
its toxicological effects. Indeed, MeHg can interfere with several crucial regulators of the antioxidant
response that are rich in thiol and selenol groups such as glutathione (GSH), the major antioxidant
and redox buffer in human cells, and the antioxidant selenoenzymes thioredoxin reductase (TrxR)
and glutathione peroxidase (Gpx). Consequently, the excessive generation of ROS is an important
phenomena that culminates in cell death. In this regard, antioxidant molecules have been reported
as important protective agents against MeHg-induced toxicity. Our understanding of the critical
targets of MeHg is incomplete, and detailed experimental data regarding the mechanism of action
are needed. For instance, given that MeHg is known to generate ROS, and that mammalian cells
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activate Nrf2-mediated transcription in response to ROS, it is not surprising that Nrf2 activation
has been demonstrated in response to MeHg exposure. However, relatively little information has
been found about the potential mechanisms involved in MeHg-induced Nrf2 activation. In addition,
the relationship between the PI3K/Akt signaling pathway and MeHg toxicity is still very limited,
and consideration should be given to future research. In conclusion, the data presented in this review
suggest that multiple mechanisms are involved in MeHg-induced oxidative stress and cell toxicity.
Taken together, the data highlight several promising directions for future research in this area.
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Abstract: After the European Food Safety Authority reviewed reports of methylmercury and
heart rate variability (HRV) in 2012, the panel concluded that, although some studies of cardiac
autonomy suggested an autonomic effect of methylmercury, the results were inconsistent among
studies and the implications for health were unclear. In this study, we reconsider this association by
adding a perspective on the physiological context. Cardiovascular rhythmicity is usually studied
within different frequency domains of HRV. Three spectral components are usually detected; in
humans these are centered at <0.04 Hz, 0.15 Hz (LF), and 0.3 Hz (HF). LF and HF (sympathetic
and parasympathetic activities, respectively) are evaluated in terms of frequency and power. By
searching PubMed, we identified 13 studies examining the effect of methylmercury exposure on
HRV in human populations in the Faroe Islands, the Seychelles and other countries. Considering
both reduced HRV and sympathodominant state (i.e., lower HF, higher LF, or higher LF/HF ratio)
as autonomic abnormality, eight of them showed the significant association with methylmercury
exposure. Five studies failed to demonstrate any significant association. In conclusion, these
data suggest that increased methylmercury exposure was consistently associated with autonomic
abnormality, though the influence of methylmercury on HRV (e.g., LF) might differ for prenatal
and postnatal exposures. The results with HRV should be included in the risk characterization of
methylmercury. The HRV parameters calculated by frequency domain analysis appear to be more
sensitive to methylmercury exposure than those by time domain analysis.
Keywords: heart rate variability; methylmercury neurotoxicity; review; sympathodominant state
1. Introduction
The measurement of heart rate variability (HRV; or, the coefficient of variation of the R-R intervals,
CVRR) using frequency domain analysis is an effective approach for the objective assessment of the
autonomic nervous function [1–3]. In a seminal study, Wheeler and Watkins observed a striking
reduction or absence of beat-to-beat variation during both quiet and deep breathing in diabetic patients
with autonomic neuropathy [4]. In 2012, the European Food Safety Authority (EFSA) reviewed several
reports examining the influence of methylmercury on HRV and concluded that, although some studies
of cardiac autonomy suggested an autonomic nervous effect of methylmercury, the results were
inconsistent across studies and the implications for health were unclear [5]. Gribble et al. [6] reached a
similar conclusion, finding that a major limitation of studies examining the influence of methylmercury
on HRV was a lack of standardized methods for performing and reporting HRV measurements.
Concerning the implications of HRV findings for health, however, the existing data may allow other
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interpretations besides those drawn by the EFSA panel. This study was intended to reconsider the
involvement of methylmercury in HRV by adding a perspective on the physiological context.
2. Materials and Methods
2.1. Data Sources and Extraction
We searched for published papers using a set of keywords (“mercury,” “heart rate variability,” and
“humans”) in PubMed, US National Library of Medicine, and identified 33 citations as of 31 January
2018. We excluded review papers (n = 6), case series (n = 3), studies addressing occupational mercury
exposure (n = 2) or studies in which data for either HRV (n = 3) or mercury biomarkers (n = 6) were not
described. Finally, included were 13 studies of methylmercury exposure and HRV: ten studies [7–16]
that were included in a previous systematic review by Gribble et al. [6] and three new studies [17–19].
In all of the identified studies, the statistical significance was set at p < 0.05.
2.2. Physiological Background
The autonomic nervous system innervates every organ in the body, and its neural organization in
the brain, spinal cord, and periphery is as complex as the somatic nervous system [1]. A vasomotor
center, located in the medulla oblongata, and vagal cardioinhibitory neurons, located primarily
within the ventrolateral subdivision of the nucleus ambiguus, are thought to be especially important
in the regulation of the cardiovascular system. The autonomic nervous system plays a role in
triggering or sustaining malignant ventricular arrhythmias. Higher sympathetic activity, unopposed
by vagal activity, promotes arrhythmia through a variety of mechanisms such as reducing the
ventricular refractory period and the ventricular fibrillation threshold, promoting triggered activity
afterpotentials, and enhancing automaticity [20]. By contrast, vagal stimulation opposes these
changes and reduces the effects of sympathetic stimulation by prolonging refractoriness, elevating the
ventricular fibrillation threshold, and reducing automaticity. For this reason, HRV testing is important
for assessing cardiac autonomic function in clinical applications because of the availability of low-cost
and non-invasive methods.
The procedure for data sampling and spectral analysis of successive R-R intervals on
electrocardiograph (ECG) is illustrated in Figure 1. The sinus rhythm shows fluctuation around
the mean R-R interval (or heart rate) due to continuous changes in the sympathovagal balance [21].
Rhythmicity is usually studied within different frequency domains. Three major spectral components,
calculated by frequency domain analysis using a fast Fourier transform (FFT) or autoregressive model,
are usually detected. In humans, these are centered at a very low frequency (VLF—below 0.04 Hz),
a low frequency (LF—around 0.15 Hz) and a high frequency (HF—around 0.3 Hz) [1]. Spectral
analysis involves subjecting a time series of R-R intervals to a mathematical transformation which
separates those R-R intervals into individual harmonics which are identifiable through their discrete
frequencies. The LF and HF are evaluated in terms of frequency and amplitude; the latter commonly
assessed by its area (i.e., power spectral density or colloquially “power”). The VLF has been equated
with a thermoregulatory or vasomotor influence, the LF with baroreflex control and arterial pressure
variations, and the HF with respiration [1,21]. Therefore, the LF and HF are thought to be mediated by
sympathetic and parasympathetic pathways, respectively [1,2]. The CVRR was defined as the ratio of
the standard deviation (SD) of the R-R intervals to the average value (RRmean). Likewise, the CVLF
and CVHF were defined as the ratios of the square roots of each component power spectral density
(i.e., LF and HF) to the RRmean, which can be compared between different populations because they
are adjusted for the mean R-R interval of each subject [3]. In addition, the LF/HF ratio and %LF
(= LF/(LF + HF) × 100, %) are used as HRV parameters for frequency domain metrics.
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Figure 1. An example of spectral analysis of ECG R-R intervals. (A) An examiner confirmed waveforms
on the electrocardiogram. (B) Electrocardiographic 300 R-R intervals or 5-min R-R intervals were
measured in real time. (C) Spectral analysis using autoregressive model was made for consecutive 100
R-R intervals with the minimal standard deviation (SD) that were automatically extracted from the
obtained data, and (D) component analysis was made for the data. Finally, a coefficient of variation
(C.V. or CVRR) was calculated from the mean and SD of the same data. VLF, LF, and HF represent very
low frequency, low frequency and high frequency bands, respectively.
2.3. Interpretation of HRV Parameters
Autonomic abnormality is thought to represent a sympathodominant state of the sympathovagal
balance during the initial stages and depressed HRV at the severe stage. The latter manifests as
a reduction in total (e.g., CVRR) and in specific power (i.e., HF, LF, CVHF, and CVLF) of spectral
components and is observed in patients after acute myocardial infarction [2], and those with autonomic
neuropathy due to diabetes mellitus [1] or alcoholism [22]. The sympathodominant state has three
patterns compared with healthy controls: (i) lower HF (with no significant difference in LF); (ii) higher
LF (with no significant difference in HF); and (iii) higher LF/HF ratio (or %LF). Previous studies on the
effects of occupational and environmental factors on HRV parameters have primarily demonstrated a
lower HF pattern (due to lead, styrene, mixed solvents such as n-hexane and toluene; local vibration in
chain-saw workers [23–30]; exposure to sarin [31]; and long commuting times of 90 min or more [32]).
In addition, Pagani et al. [33] observed a higher LF at rest in patients diagnosed with chronic fatigue
syndrome in comparison with healthy control subjects (73 ± 11 and 51 ± 10 normalized units,
respectively, p < 0.05), but responsiveness to mental stimuli (mental arithmetic) was reduced in
the patients compared with the controls. Thus, the above interpretation may be applicable for HRV
assessment in a static state, but not in an active mode, because the latter cannot preserve stationarity of
autonomic modulations.
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3. Results
3.1. Relations of Methylmercury to HRV
Table 1 shows the characteristics of epidemiological studies examining the effects of
methylmercury exposure on HRV in chronological order, together with the range of exposure levels
(i.e., minimum and maximum) for the studies that provided this information. In one case-control
study, patients officially certified as having fetal-type Minamata disease (methylmercury poisoning
due to in utero exposure) showed significantly reduced HF compared to age- and sex-matched healthy
controls, but no data on prenatal or postnatal methylmercury exposure were included [7].
Table 1. Human studies addressing the effects of methylmercury exposure on heart rate variability.





Oka et al. (2003) [7] Minamata, Japan 9 FMD patientsand 13 controls
Grandjean et al. (2004) [8] Faroe Islands,
Denmark
857 children aged 7
years
GM 22.6 μg/L, IQR 13.2~40.8
μg/L in cord blood; GM 4.22
μg/g, IQR 2.55~7.68 μg/g in
maternal hair




GM 0.96 μg/g, IQR 0.45~2.29
μg/g in hair
Murata et al. (2006) [9] Japan 136 children
Med 0.089 μg/g, range
0.017~0.367 μg/g in cord
tissue
Med 1.66 μg/g, range
0.43~6.32 μg/g in hair
Valera et al. (2008) [10] Nunavik, Canada 205 Inuit adults GM 19.6 μg/L, range 0.5~152
μg/L in blood
Choi et al. (2009) [11] Faroe Islands,Denmark 42 whaling men
GM 7.31 μg/g, IQR 4.52~13.4
μg/g in hair; GM 29.5 μg/L,
IQR 18.7~46.1 μg/L in blood
Yaginuma-Sakurai et al.





IG: 2.30 ± 1.08 μg/g (Mean ±
SD, 0th week), 8.76 ± 2.01
μg/g (15th week); CG: 2.27 ±
1.2 μg/g (0th week), 2.14 ±
1.03 μg/g (15th week) in hair
Lim et al. (2010) [13] South Korea 1589 adults GM 0.83 μg/g, IQR 0.56~1.28
μg/g in hair
Valera et al. (2011) [14] Quebec, Canada 724 Cree adults Med 5.7 μg/L, IQR 1.2~8.8
μg/L in blood
Valera et al. (2011) [15] French Polynesia
101 teenagers Med 8.5 μg/L, IQR 6.3~11.0
μg/L in blood
180 adults Med 13.5 μg/L, IQR 8.5~22.0
μg/L in blood
Valera et al. (2012) [16] Nunavik, Canada 226 Inuit children Med 16.3 μg/L, IQR 9.0~28.0
μg/L in cord blood
Med 2.9 μg/L, IQR 1.5~5.6
μg/L in blood
Periard et al. (2015) [17] Seychelles 95 adolescents Mean 6.7 μg/g, range 0.7~21.3
μg/g in maternal hair
Mean 9.5 μg/g, range 2.0~28.1
μg/g in hair
Gump et al. (2017) [18] Syracuse, NY, USA 203 children Mean 0.4 μg/L, range0.01~11.65 μg/L in blood
Miller et al. (2017) [19] Long Island, NY,USA 94 fish consumers
8.4 ± 8.6 (Mean ± SD) μg/L
in blood
* Methylmercury levels were measured only in cord tissue [26]. Abbreviations: FMD, fetal-type Minamata disease;
GM, geometric mean value; IQR, interquartile range (25th and 75th percentiles); Med, median value.
In the Faroese birth cohort study, cord-blood mercury was associated with decreased LF and
HF in children aged 14 years [8], and there were significant associations between increased mercury
levels in cord blood and hair at 7 years and decreased LF and CVLF in the children aged 7 years. In a
retrospective cohort study using dry cord tissue, methylmercury levels in cord tissue were associated
with increased LF/HF ratio and decreased HF in Japanese children at 7 years of age [9]. The median
mercury level in this population was estimated to be 2.24 (range, 0.43–9.26) μg/g in maternal hair at
parturition according to the equation of Akagi et al. [34]. In 11-year-old Inuit children, blood mercury
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was associated with decreased CVRR (adjusted β = −0.06, p = 0.01) and LF (adjusted β = −0.24, p = 0.02),
though neither cord-blood mercury nor hair mercury at 11 years was significantly associated with
any HRV parameter [16]. The Seychelles child development study found no significant associations
between prenatal or postnatal exposure to methylmercury and HRV parameters [17].
In a cross-sectional study, Lim et al. [13] reported that hair mercury was negatively related
to HF in Korean adults (p < 0.05). In Cree adults, blood and hair mercury levels were positively
related to LF/HF ratio, LF, and HF (p < 0.01) [14]. Similarly, in French Polynesians aged 12–17 years,
significant differences were observed in LF/HF ratio, LF, and HF between the second (7.9–10.0 μg/L)
and third (11.0–26.0 μg/L) tertiles of blood mercury concentration [15]. Among Faroese whaling
men, blood mercury level was associated with increased CVRR, CVHR, and CVLF, but latent mercury
level, estimated from mercury levels in blood, toe nail, and hair (7 years ago) using a structural
equation model, was not significantly associated with any HRV parameter [11]. In Inuit adults,
blood mercury was significantly correlated with CVRR and LF (r = −0.18 and r = −0.18, respectively),
but these significant associations disappeared after adjusting for potential confounders [10]. In avid
fish consumers, either blood total mercury or serum docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA) level was not significantly associated with any HRV parameter in a multiple regression
analysis [19]. Gump et al. [18] measured LF, HF, and LF/HF ratio at rest and during stress in children
aged 9–11 years to assess parasympathetic responses to acute stress, but neither blood mercury nor
lead was significantly related to baseline HRV parameters (HRV data not shown).
An intervention study reported that methylmercury exposure of 3.4 μg/kg body weight/week
for 14 weeks via fish consumption induced a temporary sympathodominant state (p = 0.014 for higher
CVLF; p = 0.076 for elevated LF/HF ratio) [12]. Also, age-, sex-, and body mass index-adjusted CVLF
was positively related to hair mercury at the 15th week (p < 0.001), though such significant relations
were not observed at baseline or at the 29th week of follow-up. Table 2 presents a summary of studies
examining the association between mercury levels and HRV parameters. A detailed discussion of
these results follows in Section 4.1.
Table 2. Summary of associations between mercury levels and heart rate variability (HRV) parameters.
Authors (Year) [Ref #]











Oka et al. (2003) [7] Patients 44.3 years,controls 42.9 years prenatal c(±) c(-) c(±)
Grandjean et al. (2004) [8]
7 years prenatal r(±) r(±) r(-) r(±)
postnatal r(±) r(±) r(-) r(±)
14 years prenatal r(-) r(-) r(-) r(±)
postnatal r(±) r(±) r(±) r(±)
Murata et al. (2006) [9] 6.9 years
prenatal r(-) r(±) r(+)
postnatal r(±) r(+) r (±)
Valera et al. (2008) [10] 52.1 years postnatal r(±) r(±) r(±) r(±)




control 23.7 years postnatal
c(±) c(±) c(+) c(±)
r(±) r(±) r(+) r(±)
Lim et al. (2010) [13] 33 years postnatal r(-) r(±)
Valera et al. (2011) [14] 35 years postnatal r(+) r(+) r(+)
Valera et al. (2011) [15]
14.2 years postnatal c(-) c(+) c(+)
48.6 years postnatal c(±) c(±) c(±)
Valera et al. (2012) [16] 11.3 years
prenatal r(±) r(±) r(±) r(±)
postnatal r(-) r(±) r(-) r(±)
Periard et al. (2015) [17] 19.5 years
prenatal r(±) r(±)
postnatal r(±) r(±)
Gump et al. (2017) [18] 10.6 years postnatal r(±) r(±) r(±)
Miller et al. (2017) [19] 48.9 years postnatal r(±) r(±) r(±)
Notes: c(-), significantly low in comparison; c(+), significantly high in comparison; c(±), not significant in comparison;
r(-), significantly negative relation; r(+), significantly positive relation; r(±), no significant relation. Gray areas show
a sympathodominant state or autonomic hypofunction.
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3.2. Measurement of HRV
HRV has been analyzed using a Holter monitoring system [10,14–16,19], an ECG analyzer with
analog-to-digital converter [7–9,12], or other ECG measuring instruments [11,13,17,18]. ECG signals
for R-R intervals were digitalized at 128 Hz [10,14–16], 200 Hz [17], 250 Hz [7], 500 Hz [18], and
1000 Hz [8,9,12]. Three reports did not mention the sampling frequency [11,13,19]. Most of the
study subjects were examined in a supine position [7–9,11,12,17] after subjects lay quietly for two
min or longer, but the subjects examined by Lim et al. [13] were sitting in a quiet and dark room.
The remaining reports did not provide any detailed information [10,14–16,18,19].
To examine the effect of sampling frequency on LF and HF, 128 consecutive R-R intervals with the
minimal SD in 61 male students aged 18–26 years [35] were reanalyzed using FFT spectral analysis,
as shown in Figure 2. The original R-R intervals were measured at a sampling frequency of 1000 Hz
after each subject rested in a supine position for 10 min, and data for lower sampling frequencies
(500 Hz, 250 Hz, 200 Hz, 125 Hz, and 100 Hz) were generated from the original data taking into
account random error. Table 3 presents the HRV parameters calculated by the spectral analysis. All the
HRV parameters were significantly different among six frequency-band groups. In particular, most




Figure 2. Results of spectral analysis of 128 consecutive R-R intervals using a fast Fourier transform in
a male student. The original R-R intervals were measured at the sampling frequency of 1000 Hz after
a subject rested in the supine position for 10 min, and data for lower sampling frequencies (500 Hz,
250 Hz and 100 Hz) were generated from the original data taking into account random error. LF and
HF represent low frequency and high frequency bands, respectively.
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Table 3. Mean +/- SD values of HRV parameters measured at different sampling frequencies in 61
male students of reference [35].
Parameters
Sampling Frequency
1000 Hz 500 Hz 250 Hz 200 Hz 125 Hz 100 Hz
RRmean (msec) 965.1 ± 162.9 965.1 ± 162.9 965.1 ± 162.9 965.1 ± 162.9 965.2 ± 162.9 * 965.2 ± 162.9
RRSD (msec) 51.74 ± 21.35 51.75 ± 21.35 51.75 ± 21.34 51.75 ± 21.33 51.82 ± 21.29 * 51.80 ± 21.27 *
CVRR (%) 5.321 ± 1.902 5.322 ± 1.903 5.323 ± 1.903 5.323 ± 1.902 5.330 ± 1.896 * 5.328 ± 1.896 *
log10 [LF (msec2)] 4.862 ± 0.480 4.862 ± 0.480 4.863 ± 0.478 4.863 ± 0.478 4.864 ± 0.478 4.858 ± 0.486 *
log10 [HF (msec2)] 4.931 ± 0.537 4.931 ± 0.537 4.932 ± 0.534 4.932 ± 0.533 4.936 ± 0.525 4.938 ± 0.521 *
%LF (%) 46.91 ± 20.01 46.89 ± 20.00 46.88 ± 19.95 46.88 ± 19.96 46.68 ± 20.06 46.33 ± 20.14 *
log10 [LF/HF ratio] −0.069 ± 0.416 −0.069 ± 0.416 −0.069 ± 0.415 −0.069 ± 0.415 −0.073 ± 0.416 −0.081 ± 0.420 *
Notes: LF (low frequency) and HF (high frequency) powers were calculated by spectral analysis shown in Figure
2; * shows p < 0.05 of significance levels obtained by two-way analysis of variance (F test) adding data of a lower
sampling-frequency band stepwise.
4. Discussion
4.1. Assessment of Methylmercury Neurotoxicity
With regard to the interpretation of HRV at rest, depressed HRV (e.g., CVRR of less than 2%) takes
precedence of a sympathodominant state because it indicates cardiac autonomic hypofunction while
other readouts reflect a result of disrupted sympathovagal balance [21,36]. Empirically, reduced HF
precedes elevated LF and LF/HF ratio, as mentioned in Section 2.3. Furthermore, elevated LF may
precede high LF/HF ratio because the ratio is a relative measure of sympathetic and parasympathetic
nerve activities and is not always suggestive of autonomic dysfunction [37]. Of course, data that
did not achieve statistical significance (c(±) or r(±)) are no longer discussed because any marginal
association was likely attributable to chance. In light of these criteria, some commonalities can be
observed across the 13 studies examined here, though Gribble et al. [6] judged the above evidence
was too limited to draw causal inferences. Namely, increased mercury levels were associated with
autonomic abnormality as shown in Table 2 (especially, gray areas). In addition, some fetal-type
and child Minamata disease patients showed vegetative symptoms including dizziness, orthostatic
syncope, palpitation, breathlessness, and nausea [38], along with hypersalivation and ileus [7].
Of the eight studies showing significant associations in Table 2, three demonstrated a potential
causal link between prenatal exposure level of methylmercury and autonomic hypofunction [7–9]; this
finding is similar to some results for cognitive deficits [39,40] and mental retardations [41]. Likewise,
five studies suggested a significant relationship existed between postnatal exposure levels and HRV
parameters analyzed using the frequency domain method. It is relatively straightforward to infer
causal relations from cohort studies [8,9] and an intervention study [12]. Contrariwise, it is difficult
to discriminate the effects of postnatal exposure to methylmercury from those of prenatal exposure
based on cross-sectional studies with no information about prenatal exposure levels [13–15], inasmuch
as there is evidence that mercury levels at 7 years of age reflect the prenatal exposure levels to some
extent [42]. In cases of this nature, it would be necessary to develop a plan estimating prenatal
exposure levels: For example, current mercury levels in hair of mothers, who had not changed their
dietary habits, might be used as a proxy for mercury exposure during pregnancy [43,44]. This method
cannot be applicable to subjects aged more than 7 years, as mentioned above. Insignificant findings
may have been attributable to extremely low exposure levels [18,19], measurements of different HRV
parameters [17] or subjects more than 45 years of average age [10,11,15,19].
Only one report seemed to show complicated findings [8]. In this study, cord blood mercury was
associated with reduced CVRR, CVHF, HF, and LF in 14-year-old children, but the 7-year-old children
showed only a significant association between cord blood mercury and lower LF. There are at least two
possible explanations for this paradox. First, since hair mercury levels at 7 years were higher than those
at 14 years (Table 1), the effect of prenatal methylmercury exposure on HRV may have been distorted
by postnatal exposure. Thereafter, as postnatal exposure levels decreased with age, the influence of
the prenatal exposure may have become predominant in the 14-year-old children. In support of this
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possibility, patients with fetal-type Minamata disease showed autonomic hypofunction approximately
45 years after the onset of the disease [7]. Second, short sleep duration in preschool children aged 5
and 6 years was associated with reduced HRV [45,46]; children who slept less than 10 h per weekday
showed significantly lower CVRR, CVLF, CVHF, LF, and HF than those who slept 10 h per weekday or
more, but no significant difference in LF/HF ratio was observed between the two groups. By contrast,
in 150 students aged 18–26 (mean 20) years, weekday sleep duration was not significantly associated
with any HRV parameter [35]; whereas, white-collar workers with commuting times of 90 min or
more showed decreased CVHF compared to those with commuting time of 60–89 min or less than
60 min (2.10 ± 1.17%, 2.25 ± 1.10%, 2.58 ± 1.33%, respectively) [32]. Thus, it is possible that sleep
duration may have confounded the HRV data for the 7-year-old children. Regrettably, the Faroes
study did not examine the participants’ sleep durations. Taken together, the data suggest that prenatal
methylmercury exposure consistently affected HRV parameters in response to the exposure dose,
i.e., ranging from a sympathodominant state to autonomic dysfunction. Nevertheless, HRV parameters
are susceptible to physiological conditions such as sleep duration in young children [45,46] and mental
stimuli [33], in addition to recent methylmercury exposure at relatively high levels.
The Seychelles child development study, which used time domain metrics, failed to find a
significant association between hair mercury levels and HRV in a cohort of 19-year-olds [7]. Likewise,
Faroese whaling men showed no significant associations between indicators of latent exposure
to methylmercury and HRV parameters [11]. In subjects of these studies, recent exposure levels
(total mercury in hair) were considerably higher (mean 9.5 μg/g for the former study and geometric
mean 7.31 μg/g for the latter study) than those in the general population of other countries. Thus,
comparison of HRV parameters between high/frequent and low/infrequent fish consumers should
probably have been made. Autonomic function may have been affected by prenatal methylmercury
exposure (though not so drastically as fetal-type Minamata disease patients [7]) and recent exposure
levels, different from prenatal ones, may have changed greatly due to diversity in habits (for instance,
consumption of methylmercury-contaminated fish). In two studies examining the same HRV
parameters, the CVRR and CVHF of the above Faroese whaling men were 2.99% and 1.30%, respectively,
which were lower than those of 23 Japanese healthy men aged 30–63 (mean 49) years (3.75% and
1.79%, respectively) [22]. The Seychelles child development study did not employ comparable HRV
parameters. Thus, not only dose-effect relationships but also comparison between subgroups of the
study population should have been attempted during the data analysis, as Varela and coworkers
did [15].
In reports demonstrating a significant relationship between methylmercury exposure and HRV
parameters, prenatal mercury levels showed a geometric mean 4.22 μg/g [8] and an equivalent
median of 2.24 μg/g [9] in maternal hair at parturition; postnatal mercury levels were 0.83 μg/g
in hair [13], 5.7 μg/L in blood [14] and 2.9 μg/L in blood [16] at the time of testing, whereas two
reports except one [16] did not describe prenatal exposure levels. It would not be straightforward
to estimate the critical concentration of methylmercury from these data. Valera et al. [15] and
Yaginuma-Sakurai et al. [12] observed significant differences in HRV parameters between comparable
subgroups with different mercury levels; specifically, the latter study indicated that a 14-week
methylmercury exposure caused significant changes in some HRV parameters. Taken together, the
data suggest that the average mercury level reported in the study by Yaginuma-Sakurai et al. [12]
(8.76 μg/g in hair) is a reasonable estimate of a critical dose of total mercury likely to affect HRV.
The EFSA panel regarded the point of departure (POD) as 11.5 μg/g for maternal mercury levels in
hair and 46 μg/L for those in blood by applying a hair-to-blood ratio of 250 [5]. Since the value of
8.76 μg/g in hair corresponds to 35 μg/L in blood, the results suggest a reference dose ranging from
10 to 20 μg/L in blood after taking uncertainty factor into account; whereas, the average mercury level
in whole blood of the same subjects measured after the 14-week exposure was 26.9 μg/L [47]. In such
cases, intake of n-3 polyunsaturated fatty acids (PUFA) and selenium resulting from fish consumption
should be considered in each country [12,48–50].
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The effect of methylmercury on cardiac autonomic function was suggested to be reversible by
an intervention study [12], separately from a cohort study by Grandjean et al. [8]. The adverse effects
in the former study disappeared after 14-week wash-out period following cessation of the exposure.
Recent mercury levels in hair of Faroese children aged 14 years were associated with a prolonged
latency between the pons and midbrain of the auditory pathway [51], and the brainstem auditory
evoked potential latency showed clear negative associations with LF and CVLF [8]. Moreover, all the
HRV parameters were largely reduced in comatose children with brainstem dysfunction [52], implying
that impairment in the higher center of cardiac autonomic function can lead to decrease both in HF
and LF power. Therefore, the pathology of autonomic imbalance due to methylmercury appears to
differ for prenatal and postnatal exposures, hypothesizing that prenatal methylmercury exposure can
readily impair the higher center of cardiac autonomic function and the postnatal exposure does the
same in the periphery. In this case, the directionality of LF would differ, with reduced LF for prenatal
exposures [8] and elevated LF for postnatal exposure [9,12,14,15].
4.2. Factors Affecting the Assessment of Cardiac Autonomic Function
The Task Force of the European Society of Cardiology and the North American Society of Pacing
and Electrophysiology recommended either a 5-min recording for frequency domain metrics or a 24-h
recording for time domain metrics [2]. The latter is useful for clarifying the pathophysiology of cardiac
autonomic function in clinical medicine—however, whether it is useful for toxicological studies in
human populations remains disputable. It would be not feasible to examine a large number of subjects
with 24-h monitor, and for time domain parameters, the longer the R-R interval sample, the greater
the natural variation of the signal due to heterogeneous influences on heart rate [1]. Moreover, time
domain variables provide no information about the sympathetic activity [2]. None of the studies in
this review used 24-h ECG monitoring. Instead, posture during measurement of R-R intervals and
sampling frequency in digitizing ECG signals differed among these studies. Subject posture during
measurement (supine rest, upright tilt, or sitting) affects the LF/HF ratio and the power of each
component directly [2,53], and spectral signal is readily distorted by movement artifacts and ectopic
beats [1]. For this reason, it is important to retain posture across measurement. Valera et al. [10,14–16],
using ambulatory 2-h Holter monitoring, excluded R-R intervals whose duration was less than 80% or
more than 120% of the running R-R average before performing frequency domain analysis; therefore,
their data might not represent a time series of successive R-R intervals. In addition, as Table 3 shows,
the data precision of R-R intervals depends on the sampling frequency [2,54]. A sampling frequency of
200 Hz or higher, in disagreement with the report by Merri et al. [54], appears to be required to preserve
measurement precision. Clearly, research in human toxicology will not progress unless researchers
employ comparable (and, if possible, R-R interval-adjusted) endpoints for HRV such as the CVRR,
CVHF, and CVLF.
When assessing a causal influence on HRV in humans, many potential confounders (age, sex,
drinking and smoking habits, sleep duration, and mental stimuli) should be considered [3,55,56].
In the data analysis, since it is difficult to control for the effect of age in subjects at an extremely
wide range of age (e.g., 5–83 years old [13]), such analyses have to be made in some age-specific
groups separately. Likewise, consumption of n-3 PUFA such as DHA and EPA is suggested to affect
HRV parameters [6,12,57], while body mass index and body fat percentage seem to be associated
with corrected Q-T (QTc) intervals on ECG and heart rate, but not with HRV parameters [35].
Several disorders have been suggested to affect HRV parameters, including: Acute myocardial
infarction, congestive heart failure, coronary artery disease, coronary atherosclerosis, myocardial
dysfunction, cardiac transplantation, Shy-Drager syndrome, Parkinsonism, Guillain-Barre syndrome,
tetraplegia, spinocerebellar degeneration, diabetic neuropathy, renal failure, chronic alcoholism, and
essential hypertension [2,3]. In addition, although levels of environmental pollutants such as PCBs and
lead are low in developed countries [58], concurrent exposure models would be necessary to consider
the interactive effects of substances other than methylmercury [59,60]. For that reason, special attention
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should be paid to subjects with such disorders, as well as potential confounders and exposure to other
neurotoxic substances, when conducting toxicological studies in humans.
Apart from HRV, using spectral analysis, QTc intervals are frequently used as another method for
assessing autonomic nervous function [35,61–66], inasmuch as Q-T interval on ECG represents the
duration between ventricular depolarization and subsequent repolarization [67]. QTc prolongation
is suggested to be associated with elevated risk of heart disease and sudden cardiac death [68–71].
Therefore, the QTc interval may be a more promising indicator than HRV parameters for investigating
the pathophysiology of cardiovascular events involved in methylmercury exposure, though it was
not significantly associated with prenatal or postnatal methylmercury exposures at relatively low
levels [9,19].
5. Conclusions
The HRV parameters analyzed using the frequency domain method, as well as CVRR, appear
to be more sensitive to methylmercury exposure than those using the time domain method. Most of
the studies addressed in this review suggested that increased mercury levels were associated with
autonomic dysfunction including a sympathodominant state, though the effect of methylmercury on
HRV (e.g., LF) might differ for prenatal and postnatal exposures. In an intervention study carried
out by Yaginuma-Sakurai et al., a significant difference in LF analyzed using spectral analysis was
observed between the experimental group (mean mercury levels of 8.76 μg/g in hair and 26.9 μg/L
in blood) and control group. Exposures near this dose may have critical effect on cardiac autonomic
function. Therefore, the POD to inform a new tolerable weekly intake should be based on this critical
concentration because it is lower than that established by the EFSA panel (11.5 μg/g in maternal hair).
This result could probably be applicable for the general population, including pregnant women and
unborn children.
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Abstract: Methylmercury (MeHg) is selectively toxic to the central nervous system, but mechanisms
related to its toxicity are poorly understood. In the present study, we identified the chemokine, C-C
motif Chemokine Ligand 4 (CCL4), to be selectively upregulated in the brain of MeHg-administered
mice. We then investigated the relationship between CCL4 expression and MeHg toxicity using
in vivo and in vitro approaches. We confirmed that in C17.2 cells (a mouse neural stem cell line)
and the mouse brain, induction of CCL4 expression occurs prior to cytotoxicity caused by MeHg.
We also show that the addition of recombinant CCL4 to the culture medium of mouse primary
neurons attenuated MeHg toxicity, while knockdown of CCL4 in C17.2 cells resulted in higher MeHg
sensitivity compared with control cells. These results suggest that CCL4 is a protective factor against
MeHg toxicity and that induction of CCL4 expression is not a result of cytotoxicity by MeHg but is
a protective response against MeHg exposure.
Keywords: methylmercury; brain; chemokine; CCL4
1. Introduction
Methylmercury (MeHg) is an environmental pollutant well known to cause Minamata disease [1].
MeHg causes central nervous system (CNS) disorders whose main symptoms include sensory
paralysis, speech disorder, ataxia, and visual field narrowing [2,3]. MeHg can easily pass through
the blood-placental barrier and can therefore affect the brain of the immature fetus [4,5]. Although
MeHg is selectively toxic in the brain, mechanisms related to this selectivity and defense mechanisms
are still unknown. We have analyzed patterns of gene expression in the brains of mice that were
administered MeHg and have identified a number of upregulated genes [6–8]. Among these genes,
many encode cytokines, such as chemokines and interleukins. One such gene is C-C motif Chemokine
Ligand 4 (CCL4), which is specifically upregulated in the brain by MeHg [9]. CCL4, also called
macrophage inflammatory protein 1β (MIP1β), was identified as an inflammatory protein produced
from macrophages [10]. CCL4, secreted extracellularly, binds to chemokine receptors (CCR1, CCR5)
and is involved in leukocyte infiltration and activation [11]. CCL4 is secreted from glial cells
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and astrocytes in the CNS and has been suggested to be involved in the progression of various
brain diseases, including Alzheimer’s disease, multiple sclerosis, and ischemic brain disease [12–15].
Nevertheless, the functions of CCL4 in the brain are unclear and the relationship between chemokines
and MeHg toxicity is poorly understood. Recently, Godefroy et al. reported that CCL2, another C-C
chemokine, attenuates MeHg toxicity in rat primary neuron cultures [16], but the mechanism for this
is not understood. In this study, we investigated the relationship between CCL4 expression and MeHg
toxicity, in vivo and in vitro, using mice and neuronal cell lines.
2. Materials and Methods
2.1. Animal Experiments
Eight-week-old male C57BL/6 mice were purchased from Japan SLC, Inc. (Shizuoka, Japan).
The mice were housed in plastic cages (five animals per cage) at 22 ± 2 ◦C with a relative humidity
of 55 ± 20% under a 12-h light-dark cycle and allowed free access to chow (F-2, Oriental Yeast,
Tokyo, Japan) and water. All experiments were performed in accordance with the Regulations
for Animal Experiments and Related Activities at Tohoku University, and were approved by the
Animal Care Committee of Tohoku University (No.: 2016PhA-001, Date: 8 February 2016). After
an adaptation period, mice were randomly divided into control (n = 5) and MeHg-treated (n = 5)
groups. Methylmercuric chloride (25 mg/kg), dissolved in physiological saline, was administered by
subcutaneous injection. After the indicated time period, the mice were dissected and each organ was
subjected to the various assays.
2.2. Immunochemistry
Immunohistochemistry was performed as described previously [17–19]. Paraffin embedded
sections were cut using a microtome, and immunohistochemistry was performed using the Vectastain
Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) with an antibody to neuronal nuclei (NeuN)
(Chemicon, Temecula, CA, USA).
2.3. Cell Culture
Mouse C17.2 neural stem cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 2 mM/L L-glutamine, and antibiotic (100 IU/mL penicillin and 100 mg/mL streptomycin) in
a humidified 5% CO2 atmosphere at 37 ◦C. Mouse primary cerebellar granule cells were cultured in
Neurobasal-A medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 2% B25 (Thermo
Fisher Scientific), 1% FBS, and 25 mM KCl in 12-well plates for 2 weeks.
2.4. siRNA Transfection
Double-stranded siRNA for CCL4 (target sequence: CTTTGTGATGGATTACTATTT) and negative
control siRNA were purchased from Sigma-Aldrich (St. Louis, MO, USA). C17.2 cells were transfected
with siRNAs using HiPerFect transfection reagent (Qiagen, Germantown, MD, USA) according to the
manufacturer’s protocol.
2.5. Cell Viability Assay
C17.2 cells and mouse primary cerebellar granule cells were cultured in media containing
methylmercuric chloride for 24 h. Cell viability was measured using the alamarBlue® assay (Biosource,
Camarillo, CA, USA). Fluorescence was measured using a Gemini XPS microplate spectrofluorometer
(Molecular Devices, Sunnyvale, CA, USA) (excitation wavelength 545 nm; emission wavelength
590 nm). Trypan blue assays were performed using a Vi-Cell XR cell viability analyzer (Beckman
coulter, San Diego, CA, USA).
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2.6. Measurement of CCL4 mRNA Levels by Quantitative Real-Time PCR
Total RNA from organs and cells was isolated using the Isogen II Kit (Nippon Gene,
Tokyo, Japan) according to the manufacturer’s protocol. The first-strand cDNA was synthesized
from 500 ng of total RNA using the PrimeScriptTM RT Reagent Kit (Takara, Shiga, Japan).
Quantitative real-time PCR analysis was performed using SYBR Premix EX Taq (Takara) with
a Thermal Cycler Dice® (Takara). The PCR primers used included the following: CCL4,
5′-ACCCTGTGACATTTCACGGAG-3′ (sense) and 5′-GTACTCGATTGATAGAGGAC-3′ (antisense);
and GAPDH, 5′-ATCACCATCTTCCAGGAGCGA-3′ (sense) and 5′-AGGGGCCATCCACAGTCTT-3′
(antisense). Fold changes in mRNA levels were determined from standard curves after calibration of
the assay. CCL4 mRNA levels were normalized to those of GAPDH.
2.7. Statistical Analysis
If not stated otherwise, statistical significance of the data was determined using analysis of
variance (ANOVA) with Dunnett’s post hoc test.
3. Results
3.1. CCL4 Expression Is Induced Prior to Neuronal Damage Caused by MeHg
To study the relationship between MeHg toxicity and CCL4 expression in mice, we administered
a single dose of methylmercuric chloride (25 mg/kg) and then used real-time qPCR to investigate
changes in CCL4 mRNA levels in cerebrum, cerebellum, kidney, and liver over time (Figure 1A). CCL4
mRNA levels were elevated in the cerebrum and cerebellum from 5 days after MeHg administration
(Figure 1B). CCL4 expression was not induced in the kidney or liver at any time point tested (Figure 1B).
This indicates that MeHg induces CCL4 expression in a brain-specific manner. We then investigated
pathological changes in the brains of mice after single-dose administration of 25 mg/kg methylmercuric
chloride. As a reference index, we counted cells that were positive for the neuronal marker, NeuN.
We observed almost no change in NeuN-positive cell numbers in the cerebellum, even at 7 days after
MeHg administration (data not shown). In the cerebrum, no changes were found in the number of
NeuN-positive cells up to 5 days, and on day 7 a slight decrease in the number of NeuN-positive
cells was observed (Figure 1C). Therefore, CCL4 expression was induced in the mouse brain prior to
neuronal damage caused by MeHg.
3.2. CCL4 Attenuates MeHg Toxicity in Primary Mouse Neuron Cultures
Godefroy et al. reported that addition of recombinant CCL2 into the medium of primary rat
neuron cultures attenuated MeHg toxicity [16]. Therefore, we used primary mouse neuron cultures
to investigate the effect of chemokines on MeHg sensitivity. Addition of recombinant CCL2 to the
culture medium significantly attenuated the MeHg toxicity on primary mouse neurons (Figure 2A).
The addition of recombinant CCL4 also significantly attenuated MeHg toxicity, to a greater extent than
CCL2, indicating that CCL4, like CCL2, is a protective factor against MeHg neurotoxicity (Figure 2B).
3.3. CCL4 Expression Is Induced Prior to MeHg-Induced Cytotoxicity in C17.2 Cells
We investigated the effect of MeHg on CCL4 expression in C17.2 cells, a neural progenitor
cell derived from the mouse brain. CCL4 expression was below detection threshold under normal
conditions. However, increased CCL4 mRNA levels were detected from 2 h after MeHg treatment, and
this increase continued over time up to 9 h (Figure 3A). However, when cell viability was measured by
the trypan blue assay, cell viability decreased from 9 h after MeHg treatment (Figure 3B). This showed
that even in C17.2 cells, CCL4 expression is induced prior to MeHg cytotoxicity.
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Figure 1. Relationship between neurological damage and CCL4 expression in the brains of mice treated
with methylmercury. C57BL/6 mice were injected once subcutaneously with methylmercuric chloride
(MeHg) (25 mg/kg). (A) Selected organs (cerebellum, cerebrum, liver and kidney) were dissected 1, 3,
5, or 7 days after the injection. Cont.: Control. (B) CCL4 mRNA levels in each organ were measured by
quantitative real-time PCR. Data are represented as mean ± SD, * p < 0.05; ** p < 0.01 compared with
“Control”. (C) NeuN (neuron marker)-positive cells in the cerebral cortex detected by immunostaining.
Scale bars represent 250 μm.
Figure 2. Cont.
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Figure 2. Effects of recombinant CCL2 or CCL4 on methylmercury-induced cytotoxicity in mouse
primary cerebellar granule cells. Mouse primary cerebellar granule cells (neurons) (1 × 106 cells/mL)
were cultured in Neurobasal A medium containing 2% B25, 1% FBS, and 25 mM KCl in 12-well plates
for 2 weeks. Recombinant CCL2 (A) or CCL4 (B) was then added to the culture medium, and 1 h later
cells were exposed to 5 μM methylmercuric chloride (MeHg) for 24 h. Cell viability was measured by
the alamarBlue® assay. Data are presented as the mean ± S.D. * p < 0.05; ** p < 0.01 compared with the
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Figure 3. Relationship between cell viability and CCL4 expression in methylmercury-treated mouse
C17.2 neural stem cells. C17.2 cells (4 × 105 cells/2 mL) were seeded into 6-well plates. After
incubation for 18 h, cells were treated with 10 μM methylmercuric chloride (MeHg) for the indicated
times. (A) CCL4 mRNA levels were measured by quantitative real-time PCR. (B) Cell viability was
determined by the trypan blue assay using the Vi-CELL cell counter. N.D.: not detected. Data are
presented as the mean ± S.D. * p < 0.05; ** p < 0.01 compared with “0 h group”.
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3.4. Knockdown of CCL4 Enhances MeHg Cytotoxicity in C17.2 Cells
To clarify the relationship between CCL4 expression and MeHg toxicity, we investigated the
effects of CCL4 knockdown on the MeHg sensitivity of C17.2 cells. The introduction of siRNA to CCL4
reduced the induction of CCL4 expression by MeHg by about 60% (Figure 4A). CCL4 knockdown cells
were more sensitive to MeHg than cells transfected with control siRNA (Figure 4B). This indicates that
CCL4 has a protective role against MeHg toxicity.
Figure 4. Effects of CCL4 knockdown on the sensitivity of C17.2 cells to methylmercury. C17.2 cells
(1 × 104 cells/90 μL) transfected with CCL4 siRNA were seeded into 96-well plates. After incubation for
18 h, transfected cells were treated with indicated concentrations of methylmercuric chloride (MeHg)
for 24 h. (A) CCL4 mRNA levels were measured by quantitative real-time PCR. (B) Cell viability
was measured by the alamarBlue® assay. Data are presented as the mean ± S.D. N.D.: not detected.
Statistical significance when compared to corresponding “control siRNA group” at each concentration
point: * p < 0.05, ** p < 0.01.
4. Discussion
The present study showed that CCL4 expression in mouse-derived neuronal precursor C17.2 cells,
as well as in the mouse brain, was induced prior to MeHg cytotoxicity. These findings indicate the
possibility that the CCL4 expression induced by MeHg is not the result of cellular damage caused
by MeHg, but a protective response to MeHg exposure. It is also known that the cell has a number
of protective systems against toxicity of environmental toxicants and that those are activated in the
early stage of exposure. Therefore, CCL4 induction in the early stage of MeHg exposure seems to be
a protective action against its toxicity.
38
Toxics 2018, 6, 36
The transcription factor, NF-κB, is involved in the induction of cytokine expression [20,21]. CCL4
expression is induced in macrophages by lipopolysaccharide (LPS) and hydrogen peroxide and NF-κB
is involved in this induction [22–24]. We recently found that knockdown of p65, a subunit of NF-κB,
slightly suppressed the induction of CCL4 expression in response to MeHg in C17.2 cells (unpublished
data). This suggests that while NF-κB is partially involved in the induction of CCL4 expression in
response to MeHg, other transcription factors are also involved. It is possible that MeHg induces CCL4
expression due to the activation of transcription factors that differ from those activated by LPS and
hydrogen peroxide. In future studies, we hope to clarify the mechanisms underlying brain-specific
MeHg toxicity by determining how CCL4 is induced in response to MeHg.
In this study, CCL4 was newly identified as a protective factor against MeHg induced cytotoxicity.
Recently, CCL2 was also identified as a protective factor against MeHg toxicity on primary rat
neurons [16]. Although the protective mechanisms against MeHg toxicity through CCL2 and CCL4 are
unknown, it is reported that expressions of CCL2 and CCL4 are increased early in the cerebral tissue
of patients with posttraumatic brain contusions [25]. This suggests that both chemokines may play
an important role as a defensive response in the brain injury.
It is known that CCL4 induces the production of cytokines including interleukin (IL)-1 and
IL-6 [26–28]. Recently, Noguchi et al. reported that IL-6 expression is induced by MeHg, and that
IL-6 has a protective role against MeHg-induced neurotoxicity [29]. It is thus thought that increased
levels of CCL4, in response to MeHg, may enhance IL-6 production, thereby reducing MeHg toxicity.
However, we could not confirm the induction of IL-6 expression in mouse brains treated with MeHg
(data not shown). This suggests that IL-6 is not involved in reducing MeHg toxicity by CCL4.
MeHg induced higher CCL4 expression in the cerebellum compared with the cerebrum (Figure 1B).
Nevertheless, loss of neurons was only observed in the cerebrum and was not confirmed in the
cerebellum (Figure 1C). We have reported that tumor necrosis factor-α (TNF-α), an inflammatory
cytokine, is selectively induced in the brain of mice treated with MeHg, and that the degree of induction
was larger in the cerebrum than in the cerebellum [8]. In addition, TNF-α may enhance MeHg toxicity
because a TNF-α antagonist attenuated MeHg toxicity for C17.2 cells [8]. Based on these findings, the
degree of induction of CCL4 expression, which reduces MeHg toxicity, was higher in the cerebellum
than in the cerebrum, and the degree of induction of TNF-α expression, which enhances MeHg toxicity,
was low in the cerebellum. Therefore, MeHg toxicity may not be observed in the cerebellum under
our experimental conditions. In addition, we found that the expression of CCL3 and of IL-19 are
also specifically induced in the brain by MeHg [9,30]. Therefore, there are many cytokines that are
specifically induced in the mouse brain by MeHg, and the combined action of these may play an
important role in neuronal damage caused by MeHg. In future studies, we hope to clarify crosstalk
between cytokine molecules that are specifically induced in the brain, which will help to elucidate the
mechanisms involved in brain-specific MeHg toxicity.
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Abstract: Mercury compounds are known to cause central nervous system disorders; however
the detailed molecular mechanisms of their actions remain unclear. Methylmercury increases the
expression of several chemokine genes, specifically in the brain, while metallothionein-III (MT-III)
has a protective role against various brain diseases. In this study, we investigated the involvement
of MT-III in chemokine gene expression changes in response to methylmercury and mercury vapor
in the cerebrum and cerebellum of wild-type mice and MT-III null mice. No difference in mercury
concentration was observed between the wild-type mice and MT-III null mice in any brain tissue
examined. The expression of Ccl3 in the cerebrum and of Cxcl10 in the cerebellum was increased by
methylmercury in the MT-III null but not the wild-type mice. The expression of Ccl7 in the cerebellum
was increased by mercury vapor in the MT-III null mice but not the wild-type mice. However,
the expression of Ccl12 and Cxcl12 was increased in the cerebrum by methylmercury only in the
wild-type mice and the expression of Ccl3 in the cerebellum was increased by mercury vapor only in
the wild-type mice. These results indicate that MT-III does not affect mercury accumulation in the
brain, but that it affects the expression of some chemokine genes in response to mercury compounds.
Keywords: methylmercury; mercury vapor; metallothionein-III; chemokine
1. Introduction
Several mercury compounds are considered hazardous, exerting mainly central nervous system
(CNS) or renal damage [1–3]. Methylmercury is a pollutant that causes severe damage [4,5],
and accumulates in fish by bioaccumulation. Recent epidemiological investigations have shown
that pregnant women who take up relatively large amounts of methylmercury are at higher risk of
delivering children with developmental disorders [6,7]. Mercury vapor also produces neuronal
damage, and the exposure of gold miners to high levels of mercury vapor through mercury
amalgamation is a great concern in developing countries [8,9]. Furthermore, the exposure of children
to mercury vapor has increased due to the use of mercury in amalgam to extract gold from ores [10].
Recently, it was reported that high concentrations of methylmercury were detected in grains yielded
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near a mercury mine in China [11]. These reports suggest that rice is a source of methylmercury
exposure in the area. In addition, the median estimated methylmercury intake for children was
0.29 μg/kg bodyweight/week, which is approximately 16% above the dietary references dose (RfD) in
Hong Kong [12]. Furthermore, a recent Japanese cohort study suggested that prenatal methylmercury
exposure affected neuronal function during child development [13,14].
Metallothionein (MT) is a defense factor against harmful metals such as mercury and cadmium.
MT is a cysteine rich, low molecular protein that reduces toxicity by binding to metals [15,16]. There are
four isoforms of MT, I to IV, which have different locations and levels of expression and varied
physiological functions [15,16]. MT-III, which is present in the brain, has a protective effect against
various brain diseases [17–19].
Recently, it has been reported that methylmercury increases the expression of several chemokine
genes specific to the mouse brain [20]. Furthermore, we examined the impact of methylmercury on
the expression of chemokine genes in various mouse tissues and found that expression of Ccl4 shows
brain specific induction by methylmercury treatment [21]. Chemokines are a type of cytokine known
to cause migration of leukocytes. They are secreted primarily from immune cells and participate in the
inflammatory response [22]. Chemokines are also secreted from various tissues, including the brain,
kidney, and liver [23–26].
In this study, we investigated the involvement of MT-III in chemokine gene expression in the
cerebrum and cerebellum in response to methylmercury and mercury vapor using the MT-III null mice.
2. Materials and Methods
2.1. Animals and Exposure Procedures
MT-III null mice and 129/Sv mice as wild-type controls were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA) and routinely bred in the vivarium of the School of Pharmacy, Aichi
Gakuin University. MT-III null mice were engineered by Erickson et al. [18] and had the 129/Sv genetic
background. Three-week-old female mice were caged in a ventilated animal room at 24 ◦C ± 1 ◦C with
50 ± 10% relative humidity, and a 12 h light–dark cycle in the animal room of the School of Pharmacy,
Aichi Gakuin University. Mice were maintained on standard laboratory food (MF, Oriental Yeast Co.,
Tokyo, Japan) and tap water ad libitum, and they received humane care throughout the experiment
according to the guidelines of the School of Pharmacy.
Mice were assigned randomly to control or experimental groups (n = 4–5). For mercury vapor
(Hg0) exposure, mice were placed in a mercury vapor exposure chamber and exposed for 8 h every
day at a mean concentration of 0.121 (range: 0.080 to 0.180) mg/m3 for 4 weeks. The concentration of
mercury in the exposure chamber was measured every day using a mercury survey meter (EMP-1A,
Nippon Instruments Co., Tokyo, Japan). For methylmercury (CH3Hg+) exposure, methylmercury
chloride (GL Sciences Inc., Tokyo, Japan) was diluted with distilled water to prepare a 5 ppm solution.
The solution containing 5 ppm methylmercury was given ad libitum instead of tap water. After 4 weeks
of exposure, the cerebrum and cerebellum were removed from each mouse under ether anesthesia.
2.2. Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from brain tissues using TRIzol® Reagent (Ambion, Grand Island, NY,
USA) according to the manufacturer’s instructions. Total RNA was incubated with a PrimeScript™
RT Reagent Kit (Perfect Real Time) (TaKaRa Bio, Shiga, Japan) to generate cDNA. Real time PCR
was performed using SYBR Premix Ex Taq™ II (Perfect Real Time) (TaKaRa Bio) and a Thermal
Cycler Dice Real time system (TaKaRa Bio). PCR conditions were: 10 s of hot start at 95 ◦C
followed by 40 cycles of 5 s at 95 ◦C and 30 s at 60 ◦C. Gene expression was normalized to β-actin
mRNA levels. Oligonucleotide sequences of the primers (sense and antisense, respectively) were:
5′-TCTAAGCGTCACCACGACTTCA-3′ and 5′-GTGCACTTGCAGTTCTTGCAG-3′ for the mouse
MT-I gene; 5′-CCTGCAATGCAAACAACAATGC-3′ and 5′-AGCTGCACTTGTCGGAAGC-3′ for the
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mouse MT-II gene; 5′-AGGGCTGCAAATGCACG-3′ and 5′-ACACACAGTCCTTGGCACACTTC-3′
for the mouse MT-III gene; 5′-ATGAAGGTCTCCACCACTGC-3′ and 5′-CCCAGGTCTCTTTGG
AGTCA-3′ for the mouse Ccl3 gene; 5′-CAAACCTAACCCCGAGCAACAC-3′ and 5′-GGTCTCATA
GTAATCCATCACAAAGC-3′ for the mouse Ccl4 gene; 5′-AATGCATCCACATGCTGCTA-3′ and
5′-CTTTGGAGTTGGGGTTTTCA-3′ for the mouse Ccl7 gene; 5′-GTCCTCAAGGTATTGGCTGGA-3′ and
5′-GGGTCAGCACAGATCTCCTT-3′ for the mouse Ccl12 gene; 5′-AAGTGCTGCCGTCATTTTCT-3′ and
5′-GTGGCAATGATCTCAACACG-3′ for the mouse Cxcl10 gene; 5′-CCTAAGGCCAACCGTGAAAA-3′
and 5′-AGGCATACAGGGACAGCACA-3′ for the mouse β-actin gene.
2.3. Analysis of Mercury Concentrations in Tissues
Mercury concentrations in tissues were measured with a cold vapor atomic absorption
spectrophotometer (RA-3 Mercury Analyzer; Nippon Instruments, Tokyo, Japan) after digestion
with a concentrated acid mixture [HNO3/HClO4 1:3 (v/v)].
2.4. Statistical Analyses
Statistical analyses were undertaken using single factor ANOVA followed by Bonferroni’s test for
post hoc comparison (P < 0.05).
3. Results
3.1. Body Weight Changes
Body weights of the MT-III null mice and wild-type mice were measured one day after completion
of exposure. The body weights of wild-type mice and MT-III null mice exposed to methylmercury were
similar to those of the corresponding control mice (Figure 1). The body weights of wild-type mice and
MT-III null mice exposed to mercury vapor were significantly lower than those of the corresponding
control mice (Figure 1). However, there was no difference in body weight fluctuation in response to
mercury exposure between wild-type mice and MT-III null mice (Figure 1).
Figure 1. Body weights of the wild-type and MT-III null mice exposed to mercury compounds.
Body weights of the wild-type and MT-III null mice were measured one day after the final mercury
exposure. Values are the mean ± S.D. (n = 4–5). * Significantly different from the control group of
wild-type mice, P < 0.05. # Significantly different from the control group of MT-III null mice, P < 0.05.
3.2. Total Mercury Concentrations in the Cerebrum and Cerebellum
The total mercury levels in the cerebrum and cerebellum of mice exposed to methylmercury or
mercury vapor are shown in Figure 2. In the cerebrum of wild-type mice, mercury concentrations
of 2380.57 ± 300.24 ng/g tissue and 519.99 ± 13.68 ng/g tissue were detected after methylmercury
exposure and mercury vapor exposure, respectively (Figure 2A). In the cerebrum of MT-III null mice,
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mercury concentrations of 2373.14 ± 957.12 ng/g tissue and 475.79 ± 56.73 ng/g tissue were detected
after methylmercury exposure and mercury vapor exposure, respectively (Figure 2A). In the cerebellum
of wild-type mice, mercury concentrations of 1715.23 ± 121.09 ng/g tissue and 783.58 ± 44.15 ng/g
tissue were detected following methylmercury exposure and mercury vapor exposure, respectively
(Figure 2B). In the cerebellum of MT-III null mice, mercury concentrations of 1643.18 ± 130.82 ng/g
tissue and 779.71 ± 54.85 ng/g tissue were detected in response to methylmercury exposure and
mercury vapor exposure, respectively (Figure 2B). However, no significant difference was observed
between wild-type mice and MT-III null mice in either the cerebrum or cerebellum (Figure 2).
Figure 2. Mercury concentrations in the cerebrum and cerebellum of wild-type mice and MT-III null
mice exposed to mercury compounds. Cerebra and cerebella were removed one day after the final
mercury exposure. Total mercury levels in the cerebrum (A) and cerebellum (B) were measured.
Values are the mean ± S.D. (n = 4–5). * P < 0.05.
3.3. The Levels of MT-I, MT-II, MT-III mRNAs in the Cerebrum and Cerebellum after Mercury Exposure
The mRNA levels of MT-I in the cerebrum were significantly increased only in the wild-type mice
exposed to methylmercury (Figure 3A). The mRNA levels of MT-II in the cerebrum were significantly
decreased only in MT-III null mice exposed to mercury vapor (Figure 3B). The MT-III mRNA levels
in the cerebrum of wild-type mice were not altered by methylmercury or mercury vapor exposure
(Figure 3C).
Figure 3. The levels of MT-I, MT-II and MT-III mRNAs in the cerebra of wild-type mice and
MT-III null mice exposed to mercury compounds. mRNA levels of MT-I (A), MT-II (B) and MT-III
(C) were determined by real time RT-PCR. mRNA levels were normalized with β-actin. Values are
the mean ± S.D. (n = 4–5). * Significantly different from the control group of wild-type mice, P < 0.05.
# Significantly different from the control group of MT-III null mice, P < 0.05.
The mRNA levels of MT-I, MT-II and MT-III in the cerebellum of each exposed group are shown
in Figure 4. MT-I mRNA levels in the cerebellum were not changed by mercury exposure in either
wild-type mice or MT-III null mice (Figure 4A). The mRNA levels of MT-II in the cerebellum were
significantly decreased only in the wild-type mice exposed to methylmercury (Figure 4B). No changes
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in MT-III mRNA levels were observed in the wild-type mice exposed to methylmercury or mercury
vapor (Figure 4C). These results indicate that MT-III does not affect the accumulation of mercury after
methylmercury or mercury vapor exposure.
Figure 4. The levels of MT-I, MT-II and MT-III mRNAs in the cerebella of wild-type mice and
MT-III null mice exposed to mercury compounds. mRNA levels of MT-I (A), MT-II (B) and MT-III
(C) were determined by real time RT-PCR. mRNA levels were normalized with β-actin. Values are the
mean ± S.D. (n = 4–5). * Significantly different from the control group of wild-type mice, P < 0.05.
3.4. Changes in Expression of Chemokine Genes in the Cerebrum in Response to Mercury Exposure
Ccl3 mRNA levels in the cerebrum were significantly increased by methylmercury exposure only
in the MT-III null mice (Figure 5A). Moreover, Ccl3 mRNA levels in the cerebrum of MT-III null mice
were higher than those of wild-type mice by methylmercury exposure (Figure 5A). Ccl4 mRNA levels
did not change after mercury exposure (Figure 5B). Ccl7 mRNA levels were markedly elevated in the
MT-III null mice and wild-type mice after methylmercury and mercury vapor exposure (Figure 5C).
Although Ccl12 mRNA levels were increased by MT-III deficiency, methylmercury exposure increased
Ccl12 mRNA levels only in the wild-type mice (Figure 5D). Cxcl10 mRNA levels were significantly
elevated only when the wild-type mice were exposed to methylmercury (Figure 5E).
Figure 5. mRNA levels of chemokine genes in the cerebra of wild-type mice and MT-III null mice
exposed to mercury compounds. mRNA levels of Ccl3 (A), Ccl4 (B), Ccl7 (C), Ccl12 (D) and Cxcl10
(E) were determined by real-time RT-PCR. mRNA levels were normalized with β-actin. Values are the
mean ± S.D. (n = 4–5). * Significantly different from the control group of wild-type mice, P < 0.05.
# Significantly different from the control group of MT-III null mice, P < 0.05. $ Significantly different
between wild-type and MT-III null mice, P < 0.05.
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3.5. Changes in Expression of Chemokine Genes in the Cerebellum after Mercury Exposure
The mRNA levels of Ccl3 in the cerebellum were significantly increased by methylmercury in the
MT-III null mice and wild-type mice, and mercury vapor significantly increased Ccl3 mRNA levels only
in the wild-type mice (Figure 6A). Ccl4 mRNA levels were significantly increased by methylmercury in
the MT-III null mice and wild-type mice (Figure 6B). Ccl7 mRNA levels were significantly increased by
methylmercury in the MT-III null mice and wild-type mice, and were significantly increased only in
the MT-III null mice in response to mercury vapor (Figure 6C). Ccl12 mRNA levels were significantly
increased by both methylmercury and mercury vapor in the MT-III null mice and wild-type mice
(Figure 6D). However, Ccl12 mRNA levels in the MT-III null mice exposed to methylmercury were
lower than those of wild-type mice (Figure 6D). Cxcl10 mRNA levels were significantly elevated only
when the MT-III null mice were exposed to methylmercury (Figure 6E).
Figure 6. mRNA levels of chemokine genes in the cerebella of wild-type mice and MT-III null mice
exposed to mercury compounds. mRNA levels of Ccl3 (A), Ccl4 (B), Ccl7 (C), Ccl12 (D) and Cxcl10
(E) were determined by real-time RT-PCR. mRNA levels were normalized with β-actin. Values are the
mean ± S.D. (n = 4–5). * Significantly different from the control group of wild-type mice, P < 0.05.
# Significantly different from the control group of MT-III null mice, P < 0.05. $ Significantly different
between wild-type and MT-III null mice, P < 0.05.
4. Discussion
MT-III is highly expressed in neurons [17], and also shows a protective effect against brain
diseases [18,19]. Mercury compounds, such as methylmercury and mercury vapor, are harmful
substances that cause disorders of the CNS, but the influence of MT-III on the disorders caused by these
mercuric compounds is poorly understood. Recently, methylmercury has been reported to increase
expression of the chemokine genes, Ccl3, Ccl4, Ccl7, Ccl12 and Cxcl10 in the mouse brain [20,21,27].
The most highlighted knowledge in this study is that Ccl3 expression in the cerebrum and the cerebellar
expression of Ccl12 and Cxcl10 were significantly different between wild-type mice and MT-III null
mice only in the methylmercury exposure. MT-III is abundantly expressed in the normal brain; on
the other hand, in a brain with Alzheimer’s disease, MT-III expression is largely reduced [17]. It was
suggested that MT-III might have a protective role in cerebral ischemia [28]. Furthermore, inflammatory
factors are upregulated upon the brain damage, as it increases phagocytosis and the release of
inflammatory mediators [29,30]. The present study suggests that the increase in chemokine expression
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may be involved in methylmercury-triggered brain damage with topical specificity. The present
study also suggest that MT-III may be the cause of the difference in inflammatory response upon
methylmercury exposure.
Our present study revealed that the MT-III deficiency had no effect on mercury concentration
in the brains of mice exposed to mercury compounds; however, the MT-III deficiency influenced the
expression of chemokine genes in response to mercury exposure. The expression of Ccl12 and Cxcl10
in the cerebrum was increased in the wild-type mice by methylmercury; but not in the cerebrum of
MT-III null mice. Moreover, in response to mercury vapor exposure, Ccl3 expression in the cerebellum
was not changed in the MT-III null mice, but was significantly elevated in the wild-type mice. In the
cerebellum of wild-type mice, the expression of Ccl7 was not changed by mercury vapor exposure and
that of Cxcl10 was not changed by methylmercury exposure; however, they were significantly elevated
in the MT-III null mice. Indeed, the fluctuation in Cxcl10 expression in response to methylmercury was
observed in the cerebrum of wild-type mice, and in the cerebellum of MT-III null mice. Taken together,
these findings indicate that MT-III may affect the expression of some chemokine genes in response to
different mercury compounds differently in the cerebrum and cerebellum. In recent years, MT-I and
MT-II have been reported to be involved in inflammatory reactions in cardiomyocytes [31]. The present
study indicates that MT-III may be involved in inflammatory reactions consequent to an exogenous
stress on the brain.
Chemokines are associated with inflammatory damage in a number of tissues, including the
brain [23–26]. Chemokines may function as signaling molecules in the CNS [32]. Accordingly,
the expression of several chemokines increases with hypoglossal nerve damage, however the role of
chemokines in cranial nerves remains unclear. Methylmercury induces a brain-specific increase in Ccl4
expression in mice [21]. In addition, it is assumed that CCL4 is involved in the pathway mediating
the toxicity of methylmercury in the CNS [33,34]. In this study, methylmercury induced Ccl4 gene
expression in the cerebellum not only in the wild-type mice but also in the MT-III null mice. Therefore,
CCL4 may be an important factor mediating methylmercury toxicity.
Previous studies revealed that postnatal mice exposed to 0.188 mg/m3 mercury vapor or 3.85 ppm
methylmercury showed a decrease in total locomotive activity in the OPF [35]. In this study, we exposed
the mice to similar doses of mercury compounds. Because several chemokine gene expressions were
increased in brain tissues of wild-type mice, chemokine genes may be associated with the influence of
mercury exposure in childhood on neuronal development.
MT-I/II null mice showed an enhanced adverse effect of neonatal mercury (HgCl2) exposure [19].
Moreover, MT-I/II null mice exposed to mercury vapor showed decreased locomotor activity [36,37].
Furthermore, the highly sensitive methylmercury toxicity in MT-I/II deficient astrocytes was rescued
by the introduction of the MT-I gene [38]. Thus, MT-I and MT-II were suggested to be involved in
mercury compound induced neuropathy, but the role of MT-III in neuropathy caused by mercury
compounds is almost unknown. Our present study revealed that MT-III deficiency is involved in
mercury-induced neuropathy through changing cerebral chemokine gene expression.
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Abstract: Methylmercury (MeHg) is a ubiquitous environmental pollutant that is known to be
neurotoxic, particularly during fetal development. However, the mechanisms responsible for
MeHg-induced changes in adult neuronal function, when their exposure occurred primarily during
fetal development, are not yet understood. We hypothesized that fetal MeHg exposure could affect
neural precursor development leading to long-term neurotoxic effects. Primary cortical precursor
cultures obtained from embryonic day 12 were exposed to 0 nM, 0.25 nM, 0.5 nM, 2.5 nM, and 5 nM
MeHg for 48 or 72 h. Total Hg accumulated in the harvested cells in a dose-dependent manner.
Not all of the concentrations tested in the study affected cell viability. Intriguingly, we observed that
cortical precursor exposed to 0.25 nM MeHg showed increased neuronal differentiation, while its
proliferation was inhibited. Reduced neuronal differentiation, however, was observed in the higher
dose groups. Our results suggest that sub-nanomolar MeHg exposure may deplete the pool of
neural precursors by increasing premature neuronal differentiation, which can lead to long-term
neurological effects in adulthood as opposed to the higher MeHg doses that cause more immediate
toxicity during infant development.
Keywords: methylmercury; cortical precursors; developmental neurotoxicity; low-dose exposure;
delayed effects
1. Introduction
Methylmercury (MeHg) is a global pollutant affecting millions of people worldwide [1,2]. Its main
target is the central nervous system, with fetuses being particularly susceptible [3]. Amin-Zaki et al. [4]
reported that the levels of MeHg in fetal blood are about 25% higher than those of the mother. It has
also been shown that fetuses can be affected in the absence of maternal toxicity [5].
A cohort study on the population of the Faroe Islands showed that prenatal exposure to MeHg
was significantly associated with deficits in fine motor control, language, and learning abilities in
children and adolescents [6]. Yorifuji et al. [7] demonstrated an increased prevalence of psychiatric
symptoms in adults who showed no sign of toxicity at birth, based on an epidemiological study on the
residents of Minamata.
Developmental exposure to MeHg in mice results in memory disturbances and induces
depression-like behavior in adult animals [8], which persists into older age [9]. Animal studies have
shown that the developing brain is extremely vulnerable to MeHg neurotoxicity [8–10], which may be
attributed to the rapid cell proliferation [11] and cell differentiation in the developing brain [12,13].
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Previous studies have demonstrated detrimental effects of MeHg at micromolar levels on neurogenesis,
including inhibition of proliferation and disturbed cell cycle progression in neuronal cells [14].
The emerging idea of the “Developmental Origin of Health and Diseases (DOHaD)”, previously
termed the "fetal origins of adult disease" in the 1990s, postulates that exposure to environmental
influences during the embryonic period is related to the risk of developing diseases in adulthood [15].
Therefore, it is important to understand not only the immediate effect of MeHg exposure on the
embryos themselves, but also its potential influences that progress into adulthood. The DOHaD
theory suggests that epigenetic alterations could be induced by environmental conditions during
development, which are maintained in adulthood. These subtle epigenetic changes, showing no effect
in early ages, can increase the risk of developing diseases later in life [16]. Therefore, there is the
necessity of understanding the effect of dietary MeHg exposure on very low levels of embryonic neural
development and its underlying mechanisms.
In this study, we investigated the effects of low-dose (nM) MeHg exposure on regulating
murine embryonic neural precursor development using a mouse cerebral cortex development model.
Our hypothesis was that a low and non-toxic dose of MeHg could disrupt the development of these
cortical precursors leading to long-term neurotoxic effects.
2. Materials and Methods
2.1. Animal Ethics
Animal care, handling and use protocols were reviewed and approved by the Animal Care
Committee of the Ottawa Hospital Research Institute, University of Ottawa on 28 July, 2017.
Animal protocol number: OHRI-2103.
2.2. Cell Culture Procedures and Experimental Treatments
Primary cultures of cortical precursors were obtained from embryonic day 12 cortices dissected
in ice-cold Hanks’ balanced salt solution (HBSS) (Life Technologies, Carlsbad, CA, USA) from CD1
mouse (Charles River Laboratories, Wilmington, MA, USA). Embryos were transferred to ice-cold
HBSS and the cerebral cortices were carefully isolated from the brain after removing the meninges.
The tissue was mechanically triturated with a plastic pipette and plated at a density of 105 cells on
coverslips pre-coated with 15% poly-L-ornithine (PLO) (Sigma, St. Louis, MO, USA) and 5% laminin
(BD Biosciences, Franklin Lakes, NJ, USA) in a 24-well plate (Thermo Scientific BioLite, Waltham,
MA, USA). The cortical precursors were cultured in a neurobasal medium (Invitrogen, Carlsbad,
CA, USA) containing 500 μM L-glutamine (Cambrex Biosciences, East Rutherford, NJ, USA), 2% B27
supplement (Invitrogen, Carlsbad, CA, USA), 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA,
USA), and 40 ng/mL FGF2 (BD Biosciences, Franklin Lakes, NJ, USA). The primary culture was
exposed to 0 nM, 0.25 nM, 0.5 nM, 2.5 nM, and 5 nM MeHg for 48 or 72 h. The dosing solution
was freshly prepared daily from a stock solution of 1 M using MeHgCl from Alfa Aesar (Ward Hill,
MA, USA).
2.3. Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde for 10 min, then blocked with 10% normal
goat serum (NGS) diluted in PBS with 0.3% Triton X-100. Primary antibodies were diluted in 10%
NGS in PBS with 0.3% Triton X-100 and incubated in a humid chamber at 4 ◦C overnight. Secondary
antibodies were diluted in PBST and incubated for 1 h at room temperature. Hoechst 33258 was
diluted in PBS. The culture was washed three times for 5 min with PBS between each step. The primary
antibodies used were mouse anti-βIII-tubulin (1:1000; Covance, Princeton, NJ, USA), rabbit anti-Pax-6
(1:2000; BioLegend, San Diego, CA, USA), rabbit anti-Sox2 (1:100; Millipore, Burlington, MA, USA),
mouse anti-Ki67 (1:400; Abcam, Cambridge, UK), and rabbit anti-Cleaved Caspase-3 (CC3) (1:400;
Cell Signalling Tech., Danvers, MA, USA). The secondary antibodies used were Alexa Fluor 555- and
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Alexa Fluor 488-conjugated goat antibodies (1:500; Life Technologies, Carlsbad, CA, USA). Nuclear
staining was performed with Hoechst 33343 (1:1000; Sigma, St. Louis, MO, USA). After rinsing with
PBS, the coverslips were mounted in a Lab Vision PermaFluor Aqueous Mounting Medium (Thermo
Fisher, Waltham, MA, USA). All experiments were repeated at least three times.
2.4. Microscopy and Quantification
Digital image acquisition was performed using a Zeiss Axioplan 2 fluorescent microscope with
Zeiss Axiovision software (Carl Zeiss Microscopy, Thornwood, NY, USA). Six random images over
300 cells per condition per experiment were taken for quantification.
2.5. Statistics
All data were expressed as the mean plus or minus the standard error of the mean (SEM) and
were tested for statistical significance with one-way ANOVA, followed by Bonferroni’s post hoc
test. A two-tailed Student’s t-test was used for between-group comparisons. The differences were
considered significant if p < 0.05. All statistical analyses were performed using Prism (version 7,
GraphPad Software, La Jolla, CA, USA, 2018).
3. Results
3.1. Cell Viability
Immunocytochemistry results showed that the percentage of CC3+ condensed nuclei was not
changed between the methylmercury treated groups and the control group (Figure 1A). One-way
ANOVA results showed that MeHg treatments did not have any effect on CC3+, F = 0.4666, d.f. = (4,10),
p > 0.05) (Figure 1B). Thus, the exposure levels of methylmercury used in our experiments did not the
affect cell viability of the cortical precursors.
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Figure 1. Methylmercury treatments at doses of 0.25 to 5 nM do not induce cell death.
Immunocytochemistry was performed in a 2-day cortical precursors culture. Images of Cleaved
Caspase-3 (CC3) (Red) and Hoechst (Blue) staining are shown. Scale bar = 50 μm (A). The bar graph
(B) shows the percentage of immunocytochemistry-positive cells. Values are mean ± SEM (n = 3).
Statistical significance was determined by a one-way ANOVA followed by a Bonferroni’s post hoc test.
No significant p value was obtained for ANOVA. Letters denote the results of the comparisons between
treatment groups, groups with the same letter were not statistically different.
3.2. Effects of Cortical Precursors on Proliferation and Differentiation
The MeHg treatments had a significant effect on the proliferation and differentiation of cortical
precursors. One-way ANOVA results showed that there was a significant MeHg treatment effect for
Pax6 (F = 13.56, d.f. = (4,10), p < 0.05) and Beta III tubulin staining (F = 50.12, d.f. = (4,10), p < 0.05).
Immunofluorescence results showed that exposure to 0.25 nM MeHg significantly increased the
percentage of new born neurons produced from E12 cortical precursors, labeled with βIII tubulin,
compared to the control (Figure 2A). Coincidentally, the population of Pax6 + cortical precursors was
significantly decreased at 0.25 nM MeHg (Figure 2B). To validate the reduced pool of cortical precursors
in the culture, we performed immunocytochemistry analysis with a pan-neural stem cell marker, Sox2,
and a cell cycling marker, Ki67. One-way ANOVA results showed that there was a significant MeHg
treatment effect for Sox2 (F = 8.849, d.f. = (4,10), p < 0.05) and Ki67 staining (F = 5.182, d.f. = (4,10),
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p < 0.05). The results showed that both the percentage of Sox2+ cortical precursors and Ki67+ cycling
cells were dramatically decreased upon exposure to 0.25 nM MeHg (Figure 2D–F). These results
suggest that exposure of cortical precursors to an extremely low dose (0.25 nM) of MeHg enhances
premature neuronal differentiation while reducing their proliferation. In comparison, exposure of
cortical precursors to MeHg from 0.5 nM to 5 nM reduced the percentage of βIII tubulin+ new born
neurons in culture (Figure 2A,C). However, while the 0.5 nM and 2.5 nM treatment groups showed a
significant decrease in the population of Pax6+ cortical precursors, the 5 nM treatment group did not
(Figure 2B). In addition, the percentage of Sox2+ NSCs and Ki67+ cycling cells were not changed in the
0.5 nM and 5 nM MeHg treatment groups (Figure 2D–F). These results show that exposure to 0.5 nM
did not show the effects that we observed at the lower dose of 0.25 nM. Its effect was more similar to
the effects observed at 2.5 and 5 nM MeHg, that showed significantly lower neuronal differentiation,
while its proliferation recovered gradually to a level comparable with the control.
Figure 2. Cont.
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Figure 2. Immunocytochemistry was performed in a 3-day NSC culture. Images of (A) Pax6
(Green), Beta III Tubulin (Red), (D) Sox2 (Green), Ki67 (Red), and Hoechst (Blue) staining are shown.
Scale bar = 50 μm. The bar graphs (B,C; E,F) show the percentage of immunocytochemistry-positive
cells. Values are mean ± SEM (n = 3). Statistical significance was determined by a one-way ANOVA
followed by a Bonferroni’s post hoc test (* p < 0.05: vs. control, letters denote the results of the
comparisons between treatment groups, groups with the same letter were not statistically different).
4. Discussion
The novel finding of this study is that the effects of MeHg on cortical precursor development are
dose-dependent. The extremely low sub-nanomolar dose of 0.25 nM MeHg increases the neuronal
differentiation of cortical precursors while reducing their proliferation. On the other hand, there was
a decrease in differentiation at higher doses (>0.5 nM), which is similar to the results reported in
the existing literature. Similar doses of MeHg (2.5–5 nM MeHg for 48 h) were shown to inhibit
the spontaneous neuronal differentiation of murine embryonic neural stem cells [12]. Fujimura &
Usuki [17] also showed that neural progenitor cell proliferation was suppressed 48 h after exposure to
10 nM MeHg, but cell death was not observed. Tamm et al. [18] identified Notch signaling as a target
for methylmercury’s inhibition of neuronal differentiation at exposure levels between 2.5 and 10 nM.
Bose et al. [19] exposed E15 primary cultures of rat embryonic cortical neural stem cells to 2.5 nM and
5 nM MeHg for 48 h and reported reduced cell proliferation with no effect on the cell death rate.
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Our new findings on the increase in premature differentiation during embryonic development
at a sub-nanomolar MeHg dose might be an outcome of epigenetic changes triggered by stress
sensors, such as AMP dependent kinase (AMPK). Even though it is not known whether MeHg
can increase AMPK activity, HgCl2 has been shown to enhance AMPK activation in the liver of
mice [20]. Hwang et al. [21] have shown that the activation (phosphorylation) of AMPK can play an
important role in reducing the toxicity of methylmercury. Therefore, the activation of AMPK could be
a biological response induced by the extremely low dose of MeHg. Our previous work has shown
that AMPK activation can stimulate a signaling-directed epigenetic pathway, atypical protein kinase
C (aPKC)-mediated S436 phosphorylation of CREB-binding protein and histone acetyltransferase,
to promote the neuronal differentiation of embryonic and adult neural precursor cells [22,23]. Moreover,
it has been reported that the levels of cysteine and glutathione (GSH) as well as the GSH/GSSG ratio
in neural stem cells progressively decreased in association with neuronal differentiation [24]. Since it is
well known that MeHg decreases GSH, this may also be a potential mechanism for the observed effects.
This enhanced neuronal differentiation by sub-nanomolar MeHg could have significant biological
consequences. The untimely enhancement of embryonic neurogenesis can lead to depletion of the
neural precursor cell pool and consequently a decreased level of adult neurogenesis resulting in
neurological functional impairment. Juliandi et al. [25] have shown that prenatal treatment of valproic
acid in mice can enhance neurogenesis and reduce the proliferation of neural precursor cells (NPCs),
leading to the depletion of the NPC pool. This depletion may cause a slower differentiation of
the residual NPCs during life. In contrast, Gallaher et al. [26] showed that a maternal IL-6 surge
aberrantly affected embryonic precursors, ultimately causing an expanded adult forebrain NPC pool
and enhanced olfactory neurogenesis in offspring, months after fetal exposure. The possibility that
different doses of prenatal exposure to MeHg can have different effects on the adult NPC pool and its
associated neurological effects is an interesting avenue to be explored in the future.
While the doses used in this in-vitro experiment cannot be extrapolated to MeHg doses
during human fetal development, the difference of effects observed between the sub-nanomolar
range and the nanomolar range has biological significance. An analysis of autopsied brain tissue
from infants prenatally exposed to methylmercury showed that the mercury levels detected were
0.026–0.295 μg/g [27]. Sakamoto et al. [28] measured total Hg concentrations in the cord blood of
54 healthy Japanese pregnant women, with no particular exposure to any Hg compounds at Fukuda
Hospital (Kumamoto City, Kumamoto, Japan) from 2006 to 2007, and reported a mean Hg concentration
of 7.26 ng/g. This means that the nM range of exposure is environmentally relevant.
In conclusion, based on our results, we propose a novel model for low-dose MeHg exposure
to neural precursor cells, as shown in Figure 3. Extremely low-dose MeHg exposure may also have
a detrimental effect on embryonic neural development, which may lead to neurodevelopmental
disorders or neurodegeneration later in life.
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Figure 3. Proposed model for low-dose MeHg exposure to NSCs. Under normal circumstances, cortical
precursor cells undergo both differentiation and proliferation. Upon administration of 0.25 nM MeHgCl,
the cell population show reduced proliferation and increased differentiation. Cell population dosed
with 0.5 nM to 5 nM MeHgCl show inhibited differentiation and gradual recovery of proliferation.
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Abstract: In 1956 methylmercury poisoning, known as Minamata disease, was discovered among
the inhabitants around the Shiranui Sea, Kyushu, Japan. Although about five hundred thousand
people living in the area had supposedly been exposed to methylmercury, administrative agencies
and research institutes had not performed any subsequent large scale, continuous health examination,
so the actual extent of the negative health effects was not clearly documented. In 2009, we performed
health surveys in order to examine residents in the polluted area and to research the extent of the
polluted area and period of pollution. We analyzed data collected on 973 people (age = 62.3 ± 11.7)
who had lived in the polluted area and had eaten the fish there and a control group, consisting of
142 persons (age = 62.0 ± 10.5), most of whom had not lived in the polluted area. Symptoms and
neurological signs were statistically more prevalent in the four groups than in the control group and
were more prevalent and severe in those who had eaten most fish. The patterns of positive findings
of symptoms and neurological findings in the four groups were similar. Our data indicates that
Minamata disease had spread outside of the central area and could still be observed recently, almost
50 years after the Chisso Company’s factory had halted the dumping of mercury polluted waste
water back in 1968.
Keywords: methylmercury; long term exposure; symptoms; neurological findings; severity; delayed
toxicity; correlation of signs and symptoms; dose-response relationship
1. Introduction
In 1956, methylmercury poisoning was discovered among the inhabitants around Minamata
Bay of Shiranui Sea in Kumamoto Prefecture, Kyushu, Japan. The condition, which was caused by
the ingestion of fish and shellfish that had been contaminated by methylmercury, became known as
Minamata disease [1]. For 36 years, from 1932 to 1968, the Nihon Chisso Company’s Minamata factory,
which produced acetaldehyde, had been discharging waste water contaminated with methylmercury,
created during the process, into the Shiranui Sea. Although it was suspected that about five hundred
thousand people living in the area had been exposed to methylmercury poisoning, there have
subsequently been very few comprehensive health surveys and examinations.
Certification of Minamata disease (methylmercury poisoning by eating fish) has been determined
by the Pollution-Related Health Damage Compensation Law (PHDCL). Those victims must themselves
Toxics 2018, 6, 39; doi:10.3390/toxics6030039 www.mdpi.com/journal/toxics61
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personally apply to the Judgment Committee for Minamata Disease Accreditation (an advisory body
to the Governor of the Kumamoto Prefecture) to be certified. According to the 1977 Diagnostic Criteria
of Minamata disease, patients must have lived in the designated area at least one year before 1968,
and four-limb somatosensory disturbance must be accompanied by at least one of the more severe
symptoms of Hunter Russell syndrome such as ataxia, visual field constriction, and so on [2].
Actual judgment is stricter. A report by a neurologists in 1997 suggested that patients with such
plural symptoms of Hunter Russell syndrome had been rejected by the Judgment Committee [3].
The designated area has not been determined by epidemiological study but restricted to the place
where severe Minamata disease victims have been discovered since the outbreak. Therefore, strangely
enough, there is an enclave (Akasegawa district) in Akune City (Figure 1). Originally, the designated
area was restricted to Minamata City, Tsunagi Town, Ashikita Town (including ex-Tanoura Town),
and ex-Izumi City area by the PHDCL in 1971. However, it later became clear that the effects were
more outspread and the extent of the area was expanded.
 
Figure 1. Surveyed area and designated area. Minamata Area: red, Northern Area: green, Southern
Area: yellow, Other Areas: beige. Designated Area: red cross-hatched pattern. Control area: around
Fukuoka, Kumamoto, and Kagoshima City.
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As of 2009, when time-limited special relief law (The Law Concerning Special Measures for
the Relief of Minamata Disease Victims and the Settlement of Minamata Disease Issues, LSRS) was
enforced, the designated area was restricted to the red cross-hatched areas in Figure 1, which consists
of Minamata City, Tsunagi Town, Ashikita Town, Goshonoura of Amakusa City, Ryuugatake of
Kami-Amakusa City, Futamisuguchi of Yatsushiro City in Kumamoto Prefecture and Izumi City,
ex-Azuma Town area of Nagashima Town, Wakimoto and Akasegawa of Akune City in Kagoshima
Prefecture (Table 1). Strictly speaking, the area designated by the PHDCL and that by LSRS are
different. The designated area we refer to in this paper is the one stipulated by the Special Law (LSRS)
that was in force between 2009 and 31 July 2012.
Table 1. Surveyed area and designated area.












Goshonoura district, Amakusa City ** Other districts of Amakusa City **
Ryuugatake district, Kami-Amakusa City *** Other districts of Kami-Amakusa City ***





All ex-Izumi City district, Izumi City ****
Other districts of Izumi City ****
Euchi, Ookubo, Kamizuru, Shimozuru,
and Shibabiki of ex-Takaono Town district,
Izumi City ****
Shimomyo district of ex-Noda Town,
Izumi City ****
All ex-Azuma Town district,
Nagashima Town *****
Other districts (All ex-Nagashima Town)
of Nagashima Town *****
Wakimoto and Akasegawa districts of
Akune City Other districts of Akune City
Other Areas
Other districts of Kumamoto Prefecture
Other districts of Kagoshima Prefecture
Other Prefectures
* On 1 January 2005, ex-Ashikita Town and ex-Tanoura Town merged and became Ashikita Town; ** On 27 March
2006, ex-Goshonoura Town, 2 cities, and 7 other towns merged and became Amakusa City; *** On 31 March 2004,
ex-Ryuugatake Town and 3 other towns merged and became Kami-Amakusa City; **** On 13 March 2006, ex-Izumi
City, ex-Noda Town, and ex-Takaono Town merged and became Izumi City; ***** On 20 March 2006, ex-Azuma
Town and ex-Nagashima Town merged and became Nagashima Town.
As of 2007, only 2268 patients were accredited by the administration [4] as suffering from
Minamata disease, despite the fact that more than 17,000 people had applied for Minamata disease
certification prior to 1999 [5]. In 1995, 8831 individuals were partially compensated for health
problems, which included somatosensory disturbance [4], but they were not certified as actually
having Minamata disease. Applicants seeking recognition were being socially discriminated against
and the lack of a comprehensive pollution survey meant that many residents with health problems
had not sought diagnosis.
However, in October 2004, after the Supreme Court of Japan ruled that the criteria stipulated
by the Japanese Environmental Protection Agency for Minamata disease accreditation was too strict,
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an increasing number of residents applied for examination, therapy, and treatment for methylmercury
poisoning. By the summer of 2009 over thirty thousand had applied and by the end of 2012 the number
had risen to sixty thousand. In order to study the signs and symptoms of residents who hoped to
be certified, we carried out a survey in September 2009 to determine the geographical extent and
chronological development of methylmercury poisoning in the area.
From November 2004 to August 2009, we had already examined 3800 residents in the polluted
area and found a lot of patients with neurological signs and symptoms. We performed this survey in
order to research the prevalence of signs and symptoms as well as the geometrical and chronological
spread of health problems caused by methylmercury.
In this study, we investigated not only the state of health (symptoms and neurological signs) in
methylmercury-exposed people at present but the extent and mutual relationship of exposure level,
onset and course of symptoms, severities of signs and symptoms and the significance of the designated
area in the polluted region.
Also, the damage to health from methylmercury poisoning has been so great in Japan that
researchers have concentrated on finding severe neurological abnormalities and have ignored milder
health disturbances. Therefore, we also analyzed the data from subjects in whom sensory disturbances
had not been detected during their physical examination.
2. Materials and Methods
2.1. Subjects
The study, which was planned for people who had lived in the methylmercury-polluted area and
hoped to be certified for Minamata disease, was carried out on 20 and 21 September 2009. Information
regarding the study was spread through media such as television, newspapers, and local government
pamphlets. We received applications from people living throughout the coastal regions of the Shiranui
Sea. Of the 1700 applicants we selected the first 1420 and informed them of the times, dates and places
for the examinations.
Examinations were conducted at twelve sites in Kumamoto Prefecture and at five sites in
Kagoshima Prefecture. A total of 1044 subjects were examined. They were given both written
and verbal information about the examination method, how the data would be used and that their
confidentiality would be protected. Of the 1044 subjects examined 974 residents agreed to having
their data analyzed. The Ethics Committee of Minamata Kyoritsu Hospital approved the implement
and analyses of this study. Among 974 subjects, one subject had not lived in the polluted area,
so we excluded this subject. Finally, we analyzed 973 residents (M/F = 482/491, age = 62.3 ± 11.7,
range = 33–92).
We grouped the exposed subjects into four categories, according to their living places at the time
of the examination. Subjects who lived in Minamata City or Ashikita County (Tsunagi Town and
Tanoura Town) at the examination time were classified as Minamata Area (n = 259, M/F = 136/123,
Age = 62.5 ± 13.6). Subjects who lived in the northern area including Amakusa City, Kami-Amakusa
City, Yatsushiro City, Yatsushiro County (Hikawa Town), or Uki City were classified as Northern Area
(n = 279, M/F = 147/132, Age = 64.0 ± 11.1). Subjects who lived in Izumi City, Izumi County
(Nagashima Town), or Akune City were classified as Southern Area (n = 246, M/F = 121/125,
Age = 63.0 ± 11.1). Subjects who lived in the polluted area from 1950s to 1970s and were now
living in other areas of Japan at the time of the examination were classified as Other Area (n = 189,
M/F = 88/101, Age = 58.6 ± 9.9) (Tables 1 and 2, Figure 1).
The Control group was comprised of 227 persons chosen from hospital staff and residents living
around Fukuoka City, Kumamoto City, and Kagoshima City in 2006 and 2007. In this control group,
younger subjects were over-represented, and were excluded. Finally, we selected 142 residents (n = 142,
M/F = 56/86, age = 62.0 ± 10.5, range = 36–86). Most of them had worked in the service sector.
The subjects in the control group were the same as those mentioned in another paper in 2008 [6].
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Table 2. Demographic characteristics of subjects in each area (n = 1115).
Control Area Minamata Area Northern Area Southern Area Other Areas
(n = 142) (n = 259) (n = 279) (n = 246) (n = 189)
Sex, n (%)
Male 56 (39.4) 136 (52.5) 147 (52.7) 121 (49.2) 88 (46.6)
Female 86 (60.6) 123 (47.5) 132 (47.3) 125 (50.8) 101 (53.4)
Age
Mean ± SD 62.0 ± 10.5 62.5 ± 13.6 64.0 ± 11.1 63.0 ± 11.1 58.6 ± 9.9
Range (min–max) 36–86 33–92 33–90 36–88 34–82
Residential history in designated area (DA) more than 1 year, n (%)
In DA > 1 year (DA) 3 (2.1) 234 (90.3) 156 (55.9) 222 (90.2) 174 (92.1)
Not in DA > 1 year (NDA) 139 (97.9) 12 (4.6) 116 (41.6) 19 (7.7) 10 (5.3)
Born after 1968 (BA1968) 0 (0.0) 13 (5.0) 7 (2.5) 5 (2.0) 5 (2.6)
Smoking, n (%)
Non-smoker 109 (77.3) 198 (76.4) 226 (81.0) 185 (75.2) 133 (70.4)
Smoker 32 (22.7) 61 (23.6) 53 (19.0) 61 (24.8) 56 (29.6)
Alcohol drinking, n (%)
Non-drinker 72 (51.1) 136 (52.5) 148 (53.0) 129 (52.4) 98 (51.9)
Drinker 69 (48.9) 123 (47.5) 131 (47.0) 117 (47.6) 91 (48.1)
Frequency of fish intake, n (%)
Three times a day 6 (4.4) 95 (36.7) 166 (59.5) 99 (40.2) 99 (52.4)
Twice a day 7 (5.1) 61 (23.6) 70 (25.1) 94 (38.2) 46 (24.3)
Once a day 27 (19.9) 59 (22.8) 27 (9.7) 35 (14.2) 25 (13.2)
More than once a week 63 (46.3) 35 (13.5) 13 (4.7) 16 (6.5) 15 (7.9)
Less than once a week 33 (24.3) 9 (3.5) 3 (1.1) 2 (0.8) 4 (2.1)
Occupation, n (%)
Fishermen (subject) 0 (0.0) 7 (2.7) 82 (29.4) 32 (13.0) 10 (5.3)
Fishermen (subject’s parent) 2 (1.4) 28 (10.8) 153 (54.8) 78 (31.7) 60 (31.7)
Complications, n (%)
Hypertension 40 (28.2) 85 (32.8) 118 (42.3) 102 (41.5) 43 (22.8)
Renal diseases 3 (2.1) 17 (6.6) 10 (3.6) 13 (5.3) 15 (7.9)
Liver diseases 6 (4.2) 20 (7.7) 17 (6.1) 20 (8.1) 14 (7.4)
Respiratory diseases 12 (8.5) 14 (5.4) 8 (2.9) 6 (2.4) 13 (6.9)
Diabetes Mellitus 3 (2.1) 17 (6.6) 37 (13.3) 24 (9.8) 15 (7.9)
Orthopedic diseases 13 (9.2) 60 (23.2) 72 (25.8) 62 (25.2) 52 (27.5)
Malignant diseases 7 (4.9) 12 (4.6) 11 (3.9) 17 (6.9) 11 (5.8)
History of application for
Minamata disease, n (%) 0 (0.0) 33 (12.7) 24 (8.6) 38 (15.4) 17 (9.0)
Family history of Minamata
disease, n (%) 0 (0.0) 164 (63.3) 108 (38.7) 123 (50.0) 151 (79.9)
Have witnessed abnormal
animal behavior, n (%) No Data 100 (38.6) 103 (36.9) 108 (43.9) 76 (40.2)
2.2. Epidemiological Conditions
Due to the absence of a comprehensive pollution survey in the Minamata area, most of the
residents have not undergone any tests to determine the mercury levels in their bodies resulting
from their exposure to mercury and methylmercury. Therefore, we prepared a questionnaire to
collect information about their places of residence, dietary habits, occupations and family health.
Such information is important and useful, because, although a large part of the local diet consists
of fish, there have been no previous surveys done to gather accurate information. All subjects had
eaten fish and shellfish from the Shiranui Sea. In order to assess the indirect methylmercury exposure,
when subjects were asked about the frequency of fish ingestion they were asked to choose from one of
the five answers (3 times/day, 2 times/day, once/day, more than once/week, less than once/week).
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According to their residential history, subjects were classified into one of the following three
categories. The first category consisted of subjects who had lived in the designated area for at least one
year (DA: n = 786, M/F = 386/400, Age = 63.0 ± 11.3). The second category consisted of subjects who
had not lived in the designated area for at least one year (NDA: n = 158, M/F = 85/72, Age = 63.6 ± 10.0).
Those who had been born or had moved to the polluted on or after 1 January 1969 were classified
under the third category (BA1968: n = 30, M/F = 21/9, Age = 37.4 ± 2.3).
In order to analyze the younger generation, we re-analyzed 30 subjects who were born after
31 December 1968. To evaluate this group, we selected 88 out of 227 subjects whose age was lower
than 49 from the Control Area (M/F = 40/48, Age = 37.5 ± 6.0), and 84 out of 786 exposed subjects
in the designated area who were born after 31 December 1968 (M/F = 44/40, Age = 44.8 ± 2.3) and
whose age was lower than 49 from the four exposed groups.
The subjects’ age, sex, smoking and alcohol drinking habits, frequency of fish intake,
the occupation of the subjects and the subjects’ parents, complications, history of application for
Minamata disease, family history of Minamata disease, and the witnessing of abnormal animal
behavior was analyzed for each group.
2.3. Onset of Symptoms
Subjects from the four polluted areas were asked about the time of onset of their first abnormal
experience supposed to be related to methylmercury exposure, muscle cramps, four-limb numbness,
stumbling tendency, difficulty in fine finger tasks, and limited peripheral vision. The time between
the appearance of the first symptom until all five symptoms (cramps, numbness, stumbling tendency,
difficulty in fine finger tasks, and limited vision) had appeared were calculated. When a subject could
not answer with certainty, the approximate year or median of the generation was used.
The latency period between methylmercury exposure and onset of health problems can be roughly
estimated by this information.
2.4. Questionnaire on Complaints
Our questionnaire consisted of 57 questions. Seven questions were related to sensory impairment,
6 related to somatic pain, 6 related to visual impairment, 3 related to hearing impairment, 3 related
to tasting and smelling problems, 9 related to in-coordination of the extremities, 5 related to other
movement impairment, 4 related to vertigo and dizziness, 3 related to general complaints, 11 related
to emotional and intellectual problems. The subjects were asked to answer each question by selecting
from one of the following four possibilities: (1) Yes, always; (2) Yes, sometimes; (3) Yes in the past
but No at present; (4) Never. The prevalence of each complaint was calculated for each group and
compared. The subjects completed the questionnaire before they were examined. Any subjects who
were unable to complete the questionnaire by themselves were questioned orally. The results of the
questionnaires were reviewed prior to the examination.
2.5. Neurological Examination
A neurological examination was performed on all subjects. The examination comprised the
following tests: dysarthria, auditory disturbance, visual constriction, gait disturbance, tandem gait,
Mann’s test, balancing on one foot (eyes open and closed), finger-to-nose test (eyes open and closed),
diadochokinesis, heel-to-knee test, postural tremor of hand, and superficial sensory disturbance
(touch and pain).
Dysarthria, auditory disturbance, visual constriction, and postural tremor were judged as present
or absent. Dysarthria, auditory disturbance, and visual field were judged by the examining physician
without using special instruments. Visual disturbance was considered present when the subject had
a lateral visual field of 80 degrees or less, as measured by the confrontation visual field test.
Limb and truncal ataxia were judged as absent, mildly abnormal, or distinctly abnormal. Tandem
gait disturbance was judged as distinctly abnormal if the subject could not walk more than 5 steps
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and as mildly abnormal if they could walk 5 steps but were unstable. The one-foot standing and
Mann’s test were judged as distinctly abnormal if it was impossible for the subject to keep their
balance for more than 3 s and as mildly abnormal if they could keep their balance for more than 3 s.
Finger-to-nose test and heel-to-knee test were judged as distinctly abnormal if there was constant
dysmetria or decomposition and as mildly abnormal if there was uncertain dysmetria, decomposition,
or slow progress to the destination. Dysdiadochokinesis was judged as distinctly abnormal if
there was a constant abnormality and as mildly abnormal if there was an uncertain abnormality
or slow movement.
For sensory disturbance, tactile sense was examined by comparing chest area and dorsal side of
both hands and both foot by using a calligraphy brush. After that, truncal and perioral tactile sense
was examined by touching the skin softly with the brush. Pain sense was examined by comparing chest
area and dorsal side of both hands and both foot by using a 20 g needle for pain inspection. After that
truncal and perioral pain sense were examined by the same needle. The needle was attached to a 20 g
handle. We evaluated the tactile and pain sense both by relative evaluation between different sites of
bodies and by absolute evaluation, especially for pain. When general tactile sensory disturbance was
suspected, a physician asked of the subject to close his or her eyes and indicate which part of their
body was being touched by the calligraphy brush.
One-hundred and forty-four doctors, including neurological specialists, carried out primary and
secondary examinations on the subjects. The sensory examination was repeated by more trained
physicians on all subjects.
All the physicians participating in the study were trained in the procedures by direct instruction,
written instruction or visual instruction in the form of video tutorials. The physicians who performed
the neurological examination in the control areas were different from those in the polluted area,
but the methods and criteria of the neurological examination was the same as those preformed in the
polluted areas.
2.6. Statistical Methods
As formerly mentioned in Section 2.1 in this chapter, we classified the methylmercury-exposed
subjects into four groups: Minamata Area, Northern Area, Southern Area, and Other Areas.
We compared them with the Control Area. All the calculations were performed using MS Excel
2010 and STATA ver.14. The prevalence of data was analyzed by using MS Excel and STATA. Logistic
regression analysis and correlation analysis were performed by STATA. When the prevalence of the
control group was zero in an item of symptoms or signs, we postulated that the eldest subject in the
control group was positive and calculated the OR and confidence interval by STATA. The analysis of
the onset year was done in MS Excel.
2.6.1. Questionnaire on Symptoms and Neurological Examination
The data percentages of the answers “always yes” and “always or sometimes yes” from the
questionnaire were summed, the results analyzed and the correlations between the control and the four
exposed groups were calculated. A total of 23 questions out of the 57 questions asked were analyzed.
Three of the 7 questions relating to sensory impairment, 2 of the 6 relating to somatic pain, 1 of the 6
relating to visual impairment, 1 of the 3 relating to hearing impairment, 2 of the 3 relating to tasting
and smelling problems, 5 of the 9 relating to in-coordination of the extremities, 2 of the 5 relating to
other movement impairment, 1 of the 4 relating to vertigo and dizziness, 1 of the 3 relating to general
complaints, and 5 of the 11 relating to emotional and intellectual problems were selected and analyzed.
The prevalence of each sign and symptom from the five groups (1 control and 4 exposed groups)
were calculated. Odd’s ratio for the association between area and symptoms or signs were calculated
by logistic regression analysis. Correlation of prevalence among the control group and the four other
exposed groups were calculated for symptoms (always “yes”), symptoms (always or sometimes “yes”),
and neurological signs.
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2.6.2. Score for Symptoms (Always), Symptoms (Always and Sometimes), and Neurological Signs
To evaluate the severity of the neurological signs, we added (a) mark(s) to positive signs and
symptoms, and we calculated the total score in the exposed four groups.
As to the symptom score (always), we added 1 point when a subject’s answer was “always”.
Symptoms score (always) ranged from 0 to 23. As to symptoms (always and sometimes), we added
2 points when a subject’s answer was “always”, and added 1 point when a subject’s answer was
“sometimes”. Symptoms score (always and sometimes) ranged from 0 to 46. A score of zero was given
to “no answer” items.
As to the neurological signs, the cranial nerve score (6 points) consists of dysarthria (2), auditory
disturbance (2), visual constriction (2). The upper, lower ataxia and tremor score (5 points) consists of
finger-to-nose test (eyes open) (1), finger-to-nose test (eyes closed) (1), diadochokinesis (1), heel-to-knee
test (1), and postural tremor (1). The truncal ataxia score (5 points) consists of normal gait disturbance
(1), tandem gait disturbance (1), Mann’s test (1), balancing on one foot (eyes open) (1), and balancing
on one foot (eyes closed) (1). To evaluate upper, lower, and truncal ataxia, 1 point was given for both
mild and distinct abnormalities. The sensory score (6 points) consists of four-limb peripheral touch
disturbance (1), perioral touch disturbance (1), systemic touch disturbance below the neck (1), four-limb
peripheral pain disturbance (1), perioral pain disturbance (1), systemic pain disturbance below the
neck (1). We finally totaled the four scores (22 points) for cranial nerve (6), upper, lower ataxia and
tremor (5), truncal ataxia (5), and sensory (6). A score of zero was given to the “no data” item.
The scores were calculated for each area. To research the presence of dose-response relationship,
each score according to the frequency of fish ingestion in the exposed groups were calculated.
2.6.3. Analyses among Fish Ingestion, Score of Signs and Symptoms, and the Onset of Symptoms
In Minamata, most of the residents had not had their mercury levels measured during the most
polluted period or in the subsequent period when mercury level had decreased. Instead of such
direct mercury pollution values, we used frequency of fish ingestion as an indirect indication of
methylmercury exposure.
To estimate dose-response (from methylmercury exposure to health effects) relationships,
we calculated scores of signs and symptoms for each frequency of fish ingestion. In order to estimate
the difference of latency period from exposure of mercury by exposure levels, we calculated the average
year of onset and the average interval between the first symptom and the onset of each following
symptom in each frequency of fish ingestion.
Lastly, we evaluated the correlation between the score for signs and symptoms, and onset period
of symptoms to estimate difference of latency period and severity of methylmercury poisoning.
2.6.4. Characteristics of Signs and Symptoms in Subjects Whose Sensory Disturbance Was
Not Recognized
To estimate the degree of health disturbance in subjects in whom sensory disturbance had not
been detected during their physical examination, we re-classified the exposed subjects into two groups.
Sensory disturbance (−) group (n = 91, M/F = 64/27, Age = 59.7 ± 13.3) consisted of subjects whose
sensory score was zero, in whom neither four-limb peripheral disturbance, perioral disturbance,
systemic disturbance below the neck in tactile or pain examination met the criteria required for
recognition. Sensory disturbance (+) group consisted of other subjects whose sensory score was one to
six (n = 882, M/F = 428/454, Age = 62.6 ± 11.6). The control group was the same as those used in the
first analysis. We compared signs and symptoms between the three groups.
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3. Results
3.1. The Subjects’ Background
The demographic characteristics of the subjects from the five groups are shown in Table 2. The age
for Other Areas was significantly lower than other groups. Smoking and alcohol drinking was almost
the same in the different groups. The frequency of fish intake was significantly higher in the exposed
groups than the control. Hypertension, diabetes mellitus, and orthopedic diseases were significantly
more prevalent in the polluted area. Subjects who had applied for Minamata disease certification were
only 8.6% to 15.4%, even in the polluted area, although many (38.7–79.9%) of them had a family history
of Minamata disease.
3.2. Questionnaire on Symptoms
The symptoms (always) are shown in Table 3 and Figure 2. For most of the symptoms (always),
Odds ratio (OR) for the association between area and signs or symptoms calculated by logistic
regression analysis and adjusted for age, sex, diabetes mellitus, and orthopedic diseases were very
high and the lower limits of the OR were higher than 1, except for two questions (“perioral numbness”
and “swaying or dizziness” between control and Minamata Area). The correlation among the four
exposed groups on the prevalence of symptoms (always) (Table 4) were extremely high (0.9246–0.9611)
whereas the correlation between the control and the four exposed groups were very low (0.2751–0.3866).
Table 3. Prevalence of symptoms (Always) and adjusted * odds ratios (OR) for the association between
area and symptoms (n = 1115).
Control Area Minamata Area Northern Area Southern Area Other Areas
Sensory numbness in both hands
case/N (%) 3/138 (2.2) 98/259 (37.8) 116/278 (41.7) 126/246 (51.2) 73/189 (38.6)
OR (95% CI) 1 (reference) 27 (8.3–87) 30 (9.4–98) 46 (14–148) 29 (9.0–96)
Sensory numbness in both legs
case/N (%) 1/139 (0.7) 98/259 (37.8) 125/279 (44.8) 126/246 (51.2) 68/189 (36.0)
OR (95% CI) 1 (reference) 80 (11–586) 100 (14–731) 140 (19–1022) 86 (12–633)
Perioral numbness **
case/N (%) 0/107 (0.0) 15/259 (5.8) 25/279 (9.0) 31/246 (12.6) 14/189 (7.4)
OR (95% CI) 1 (reference) 5.8 (0.7–45) 8.8 (1.2–66) 13.9 (1.9–104) 9.6 (1.2–75)
Headache **
case/N (%) 0/137 (0.0) 44/259 (17.0) 52/279 (18.6) 59/246 (24) 47/189 (24.9)
OR (95% CI) 1 (reference) 31 (4.2–228) 35 (4.7–254) 47 (6.4–344) 49 (6.6–358)
Muscle cramps
case/N (%) 5/137 (3.6) 62/259 (23.9) 65/279 (23.3) 59/245 (24.1) 42/189 (22.2)
OR (95% CI) 1 (reference) 8.5 (3.3–22) 8.1 (3.2–21) 8.5 (3.3–22) 8.3 (3.2–22)
Limited peripheral vision
case/N (%) 1/138 (0.7) 67/259 (25.9) 91/279 (32.6) 94/246 (38.2) 59/72 (81.9)
OR (95% CI) 1 (reference) 47 (6.5–347) 63 (8.6–457) 84 (12–614) 71 (9.6–520)
Difficulty in hearing
case/N (%) 12/137 (8.8) 90/259 (34.7) 106/278 (38.1) 130/246 (52.8) 71/189 (37.6)
OR (95% CI) 1 (reference) 5.1 (2.7–9.9) 5.5 (2.9–11) 11 (5.9–22) 7.2 (3.7–14)
Difficulty in smelling
case/N (%) 1/139 (0.7) 45/259 (17.4) 58/279 (20.8) 46/245 (18.8) 31/189 (16.4)
OR (95% CI) 1 (reference) 29 (3.9–213) 36 (5.0–266) 32 (4.4–238) 31 (4.1–228)
Difficulty in tasting **
case/N (%) 0/140 (0.0) 34/259 (13.1) 50/279 (17.9) 46/245 (18.8) 23/189 (12.2)
OR (95% CI) 1 (reference) 20 (2.7–146) 28 (3.9–208) 31 (4.2–226) 20 (2.7–151)
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Table 3. Cont.
Control Area Minamata Area Northern Area Southern Area Other Areas
Stumbling tendency **
case/N (%) 0/106 (0.0) 72/259 (27.8) 99/279 (35.5) 89/246 (36.2) 48/189 (25.4)
OR (95% CI) 1 (reference) 41 (5.6–304) 59 (8.0–429) 63 (8.6–463) 45 (6.1–336)
Staggering **
case/N (%) 0/107 (0.0) 57/259 (22.0) 76/278 (27.3) 73/246 (29.7) 33/189 (17.5)
OR (95% CI) 1 (reference) 29 (3.9–212) 38 (5.2–280) 46 (6.2–337) 29 (3.8–215)
Difficulty in fine finger tasks **
case/N (%) 0/140 (0.0) 94/259 (36.3) 136/279 (48.7) 139/246 (56.5) 87/189 (46.0)
OR (95% CI) 1 (reference) 77 (11–562) 128 (18–930) 182 (25–1326) 135 (18–987)
Difficulty in buttoning **
case/N (%) 0/140 (0.0) 52/259 (20.1) 73/279 (26.2) 53/245 (21.6) 28/189 (14.8)
OR (95% CI) 1 (reference) 31 (4.2–228) 43 (5.9–319) 36 (4.9–267) 30 (4.0–228)
Dropping things held in the hand **
case/N (%) 0/140 (0.0) 39/259 (15.1) 60/279 (21.5) 56/246 (22.8) 22/189 (11.6)
OR (95% CI) 1 (reference) 24 (3.2–176) 36 (4.9–266) 41 (5.6–303) 22 (3.0–170)
Difficulty in speaking words or sentences well **
case/N (%) 0/140 (0.0) 29/259 (11.2) 41/279 (14.7) 41/246 (16.7) 16/189 (8.5)
OR (95% CI) 1 (reference) 17 (2.3–125) 23 (3.1–167) 28 (3.8–206) 15 (2.0–118)
Postural hand tremor
case/N (%) 2/138 (1.4) 41/259 (15.8) 50/279 (17.9) 48/246 (19.5) 31/189 (16.4)
OR (95% CI) 1 (reference) 12 (2.9–51) 14 (3.2–57) 16 (3.8–67) 16 (3.7–68)
Swaying or dizziness **
case/N (%) 0/140 (0.0) 10/259 (3.9) 22/279 (7.9) 15/246 (6.1) 14/189 (7.4)
OR (95% CI) 1 (reference) 5.5 (0.7–44) 12 (1.5–88) 9.1 (1.2–70) 13 (1.7–105)
General fatigue
case/N (%) 1/140 (0.7) 99/259 (38.2) 112/279 (40.1) 131/246 (53.3) 74/189 (39.2)
OR (95% CI) 1 (reference) 90 (12–657) 98 (14–714) 166 (23–1205) 94 (13–686)
Lack of motivation to do things
case/N (%) 1/140 (0.7) 43/259 (16.6) 55/279 (19.7) 63/246 (25.6) 40/189 (21.2)
OR (95% CI) 1 (reference) 32 (4.4–237) 40 (5.5–294) 56 (7.6–409) 46 (6.2–341)
Losing your train of thought during conversations **
case/N (%) 0/139 (0.0) 32/259 (12.4) 29/279 (10.4) 44/246 (17.9) 17/189 (9.0)
OR (95% CI) 1 (reference) 20 (2.6–146) 16 (2.1–118) 31 (4.1–225) 15 (2.0–118)
Forgetfulness
case/N (%) 1/140 (0.7) 71/259 (27.4) 89/279 (31.9) 93/246 (37.8) 47/189 (24.9)
OR (95% CI) 1 (reference) 54 (7.4–396) 65 (8.9–473) 89 (12–651) 57 (7.7–419)
Irritation **
case/N (%) 0/140 (0.0) 63/259 (24.3) 87/279 (31.2) 74/246 (30.1) 50/189 (26.5)
OR (95% CI) 1 (reference) 46 (6.3–337) 65 (9.0–475) 61 (8.4–446) 51 (6.9–373)
Anxiety **
case/N (%) 0/106 (0.0) 78/259 (30.1) 77/279 (27.6) 72/246 (29.3) 56/189 (29.6)
OR (95% CI) 1 (reference) 48 (6.6–354) 43 (5.8–312) 46 (6.2–335) 48 (6.5–351)
* Adjusted for age, sex, diabetes mellitus and orthopedic diseases; ** When prevalence of the control group was
zero, we postulated that a positive finding was found in the eldest subject in the control group and calculated the
OR and 95% confidence interval.
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Figure 2. Prevalence of symptoms (Always) in each area. Prevalence was higher in the four exposed
groups than that in the control area. The symptomatic patterns were similar among the four groups.
Table 4. Correlation of prevalence of symptoms (Always) among each area.
Correlation/(p-value) Control Area Minamata Area Northern Area Southern Area
Minamata Area 0.3641 1.0000
(p-value) (0.0876)
Northern Area 0.2751 0.9611 1.0000
(p-value) (0.2040) (0.0000)
Southern Area 0.3866 0.9540 0.9581 1.0000
(p-value) (0.0684) (0.0000) (0.0000)
Other Areas 0.3609 0.9417 0.9246 0.9460
(p-value) (0.0906) (0.0000) (0.0000) (0.0000)
As to the symptoms (always or sometimes), the OR for the same analysis and adjustment were
very high and the lower limits of the OR were all higher than 1 (Table 5, Figure 3). The correlation
among the four exposed groups on the prevalence of symptoms (always and sometimes) (Table 6)
were extremely high (0.9778–0.9875) whereas the correlation between the control and the four exposed
groups were lower (0.6501–0.7046).
Table 5. Prevalence of symptoms (Always and Sometimes) and adjusted * odds ratios (OR) for the
association between area and symptoms (n = 1115).
Control Area Minamata Area Northern Area Southern Area Other Areas
Sensory numbness in both hands
case/N (%) 10/138 (7.2) 221/259 (85.3) 244/278 (87.8) 223/246 (90.7) 160/189(84.7)
OR (95% CI) 1 (reference) 79 (38–165) 97 (46–206) 130 (59–284) 75 (35–161)
Sensory numbness in both legs
case/N (%) 10/139 (7.2) 219/259 (84.6) 237/279 (84.9) 215/246 (87.4) 159/189(84.1)
OR (95% CI) 1 (reference) 77 (37–161) 75 (36–156) 94 (44–201) 81 (37–175)
Perioral numbness **
case/N (%) 0/107 (0.0) 104/259 (40.2) 136/279 (48.7) 118/246 (48.0) 81/189 (42.9)
OR (95% CI) 1 (reference) 73 (10–533) 104 (14–760) 101 (14–738) 87 (12–636)
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Table 5. Cont.
Control Area Minamata Area Northern Area Southern Area Other Areas
Headache
case/N (%) 31/137 (22.6) 208/259 (80.3) 219/279 (78.5) 198/246 (80.5) 154/189(81.5)
OR (95% CI) 1 (reference) 17 (10–29) 16 (9.8–28) 18 (10–30) 17 (9.7–30)
Muscle cramps
case/N (%) 53/137 (38.7) 237/259 (91.5) 256/279 (91.8) 220/245 (89.8) 172/189(91.0)
OR (95% CI) 1 (reference) 18 (10–32) 19 (11–33) 15 (8.4–25) 17 (9.2–32)
Limited peripheral vision
case/N (%) 10/138 (7.2) 171/259 (66.0) 198/279 (71.0) 192/246 (78.0) 132/189(69.8)
OR (95% CI) 1 (reference) 25 (12–49) 29 (15–59) 44 (22–90) 31 (15–63)
Difficulty in hearing
case/N (%) 25/137 (18.2) 178/259 (68.7) 212/278 (76.3) 196/246 (79.7) 133/189(70.4)
OR (95% CI) 1 (reference) 9.8 (5.8–16) 13 (8.0–23) 17 (10–30) 12 (6.8–21)
Difficulty in smelling
case/N (%) 7/139 (0.5) 124/259 (47.9) 137/279 (49.1) 139/245 (56.7) 96/189 (50.8)
OR (95% CI) 1 (reference) 17 (7.8–39) 18 (8.1–40) 25 (11–55) 20 (8.8–45)
Difficulty in tasting
case/N (%) 3/140 (2.1) 119/259 (45.9) 148/279 (53.0) 140/245 (57.1) 95/189 (50.3)
OR (95% CI) 1 (reference) 39 (12–126) 51 (16–166) 61 (19–196) 47 (14–152)
Stumbling tendency
case/N (%) 20/106 (18.9) 213/259 (82.2) 250/279 (89.6) 217/246 (88.2) 165/189(87.3)
OR (95% CI) 1 (reference) 25 (13–46) 42 (22–81) 37 (19–72) 39 (20–78)
Staggering
case/N (%) 10/107 (9.3) 197/259 (76.1) 227/278 (81.7) 205/246 (83.3) 149/189(78.8)
OR (95% CI) 1 (reference) 35 (17–73) 47 (22–98) 53 (25–113) 45 (21–97)
Difficulty in fine finger tasks
case/N (%) 11/140 (7.9) 195/259 (75.3) 224/279 (80.3) 215/246 (87.4) 148/189(78.3)
OR (95% CI) 1 (reference) 36 (18–71) 46 (23–92) 81 (39–167) 45 (22–93)
Difficulty in buttoning **
case/N (%) 0/140 (0.0) 139/259 (53.7) 177/279 (63.4) 149/245 (60.8) 106/189(56.1)
OR (95% CI) 1 (reference) 158 (22–1147) 224 (31–1629) 211 (29–1536) 199 (27–1458)
Dropping things held in the hand
case/N (%) 9/140 (6.4) 173/259 (66.8) 212/279 (76.0) 187/246 (76.0) 139/189(73.5)
OR (95% CI) 1 (reference) 33 (16–68) 51 (24–106) 50 (24–106) 47 (22–100)
Difficulty in speaking words or sentences well
case/N (%) 4/140 (2.9) 136/259 (52.5) 157/279 (56.3) 154/246 (62.6) 101/189(53.4)
OR (95% CI) 1 (reference) 39 (14–108) 46 (16–128) 60 (21–167) 43 (15–122)
Postural hand tremor
case/N (%) 7/138 (5.1) 160/259 (61.8) 188/279 (67.4) 171/246 (69.5) 116/189(61.4)
OR (95% CI) 1 (reference) 30 (13–66) 37 (17–83) 42 (19–94) 31 (14–70)
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Table 5. Cont.
Control Area Minamata Area Northern Area Southern Area Other Areas
Swaying or dizziness
case/N (%) 8/140 (5.7) 117/259 (45.2) 157/279 (56.3) 138/246 (56.1) 101/189(53.4)
OR (95% CI) 1 (reference) 14 (6.6–30) 22 (10–47) 22 (10–47) 20 (9.2–43)
General fatigue
case/N (%) 30/140 (21.4) 234/259 (90.3) 253/279 (90.7) 230/246 (93.5) 171/189(90.5)
OR (95% CI) 1 (reference) 43 (23–79) 46 (25–85) 65 (33–128) 37 (19–71)
Lack of motivation to do things
case/N (%) 31/140 (22.1) 202/259 (78.0) 233/279 (83.5) 215/246 (87.4) 153/189(81.0)
OR (95% CI) 1 (reference) 15 (9.0–25) 22 (13–38) 30 (17–52) 16 (9.2–28)
Losing your train of thought during conversations
case/N (%) 11/139 (7.9) 169/259 (65.3) 204/279 (73.1) 183/246 (74.4) 125/189(66.1)
OR (95% CI) 1 (reference) 24 (12–46) 34 (17–67) 36 (18–72) 26 (13–51)
Forgetfulness
case/N (%) 79/140 (56.4) 240/259 (92.7) 257/279 (92.1) 235/246 (95.5) 176/189(93.1)
OR (95% CI) 1 (reference) 11 (6.2–20) 10 (5.4–17) 18 (8.8–37) 13 (6.4–25)
Irritation
case/N (%) 46/140 (32.9) 204/259 (78.8) 242/279 (86.7) 214/246 (87.0) 164/189(86.8)
OR (95% CI) 1 (reference) 8.0 (5.0–13) 14 (8.6–24) 14 (8.5–24) 13 (7.6–23)
Anxiety
case/N (%) 8/106 (7.5) 205/259 (79.2) 225/279 (80.6) 209/246 (85.0) 155/189(82.0)
OR (95% CI) 1 (reference) 49 (23–109) 55 (25–122) 74 (33–166) 60 (27–136)
* Adjusted for age, sex, diabetes mellitus and orthopedic diseases; ** When prevalence of the control group was
zero, we postulated that a positive finding was found in the eldest subject in the control group and calculated the
OR and 95% confidence interval.
 
Figure 3. Prevalence of symptoms (Always and Sometimes) in each area. Prevalence was higher in the
four exposed groups than that in the control area. The symptomatic patterns were similar among the
four groups.
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Table 6. Correlation of prevalence of symptoms (Always and Sometimes) among each area.
Correlation/(p-Value) Control Area Minamata Area Northern Area Southern Area
Minamata Area 0.6921 1.0000
(p-value) (0.0003)
Northern Area 0.6708 0.9778 1.0000
(p-value) (0.0005) (0.0000)
Southern Area 0.6501 0.9787 0.9786 1.0000
(p-value) (0.0008) (0.0000) (0.0000)
Other Areas 0.7046 0.9875 0.9849 0.9795
(p-value) (0.0002) (0.0000) (0.0000) (0.0000)
3.3. Neurological Signs
The results of the neurological signs are shown in Table 7 and Figure 4. Almost all signs were
higher in the exposed groups than the control except for the “finger-nose test (opening eyes) (distinct)”
in the three polluted areas and “adiadokokinesis (distinct)” in the two polluted areas.
The correlation among the four exposed groups on the prevalence of neurological signs (Table 8)
were extremely high (0.9716–0.9864), compared to the correlation between the control and the four
exposed groups (0.6327–0.6802).
Table 7. Prevalence of neurological findings and adjusted* odds ratios (OR) for the association between
area and neurological findings (n = 1115).
Control Area Minamata Area Northern Area Southern Area Other Areas
Dysarthria
case/N (%) 2/141 (1.4) 34/256 (13.3) 37/276 (13.4) 41/242 (16.9) 22/186 (11.8)
OR (95% CI) 1 (reference) 9.7 (2.3–41) 9.3 (2.2–39) 13 (3.1–55) 9.5 (2.2–41)
Hearing loss
case/N (%) 10/141 (7.1) 59/258 (22.9) 54/279 (19.4) 65/244 (26.6) 27/186 (14.5)
OR (95% CI) 1 (reference) 3.5 (1.7–7.1) 2.6 (1.3–5.4) 4.4 (2.1–9.0) 2.6 (1.2–5.7)
Visual field disturbance **
case/N (%) 0/142 (0.0) 51/255 (20.0) 66/276 (23.9) 61/243 (25.1) 49/187 (26.2)
OR (95% CI) 1 (reference) 33 (4.4–240) 39 (5.4–288) 44 (6.0–322) 53 (7.2–392)
Normal gait disturbance (distinct) **
case/N (%) 0/137 (0.0) 24/238 (10.1) 25/255 (9.8) 36/221 (16.3) 15/174 (8.6)
OR (95% CI) 1 (reference) 12 (1.5–87) 11 (1.5–83) 22 (3.0–164) 14 (1.8–107)
Normal gait disturbance (mild-distinct) **
case/N (%) 0/137 (0.0) 50/238 (21.0) 41/255 (16.1) 52/221 (23.5) 26/174 (14.9)
OR (95% CI) 1 (reference) 30 (4.0–222) 21 (2.8–156) 39 (5.3–292) 32 (4.2–242)
Tandem gait disturbance (distinct)
case/N (%) 3/141 (2.1) 32/248 (12.9) 41/271 (15.1) 32/241 (13.3) 14/186 (7.5)
OR (95% CI) 1 (reference) 6.0 (1.8–21) 8.0 (2.4–27) 7.2 (2.1–24) 5.7 (1.6–21)
Tandem gait disturbance (mild-distinct)
case/N (%) 15/141 (10.6) 115/248 (46.4) 151/271 (55.7) 135/241 (56.0) 84/186 (45.2)
OR (95% CI) 1 (reference) 8.0 (4.3–15) 11 (6.0–20) 12 (6.7–23) 10 (5.3–19)
Mann test (distinct)
case/N (%) 3/109 (2.8) 67/252 (26.6) 76/268 (28.4) 62/242 (25.6) 39/187 (20.9)
OR (95% CI) 1 (reference) 12 (3.7–40) 13 (3.9–42) 12 (3.5–39) 11 (3.3–37)
Mann test (mild-distinct)
case/N (%) 26/109 (23.9) 153/252 (60.7) 176/268 (65.7) 151/242 (62.4) 114/187 (61.0)
OR (95% CI) 1 (reference) 5.4 (3.2–9.2) 6.2 (3.6–11) 5.6 (3.3–9.5) 6.3 (3.6–11)
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Table 7. Cont.
Control Area Minamata Area Northern Area Southern Area Other Areas
One-foot standing abnormality (eyes open) (distinct)
case/N (%) 2/141 (1.4) 43/253 (17.0) 61/269 (22.7) 47/242 (19.4) 27/189 (14.3)
OR (95% CI) 1 (reference) 14 (3.3–60) 21 (5.0–89) 18 (4.3–78) 19 (4.4–85)
One-foot standing abnormality (eyes open) (mild-distinct)
case/N (%) 16/141 (11.3) 121/253 (47.8) 151/269 (56.1) 125/242 (51.7) 85/189 (45.0)
OR (95% CI) 1 (reference) 8.4 (4.6–15) 11 (6.0–20) 9.7 (5.3–18) 9.7 (5.2–18)
One-foot standing abnormality (eyes shut) (distinct)
case/N (%) 16/142 (11.3) 128/252 (50.8) 135/269 (50.2) 115/243 (47.3) 78/188 (41.5)
OR (95% CI) 1 (reference) 9.7 (5.3–18) 8.4 (4.6–15) 8.0 (4.4–15) 8.2 (4.4–15)
One-foot standing abnormality (eyes shut) (mild-distinct)
case/N (%) 75/142 (52.8) 202/252 (80.2) 228/269 (84.8) 195/243 (80.2) 150/188 (79.8)
OR (95% CI) 1 (reference) 4.5 (2.7–7.4) 5.1 (3.1–8.5) 3.9 (2.4–6.4) 4.9 (2.9–8.3)
Finger-nose test (eyes open) (distinct) **
case/N (%) 0/140 (0.0) 10/254 (3.9) 13/264 (4.9) 13/233 (5.6) 11/183 (6.0)
OR (95% CI) 1 (reference) 5.2 (0.6–41) 6.5 (0.8–51) 7.8 (0.99995–61) 9.4 (1.2–75)
Finger-nose test (eyes open) (mild-distinct) **
case/N (%) 0/140 (0.0) 32/254 (12.6) 61/264 (23.1) 50/233 (21.5) 29/183 (15.8)
OR (95% CI) 1 (reference) 19 (2.6–142) 39 (5.4–288) 37 (5.0–272) 29 (3.8–214)
Finger-nose test (eyes shut) (distinct) **
case/N (%) 0/139 (0.0) 34/251 (13.5) 31/262 (11.8) 35/233 (15) 28/182 (15.4)
OR (95% CI) 1 (reference) 21 (2.9–157) 18 (2.5–137) 25 (3.4–185) 29 (3.8–215)
Finger-nose test (eyes shut) (mild-distinct)
case/N (%) 3/139 (2.2) 69/251 (27.5) 95/262 (36.3) 86/233 (36.9) 52/182 (28.6)
OR (95% CI) 1 (reference) 17 (5.1–54) 24 (7.4–78) 26 (7.9–84) 20 (5.9–64)
Adiadokokinesis (distinct) **
case/N (%) 0/135 (0.0) 11/245 (4.5) 17/270 (6.3) 19/228 (8.3) 15/178 (8.4)
OR (95% CI) 1 (reference) 5.3 (0.7–42) 7.4 (0.96–56) 10.3 (1.4–79) 11.8 (1.5–91)
Adiadokokinesis (mild-distinct)
case/N (%) 3/135 (2.2) 40/245 (16.3) 85/270 (31.5) 61/228 (26.8) 43/178 (24.2)
OR (95% CI) 1 (reference) 7.9 (2.4–26) 18 (5.6–59) 15 (4.6–49) 16 (4.7–52)
Heel-knee test (distinct) **
case/N (%) 0/135 (0.0) 17/226 (7.5) 15/239 (6.3) 19/207 (9.2) 9/163 (5.5)
OR (95% CI) 1 (reference) 9.8 (1.3–75) 7.8 (1.0–60) 12 (1.6–93) 8.4 (1.0–68)
Heel-knee test (mild-distinct)
case/N (%) 3/135 (2.2) 60/226 (26.5) 66/239 (27.6) 68/207 (32.9) 49/163 (30.1)
OR (95% CI) 1 (reference) 16 (4.8–51) 16 (4.9–52) 21 (6.5–70) 22 (6.6–73)
Postural Hand tremor
case/N (%) 6/136 (4.4) 48/259 (18.5) 58/279 (20.8) 56/246 (22.8) 38/189 (20.1)
OR (95% CI) 1 (reference) 4.7 (2.0–11) 5.3 (2.2–13) 6.1 (2.5–15) 5.6 (2.3–14)
Touch disturbance (four-limb peripheral)
case/N (%) 1/142 (0.7) 159/259 (61.4) 204/279 (73.1) 164/246 (66.7) 126/189 (66.7)
OR (95% CI) 1 (reference) 218 (30–1581) 368 (50–2678) 271 (37–1977) 265 (36–1944)
Touch disturbance (perioral) **
case/N (%) 0/142 (0.0) 63/259 (24.3) 71/279 (25.4) 50/246 (20.3) 45/189 (23.8)
OR (95% CI) 1 (reference) 45 (6.2–331) 48 (6.6–353) 36 (4.9–264) 45 (6.1–330)
Touch disturbance (systemic) **
case/N (%) 0/142 (0.0) 43/259 (16.6) 49/279 (17.6) 43/246 (17.5) 25/189 (13.2)
OR (95% CI) 1 (reference) 28 (3.9–209) 30 (4.1–223) 31 (4.2–225) 24 (3.2–179)
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Table 7. Cont.
Control Area Minamata Area Northern Area Southern Area Other Areas
Pain disturbance (four-limb peripheral)
case/N (%) 2/142 (1.4) 185/259 (71.4) 224/279 (80.3) 167/246 (67.9) 136/189 (72.0)
OR (95% CI) 1 (reference) 183 (44–760) 296 (71–1238) 153 (37–636) 183 (44–767)
Pain disturbance (perioral) **
case/N (%) 0/142 (0.0) 103/259 (39.8) 104/279 (37.3) 65/246 (26.4) 60/189 (31.7)
OR (95% CI) 1 (reference) 93 (13–673) 83 (11–603) 50 (6.9–367) 67 (9.1–491)
Pain disturbance (systemic) **
case/N (%) 0/142 (0.0) 56/259 (21.6) 73/279 (26.2) 56/246 (22.8) 38/189 (20.1)
OR (95% CI) 1 (reference) 38 (5.2–281) 49 (6.7–355) 41 (5.6–300) 37 (5.0–273)
* Adjusted for age, sex, diabetes mellitus and orthopedic diseases; ** When prevalence of the control group was
zero, we postulated that a positive finding was found in the eldest subject in the control group and calculated the
OR and 95% confidence interval.
 
Figure 4. Prevalence of neurological signs in each area. Prevalence was higher in the four exposed
groups than that in the control area. The patterns of signs were similar among the four groups.
Table 8. Correlation of prevalence of neurological findings among each area.
Correlation/(p-Value) Control Area Minamata Area Northern Area Southern Area
Minamata Area 0.6709 1.0000
(p-value) (0.0001)
Northern Area 0.6327 0.9792 1.0000
(p-value) (0.0003) (0.0000)
Southern Area 0.6802 0.9716 0.9823 1.0000
(p-value) (0.0001) (0.0000) (0.0000)
Other Areas 0.6518 0.9778 0.9864 0.9771
(p-value) (0.0002) (0.0000) (0.0000) (0.0000)
3.4. Scores of Signs and Symptoms
Scores of signs and symptoms were shown in Table 9. All scores were significantly higher and also
similar in the four exposed groups. After recalculating the data in DA, NDA, and BA1968, even NDA
and BA1968, scores were extremely high in the exposed groups (Table 10).
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Table 9. Score of signs and symptoms in each area (n = 1115).
Control Area Minamata Area Northern Area Southern Area Other Areas
(n = 142) (n = 259) (n = 279) (n = 246) (n = 189)
Symptom score (always)
Mean ± SD 0.2 ± 0.5 5.1 ± 4.9 6.1 ± 5.0 6.9 ± 5.4 5.3 ± 4.9
Range (min–max) 0–3 0–22 0–23 0–22 0–23
Symptom score (always and sometimes)
Mean ± SD 3.2 ± 3.0 21.2 ± 9.2 23.3 ± 9.0 24.7 ± 9.2 21.9 ± 9.4
Range (min–max) 0–15 2–45 1–46 3–45 2–46
Cranial nerve score
Mean ± SD 0.2 ± 0.6 1.1 ± 1.7 1.1 ± 1.5 1.4 ± 1.8 1 ± 1.5
Range (min–max) 0–2 0–6 0–6 0–6 0–6
Upper, lower ataxia and tremor score
Mean ± SD 0.1 ± 0.4 1.0 ± 1.2 1.3 ± 1.5 1.3 ± 1.5 1.1 ± 1.4
Range (min–max) 0–3 0–5 0–5 0–5 0–5
Truncal ataxia score
Mean ± SD 0.9 ± 1.0 2.5 ± 1.7 2.7 ± 1.6 2.7 ± 1.6 2.4 ± 1.6
Range (min–max) 0–3 0–5 0–5 0–5 0–5
Sensory score
Mean ± SD 0.0 ± 0.2 2.4 ± 1.5 2.6 ± 1.5 2.2 ± 1.3 2.3 ± 1.2
Range (min–max) 0–2 0–6 0–6 0–6 0–5
Total neurological score
Mean ± SD 1.2 ± 1.4 6.9 ± 4.5 7.7 ± 4.2 7.6 ± 4.3 6.8 ± 4.0
Range (min–max) 0–8 0–20 0–21 0–21 0–19
Table 10. Score of signs and symptoms in DA, NDA, and BA1968 (n = 1115).
Control Area DA NDA BA1968
Age (Mean ± SD) 62.0 ± 10.5 63.0 ± 11.3 63.6 ± 10.0 37.4 ± 2.3
(n) (142) (786) (158) (30)
Symptom score (always)
Mean ± SD 0.2 ± 0.5 5.9 ± 5.2 6.1 ± 4.9 4.0 ± 5.0
Range (min–max) 0–3 0–23 0–23 0–19
Symptom score (always and sometimes)
Mean ± SD 3.2 ± 3.0 22.9 ± 9.2 23.1 ± 9.2 19.7 ± 9.9
Range (min–max) 0–15 2–46 1–46 2–42
Cranial nerve score
Mean ± SD 0.2 ± 0.6 1.2 ± 1.7 1.1 ± 1.6 0.4 ± 0.8
Range (min–max) 0–2 0–6 0–6 0–2
Upper, lower ataxia and tremor score
Mean ± SD 0.1 ± 0.4 1.2 ± 1.4 1.3 ± 1.5 1.0 ± 1.2
Range (min–max) 0–3 0–5 0–5 0–4
Truncal ataxia score
Mean ± SD 0.9 ± 1.0 2.6 ± 1.6 2.7 ± 1.7 1.7 ± 1.3
Range (min–max) 0–3 0–5 0–5 0–4
Sensory score
Mean ± SD 0.0 ± 0.2 2.4 ± 1.4 2.4 ± 1.4 2.0 ± 1.7
Range (min–max) 0–2 0–6 0–6 0–6
Total neurological score
Mean ± SD 1.2 ± 1.4 7.3 ± 4.3 7.5 ± 4.2 5.1 ± 3.8
Range (min–max) 0–8 0–21 0–20 0–13
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Relations between scores and frequency of fish ingestion are shown in Table 11 and Figure 5.
The symptom (always) score was higher when the frequency of fish ingestion was more. Although
scores in the “<1/week” group were higher than in the “1/day” and “≥1/week” groups, the causes
were unknown, so we merged the scores in “≥1/week” and “<1/week” into “<1/day” in Figure 5.
The symptom (always and sometimes) score was higher when frequency of fish ingestion was
more. As with the symptom (always) score, scores in the “<1/week” group were higher than those
in the “≥1/week” group, the causes were unknown, so we merged the scores in “≥1/week” and
“<1/week” into “<1/day” in Figure 5.
The total neurological score was higher when frequency of fish ingestion was more
(Table 11, Figure 5).
Table 11. Frequency of fish ingestion and scores (n = 973).







Mean ± SD 62.9 ± 11.6 6.7 ± 5.5 24.4 ± 9.3 7.9 ± 4.3
Min–Max 33–90 0–23 3–46 0–21
2/day 271
Mean ± SD 62.2 ± 11.5 5.9 ± 4.7 23.0 ± 8.8 7.1 ± 4.3
Min–Max 36–92 0–21 1–44 0–21
1/day 146
Mean ± SD 61.9 ± 12.7 4.8 ± 4.7 20.8 ± 8.7 7.0 ± 4.3
Min–Max 34–89 0–21 2–44 0–20
≥1/week 79 Mean ± SD 61.0 ± 11.3 3.4 ± 3.7 17.0 ± 8.4 5.7 ± 3.7Min–Max 35–86 0–15 2–36 0–16
<1/week 18
Mean ± SD 58.9 ± 12.3 5.1 ± 4.6 20.7 ± 10 4.4 ± 3.3
Min–Max 39–81 0–16 4–38 1–11
<1/day
97
Mean ± SD 60.6 ± 11.4 3.7 ± 3.9 17.7 ± 8.8 5.5 ± 3.6
(≥1/week & <1/week) Min–Max 35–86 0–16 2–38 0–16
Total 973
Mean ± SD 62.3 ± 11.7 5.9 ± 5.1 22.8 ± 9.3 7.3 ± 4.3
Min–Max 33–92 0–23 1–46 0–21
Figure 5. Cont.
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Figure 5. Scores and frequency of fish ingestion (n = 973). Scores increased as the frequency of fish
ingestion increased.
In each of the four neurological scores (cranial nerve score, upper, lower ataxia and tremor score,
truncal ataxia score, and sensory score), the higher the frequency of fish ingestion, the more the score
increased. But the range of scores in each frequency group was greater between the zero to maximum
score (Figure 6).
Figure 6. Each score increased as the frequency of fish ingestion increased.
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3.5. Onset of Symptoms
3.5.1. Onset of Symptoms in Each Group
Table 12 shows onset year of symptoms in each group. Average year of the first symptom is
1979.0 ± 14.8 in the Minamata Area. That is more than 10 years after the Chisso Factory stopped
releasing polluted waste-water in May 1968. Sixty-five percent (628/996) in the exposed groups
displayed the first symptom later than 1968. The onset of the first symptom, muscle cramps, four-limb
numbness, stumbling tendency, difficulty in fine finger task, and limited peripheral vision were
slightly later in subjects in the Minamata Area, but almost the same among four exposed groups.
In the Minamata Area, more residents had already been examined for methylmercury poisoning than
in other groups, which might be related to the reason why the average year of onset was later than
other places.
Muscle cramps occurred 4.8 ± 8.9 years after the first symptom. Four-limb numbness
(8.7 ± 11.8 years), difficulty in fine finger task (13.2 ± 12.7 years), stumbling tendency (14.3 ± 13.5 years),
and limited peripheral vision (17.3 ± 13.3 years) were followed. Figure 7 shows the total number of
subjects with each symptom.
Table 12. Average onset year of symptoms and interval between the first symptom and the onset of
each following symptom in each area.
Minamata Area Northern Area Southern Area Other Areas
Total of
Polluted Areas
First symptom 1979.0 ± 14.8 1974.9 ± 16.1 1973.6 ± 14.2 1974.6 ± 13.7 1975.6 ± 15
case/N (%) 256/259 (98.8) 275/279 (98.6) 245/246 (99.6) 189/189 (100) 965/973 (99.2)
>1968/case (%) 185/256 (72.3) 175/275 (63.6) 143/245 (58.4) 124/189 (65.6) 627/965 (65.0)
Muscle cramps 1982.2 ± 15.1 1979.5 ± 15.6 1978.1 ± 15.1 1978.4 ± 14.1 1979.6 ± 15.1
case/N (%) 235/259 (90.7) 255/279 (91.4) 227/246 (92.3) 182/189 (96.3) 899/973 (92.4)
>1968/case (%) 185/235 (78.7) 192/255 (75.3) 157/227 (69.2) 139/182 (76.4) 673/899 (74.9)
First symptom-Muscle cramps 4.4 ± 8.8 5.5 ± 10.4 4.9 ± 8.6 4.2 ± 7.2 4.8 ± 8.9
Four limb numbness 1987.8 ± 14.2 1982.2 ± 15.9 1982.3 ± 14.5 1983.9 ± 13.9 1984 ± 14.9
case/N (%) 237/259 (91.5) 254/279 (91.0) 235/246 (95.5) 172/189 (91.0) 898/973 (92.3)
>1968/case (%) 205/237 (86.5) 205/254 (80.7) 189/235 (80.4) 151/172 (87.8) 750/898 (83.5)
First symptom-Four
limb numbness 9.1 ± 12.5 8.1 ± 12.0 8.5 ± 11.2 9.4 ± 11.4 8.7 ± 11.8
Stumbling tendency 1990.7 ± 13.1 1989.2 ± 13.7 1987.9 ± 14.3 1986.8 ± 13.4 1988.8 ± 13.7
case/N (%) 188/259 (72.6) 216/279 (77.4) 196/246 (79.7) 144/189 (76.2) 744/973 (76.5)
>1968/case (%) 176/188 (93.6) 196/216 (90.7) 175/196 (89.3) 133/144 (92.4) 680/744 (91.4)
First symptom-Stumbling
tendency 12.7 ± 13.2 15.4 ± 13.2 14.9 ± 14.0 14.1 ± 13.7 14.3 ± 13.5
Difficulty in fine finger tasks 1989.5 ± 13.6 1986.9 ± 14.4 1985.8 ± 13.5 1983.1 ± 13.8 1986.5 ± 14.0
case/N (%) 144/259 (55.6) 182/279 (65.2) 178/246 (72.4) 114/189 (60.3) 618/973 (63.5)
>1968/case (%) 135/144 (93.8) 161/182 (88.5) 157/178 (88.2) 95/114 (83.3) 548/618 (88.7)
First symptom-Difficulty in fine
finger tasks 12.3 ± 12.7 14.4 ± 13.1 13.4 ± 12.9 12.1 ± 12.0 13.2 ± 12.7
Limited peripheral vision 1992.2 ± 13.8 1988.8 ± 14.6 1991.9 ± 10.9 1988.9 ± 12.7 1990.5 ± 13.2
case/N (%) 134/259 (51.7) 179/279 (64.2) 168/246 (68.3) 110/189 (58.2) 591/973 (60.7)
>1968/case (%) 126/134 (94.0) 160/179 (89.4) 165/168 (98.2) 103/110 (93.6) 554/591 (93.7)
First symptom-Limited
peripheral vision 16.5 ± 13.6 16.9 ± 12.9 18.7 ± 13.1 16.8 ± 13.7 17.3 ± 13.3
The appearance of symptoms was almost the same among the four exposed groups. Figure 8
shows the cumulative rate of onset year of the first symptom in each exposed group.
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Figure 7. Onset year of each neurological symptom (actual number). Sixty-five percent of the subjects
in the exposed area experienced their first symptoms after 1968, when polluted waste water from the
Chisso Company’s factory was halted. Symptoms have even appeared in recent years.
 
Figure 8. Onset year of the first symptom in each exposed group (percentage). Cumulative curves of
the onset were almost the same among the four exposed groups.
3.5.2. Relation between the Onset of Symptoms and Frequency of Fish Ingestion
The frequency of fish ingestion was closely related to the onset year of other symptoms (Table 13,
Figure 9). Figure 10 shows duration between the first symptom and each other symptom. The duration
between the first symptom and four-limb numbness was related to the frequency of ingestion, but there
were almost no relations in other symptoms.
Table 13. Average onset year of symptoms and interval from the first symptom in each category of fish
ingestion (n = 965).
3/day 2/day 1/day ≥1/week <1/week
(n = 455) (n = 269) (n = 144) (n = 79) (n = 18)
First symptom 1974.2 ± 15.1 1975.6 ± 14.6 1978.2 ± 14.8 1977.7 ± 15 1982.5 ± 15.2
>1968/case (%) 277/455 (60.9) 174/269 (64.7) 105/144 (72.9) 56/79 (70.9) 15/18 (83.3)
Muscle cramps 1978 ± 15.1 1980.6 ± 14.9 1981.7 ± 14.5 1980.9 ± 15.5 1986.4 ± 17
case/N (=965) (%) 428/455 (94.1) 255/269 (94.8) 133/144 (92.4) 69/79 (87.3) 14/18 (77.8)
>1968/case (%) 308/428 (72.0) 194/255 (76.1) 108/133 (81.2) 52/69 (75.4) 11/14 (78.6)
First symptom-Muscle cramps 4.6 ± 8.2 5.4 ± 10.4 4.9 ± 9.3 3.9 ± 6.3 5.7 ± 10.5
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Table 13. Cont.
3/day 2/day 1/day ≥1/week <1/week
(n = 455) (n = 269) (n = 144) (n = 79) (n = 18)
Four limb numbness 1981.3 ± 15.5 1984.6 ± 13.8 1987.5 ± 14.6 1990.2 ± 12.6 1991.8 ± 11.7
case/N (=965) (%) 430/455 (94.5) 251/269 (93.3) 129/144 (89.6) 73/79 (92.4) 15/18 (83.3)
>1968/case (%) 339/430 (78.8) 216/251 (86.1) 111/129 (86.0) 69/73 (94.5) 15/15 (100)
First symptom-Four
limb numbness 7.6 ± 11.1 8.9 ± 11.6 9.6 ± 12.4 13.1 ± 14.4 9.5 ± 13.1
Stumbling tendency 1987.2 ± 13.9 1988.9 ± 14.1 1990.6 ± 12.5 1994.5 ± 11.5 1993.8 ± 10.5
case/N (=965) (%) 368/455 (80.9) 206/269 (76.6) 112/144 (77.8) 48/79 (60.8) 10/18 (55.6)
>1968/case (%) 332/368 (90.2) 185/206 (89.8) 105/112 (93.8) 48/48 (100) 10/10 (100)
First symptom-Stumbling
tendency 14.3 ± 13.0 14.2 ± 13.8 13 ± 13.2 18.9 ± 16.2 14.5 ± 15.2
Difficulty in fine finger tasks 1985.4 ± 13.6 1986.3 ± 14.4 1989.1 ± 14.2 1989.1 ± 14.4 1996.9 ± 8.4
case/N (=965) (%) 320/455 (70.3) 168/269 (62.5) 82/144 (56.9) 40/79 (50.6) 8/18 (44.4)
>1968/case (%) 284/320 (88.8) 147/168 (87.5) 73/82 (89.0) 36/40 (90.0) 8/8 (100)
First symptom-Difficulty in fine
finger tasks 13.1 ± 12.3 13 ± 12.7 13.9 ± 13.9 13.1 ± 13.7 12.5 ± 16.7
Limited peripheral vision 1989.7 ± 12.8 1990.8 ± 13.3 1991.8 ± 12.9 1991.3 ± 16.1 1993.8 ± 13.8
case/N (=965) (%) 302/455 (66.4) 165/269 (61.3) 80/144 (55.6) 36/79 (45.6) 8/18 (44.4)
>1968/case (%) 281/302 (93.0) 155/165 (93.9) 77/80 (96.3) 33/36 (91.7) 8/8 (100)
First symptom-Limited
peripheral vision 17.5 ± 12.9 17.3 ± 13.7 16.3 ± 13.4 19.1 ± 14.3 13.1 ± 16.3
 
Figure 9. Onset of symptoms and frequency of fish ingestion. The time of onset of subsequent
symptoms increased as the frequency of fish ingestion decreased.
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Figure 10. Years of each symptom after the first symptom. There was almost no relation
between fish ingestion and duration from the first symptom to each following symptom, except
for four-limb numbness.
3.5.3. Relations between Onset of Symptom and Scores of Signs and Symptoms
The onset of symptoms was related to scores. When the onset year was earlier, the score became
greater (Table 14).














R2 0.0496 0.0329 0.0789 0.0453 0.0383 0.0567
p-value (0.000) (0.000) (0.000) (0.000) (0.000) (0.000)
Symptom score (always and sometimes)
R2 0.0845 0.0612 0.1134 0.0641 0.0443 0.0716
p-value (0.000) (0.000) (0.000) (0.000) (0.000) (0.000)
Cranial nerve score
R2 0.0193 0.0127 0.0222 0.0098 0.0105 0.0062
p-value (0.000) (0.000) (0.000) (0.004) (0.006) (0.031)
Upper, lower ataxia and tremor score
R2 0.0298 0.0173 0.0438 0.0237 0.0121 0.0141
p-value (0.000) (0.000) (0.000) (0.000) (0.004) (0.002)
Truncal ataxia score
R2 0.0143 0.0046 0.0291 0.0165 0.0115 0.008
p-value (0.023) (0.000) (0.000) (0.004) (0.017) (0.000)
Sensory score
R2 0.0219 0.0163 0.0309 0.0272 0.022 0.0058
p-value (0.000) (0.000) (0.000) (0.000) (0.000) (0.035)
Total neurological score
R2 0.0428 0.0248 0.0633 0.0385 0.0289 0.0189
p-value (0.000) (0.000) (0.000) (0.000) (0.000) (0.000)
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3.6. Health Effect in Younger Generation
3.6.1. Characteristics of Younger Subjects in the Exposed and the Control Area
The demographic characteristics of subjects in younger subjects are shown in Table 15. Many of
the younger subjects who were born later than 1968 (BA1968) in the exposed areas had also lived in
fishermen families (30.0%) and had eaten more fish (3 times/day in 50.0%) than the elderly exposed
subjects. While the prevalence of subjects whose parents were fishermen and the prevalence of
subjects who had a family history of Minamata disease were almost the same between BA1968
(n = 30, in Table 15) and Designated Area (n = 84, in Table 15), there was no significant difference in
complications between BA1968 and the Control Area (n = 88, in Table 15).
Table 15. Demographic characteristics of subjects in younger subjects (n = 202).
Control Area BA1968 Designated Area Total
(n = 88) (n = 30) (n = 84) (n = 202)
Sex, n (%)
Male 40 (45.5) 21 (70.0) 44 (52.4) 105 (52.0)
Female 48 (54.6) 9 (30.0) 40 (47.6) 97 (48.0)
Age
Mean ± SD 37.5 ± 6.0 37.4 ± 2.3 44.8 ± 2.3 40.5 ± 5.6
Range (min–max) 30–48 33–40 40–48 30–48
Smoking, n (%)
Non-smoker 56 (65.1) 19 (63.3) 49 (58.3) 124 (62.0)
Smoker 30 (34.9) 11 (36.7) 35 (41.7) 76 (38.0)
Alcohol drinking, n (%)
Non-drinker 41 (47.7) 11 (36.7) 30 (35.7) 82 (41.0)
Drinker 45 (52.3) 19 (63.3) 54 (64.3) 118 (59.0)
Frequency of fish intake, n (%)
Three times a day 3 (3.4) 15 (50.0) 30 (35.7) 48 (23.8)
Twice a day 1 (1.1) 6 (20.0) 24 (28.6) 31 (15.4)
Once a day 9 (10.2) 5 (16.7) 21 (25.0) 35 (17.3)
More than once a week 53 (60.2) 2 (6.7) 8 (9.5) 63 (31.2)
Less than once a week 20 (22.7) 2 (6.7) 1 (1.2) 23 (11.4)
Occupation, n (%)
Fishermen (subject) 0 (0.0) 1 (3.3) 5 (6.0) 6 (3.0)
Fishermen (subject’s parent) 1 (1.2) 9 (30.0) 23 (27.4) 33 (16.6)
Complications, n (%)
Hypertension 1 (1.1) 0 (0.0) 8 (9.5) 9 (4.5)
Renal diseases 0 (0.0) 0 (0.0) 3 (3.6) 3 (1.5)
Liver diseases 1 (1.1) 0 (0.0) 2 (2.4) 3 (1.5)
Respiratory diseases 8 (9.1) 1 (3.3) 6 (7.1) 15 (7.4)
Diabetes Mellitus 0 (0.0) 1 (3.3) 2 (2.4) 3 (1.5)
Orthopedic diseases 3 (3.4) 3 (10) 14 (16.7) 20 (9.9)
Malignant diseases 0 (0.0) 0 (0.0) 1 (1.2) 1 (0.5)
History of application for inamata disease, n (%) 0 (0.0) 1 (3.3) 13 (15.5) 14 (6.9)
Family history of Minamata disease, n (%) 0 (0.0) 29 (96.7) 76 (90.5) 105 (52.0)
Have witnessed abnormal animal behavior, n (%) No Data 9 (30.0) 27 (32.1) 36 (31.6)
3.6.2. Symptoms and Neurological Signs in the Younger Generation
Symptoms and neurological signs in younger age (BA1968) were much more prevalent than
in the Control Area, and the pattern of positive findings resembled those in the Designated Area
(Figures 11–13). The score of signs and symptoms showed similar results (Table 16).
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Figure 11. Prevalence of symptoms (Always) in the younger generation. Prevalence in BA1968 and the
Designated Area were higher than in the Control Area. The symptomatic patterns in BA1968 and the
Designated Area were similar.
 
Figure 12. Prevalence of symptoms (Always and Sometimes) in the younger generation. Prevalence in
BA1968 and the Designated Area were higher than in the Control Area. The symptomatic patterns in
BA1968 and the Designated Area were similar.
85
Toxics 2018, 6, 39
 
Figure 13. Prevalence of neurological signs in the younger generation. Prevalence in BA1968 and
the Designated Area were higher than in the Control Area. The patterns of signs in BA1968 and the
Designated Area were similar.
Table 16. Score of signs and symptoms in younger subjects.
Control Area BA1968 Designated Area
Age (Mean ± SD) 37.5 ± 10.0 37.4 ± 10.0 44.8 ± 10.0
(n) (88) (30) (84)
Symptom score (always)
Mean ± SD 0.1 ± 0.4 4.0 ± 5.0 4.2 ± 4.3
Range (min–max) 0–3 0–19 0–19
Symptom score (always and sometimes)
Mean ± SD 2.5 ± 2.9 19.7 ± 9.9 19.8 ± 9.1
Range (min–max) 0–16 2–42 2–42
Cranial nerve score
Mean ± SD 0.0 ± 0.2 0.4 ± 0.8 0.5 ± 1.1
Range (min–max) 0–2 0–2 0–4
Upper, lower ataxia and tremor score
Mean ± SD 0.0 ± 0.0 1.0 ± 1.2 0.6 ± 1.0
Range (min–max) 0–0 0–4 0–4
Truncal ataxia score
Mean ± SD 0.2 ± 0.5 1.7 ± 1.3 1.7 ± 1.5
Range (min–max) 0–3 0–4 0–5
Sensory score
Mean ± SD 0.0 ± 0.1 2.0 ± 1.7 2.2 ± 1.3
Range (min–max) 0–1 0–6 0–5
Total neurological score
Mean ± SD 0.2 ± 0.7 5.1 ± 3.8 5.0 ± 3.3
Range (min–max) 0–5 0–13 0–16
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3.6.3. Onset of Symptoms of Designated, Non-Designated Area and Subjects Born after 1968
Figure 14 shows the onset of the first symptom in the designated area (DA), non-designated area
(NDA) and subjects born after the end of 1968 (BA1968). The classifications for these groups were the
same as those in Table 10 (not in Table 15). The cumulative curves were almost the same between
subjects who had lived in the designated and non-designated area. 82.8% (24/30) of the subjects who
were born after 1968 had developed their first symptom by 1987.
 
Figure 14. Onset year of the first symptom of subjects with and without residential history in the
designated area (percentage).
3.7. Signs and Symptoms in Subjects in Whom Sensory Disturbance had not been Detected during Their
Physical Examination
The demographic characteristics of subjects with and without sensory disturbance are shown
in Table 17. Overall, the prevalence of symptoms (Always) and symptoms (Always and Sometimes)
without sensory disturbance were a little lower than the subjects with some sort of sensory disturbance
(Figures 15 and 16). However, most of their symptoms were more prevalent than the control group.
Furthermore, the prevalence pattern of neurological signs other than sensory disturbance in subjects
without sensory disturbance was similar to that in subjects with some sort of sensory disturbance
(Figure 17).






(n = 142) (n = 91) (n = 882)
Sex, n (%)
Male 56 (39.4) 64 (70.3) 428 (48.5)
Female 86 (60.6) 27 (29.7) 454 (51.5)
Age
Mean ± SD 62.0 ± 10.5 59.7 ± 13.3 62.6 ± 11.6
Range (min–max) 36–86 33–87 33–92
Residential history in designated area (DA) more than 1 year, n (%)
In DA > 1 year (DA) 3 (2.1) 69 (75.8) 717 (81.3)
Not in DA > 1 year (NDA) 139 (97.9) 13 (14.3) 144 (16.3)
Born after 1968 (BA1968) 0 (0.0) 9 (5.0) 21 (2.4)
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(n = 142) (n = 91) (n = 882)
Smoking, n (%)
Non-smoker 109 (77.3) 66 (72.5) 676 (81.0)
Smoker 32 (22.7) 25 (27.5) 206 (19.0)
Alcohol drinking, n (%)
Non-drinker 72 (51.1) 43 (47.3) 468 (53.1)
Drinker 69 (48.9) 48 (52.7) 414 (47.0)
Frequency of fish intake, n (%)
Three times a day 6 (4.4) 34 (37.4) 425 (48.2)
Twice a day 7 (5.1) 30 (33.0) 241 (27.3)
Once a day 27 (19.9) 12 (13.2) 134 (15.2)
More than once a week 63 (46.3) 13 (14.3) 66 (7.5)
Less than once a week 33 (24.3) 2 (2.2) 16 (1.8)
Occupation, n (%)
Fishermen (subject) 0 (0.0) 13 (14.3) 118 (13.4)
Fishermen (subject’s parent) 2 (1.6) 28 (30.8) 291 (33.0)
Complications, n (%)
Hypertension 40 (28.2) 28 (30.8) 320 (36.3)
Renal diseases 3 (2.1) 7 (7.7) 48 (5.4)
Liver diseases 6 (4.2) 10 (11.0) 61 (6.9)
Respiratory diseases 12 (8.5) 4 (4.4) 37 (4.2)
Diabetes Mellitus 3 (2.1) 9 (9.9) 84 (9.5)
Orthopedic diseases 13 (9.2) 22 (24.2) 224 (25.4)
Malignant diseases 7 (4.9) 3 (3.3) 48 (5.4)
History of application for Minamata disease, n (%) 0 (0.0) 3 (3.3) 109 (12.4)
Family history of Minamata disease, n (%) 0 (0.0) 48 (52.7) 498 (56.5)
Have witnessed abnormal animal behavior, n (%) No Data 27 (29.7) 360 (40.8)
 
Figure 15. Prevalence of symptoms (Always) in subjects with and without sensory disturbance.
The prevalence of symptoms was a little lower in subjects without sensory disturbance than in subjects
with sensory disturbance but was apparently higher than the Control Area. The prevalence patterns
were similar in exposed subjects with and without sensory disturbance.
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Figure 16. Prevalence of symptoms (Always and Sometimes) in subjects with and without sensory
disturbance. The prevalence of symptoms was a little lower in subjects without sensory disturbance
than in subjects with sensory disturbance but was apparently higher than the Control Area.
The prevalence patterns were similar in exposed subjects with and without sensory disturbance.
 
Figure 17. Prevalence of neurological signs in subjects with and without sensory disturbance. Except
for the prevalence of sensory disturbance, that of other symptoms was lower in subjects without sensory
disturbance than in subjects with sensory disturbance but was generally higher than the Control Area.
The prevalence patterns were similar in exposed subjects with and without sensory disturbance except
for the prevalence of sensory disturbance.
The scores of signs and symptoms in subjects without sensory disturbance were lower than those
in subjects in the exposed area and higher than those in the control area (Table 18).
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Table 18. Score of signs and symptoms in subjects with and without sensory disturbance (n = 1115).
Control Area Sensory Disturbance (−) Sensory Disturbance (+)
Age (Mean ± SD) 62.0 ± 10.5 59.7 ± 13.3 62.6 ± 11.6
(n) (142) (91) (882)
Symptom score (always)
Mean ± SD 0.2 ± 0.5 4.0 ± 4.0 6.1 ± 5.2
Range (min–max) 0–3 0–16 0–23
Symptom score (always and sometimes)
Mean ± SD 3.2 ± 3.0 18.0 ± 8.7 23.3 ± 9.2
Range (min–max) 0–15 2–38 1–46
Cranial nerve score
Mean ± SD 0.2 ± 0.6 0.9 ± 1.4 1.2 ± 1.7
Range (min–max) 0–2 0–6 0–6
Upper, lower ataxia and tremor score
Mean ± SD 0.1 ± 0.4 0.6 ± 1.0 1.2 ± 1.4
Range (min–max) 0–3 0–4 0–5
Truncal ataxia score
Mean ± SD 0.9 ± 1.0 1.8 ± 1.7 2.7 ± 1.6
Range (min–max) 0–3 0–5 0–5
Sensory score
Mean ± SD 0.0 ± 0.2 0.0 ± 0.0 2.6 ± 1.2
Range (min–max) 0–2 0–0 1–6
Total neurological score
Mean ± SD 1.2 ± 1.4 3.4 ± 3.0 7.7 ± 4.2
Range (min–max) 0–8 0–15 1–21
4. Discussion
4.1. Characteristics of the Subjects
The data collected on the occupations and dietary habits of the four methylmercury-exposed
groups showed clearly that the majority are connected to the fishing industry and that their diets
consist of large amounts of fish and shellfish.
Certified Minamata disease patients and compensated patients had lived in the designated area,
which consisted of the whole Minamata Area, a large part of the Southern Area, and a small part of the
Northern Area. In these areas, thousands of residents had already been examined for Minamata disease.
But in the non-designated area, which included a part of the Northern and Southern Areas, as well
as some other smaller areas, residents had not received information about methylmercury poisoning
and had had little opportunity to be examined for methylmercury poisoning. These situations were
reflected in the higher percentage of subjects (41.6%) who had not lived in the designated area in the
Northern Area than the other three exposed groups (Table 1).
To adjust the higher prevalence of diabetes mellitus and orthopedic diseases in the exposed groups,
we used logistic regression analysis. After adjustment for age, sex, diabetes mellitus, and orthopedic
diseases, the prevalence of most signs and symptoms were extremely higher in the four exposed groups.
This means that neither diabetes mellitus nor orthopedic diseases were the cause of these signs
and symptoms. However, on the contrary, methylmercury exposure might increase diabetes mellitus
and orthopedic diseases. Shigenaga reported that in infantile and acute adult Minamata disease cases,
injury to the pancreatic islet cells occurred [7]. Harada reported that deformity of four limbs (19%) and
four-limb pain (36%) were observed in 145 family members of certified Minamata disease patients [8].
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4.2. Characteristics of Signs and Symptoms of Chronic Methylmercury Poisonings
In this study, symptoms of methylmercury-intoxicated subjects varied widely. In 1973, Tatetsu et al.
reported symptoms in 215 patients whom they diagnosed with Minamata disease and examined
precisely using a two-point scale (“yes” or “no”). The symptoms (prevalence) included numbness
of hands and feet (82%), dysesthesia of hands and feet (50%), pain in the head, back, lower back,
four limbs (79%), fatigue (65%), visual disturbance (55%), limited peripheral vision (31%), difficulty
in hearing (60%), difficulty in smelling (28%), difficulty in tasting (22%), stumbling tendency (58%),
difficulty in fine finger tasks (37%), difficulty in buttoning (34%), difficulty in speaking (41%), muscle
cramps (71%), hand tremor (43%), insomnia (43%), and forgetfulness (75%) [9].
From 1974 to 1979, Fujino used a two-point scale questionnaire to interview adult residents
of Katsurajima Island, Izumi City and reported general fatigue (100%), forgetfulness, difficulty in
calculation, inability to concentrate (95%), numbness (95%), difficulty in hearing (90%), muscle cramps
(90%), insomnia (90%), staggering or stumbling (93%), difficulty in buttoning (88%), hand tremor
(71%), limited peripheral vision (78%), difficulty in smelling (68%) in 41 adult residents [10]. The lower
the age of the Katsurajima Island residents, the milder the symptoms.
In 1985, Kinjo et al. used a two-point scale questionnaire to interview certified Minamata disease
patients in these designated areas. In Kinjo’s study, constriction of visual field (19.3%), difficulty in
hearing (54.0%), difficulty in speaking (38.2%), difficulty in buttoning (52.8%), stumbling (69.3%),
tremor (39.5%), hypoesthesia of the limbs (67.1%), dysesthesia of the limbs (88.4%), hypoesthesia of
the mouth (25.4%), forgetfulness (88.4%), fatigue (82.9%), cramps (80.0%) were observed [11]. 24 years
later the variety of symptoms was the same in non-certified residents as had been observed earlier in
the certified patients.
In 2005, we performed a study of residents who had been exposed to methylmercury.
The symptoms in the group without neurological complications (Always and Sometimes) were
numbness of hands and feet (89%), limited peripheral vision (66%), difficulty in hearing (61%),
stumbling tendency (63%), difficulty in buttoning (54%), muscle cramps (97%), hand tremor (75%),
fatigue (88%), and forgetfulness (97%) [6].
The prevalence pattern of symptoms (Always and Sometimes) were similar to questions common
to three of the earlier studies—Tatetsu et al., Kinjo et al. and Takaoka (2005), as well as the present
Takaoka study. Fujino’s study showed much more severe symptoms than the four previously
mentioned studies (Figure 18). The similarities in symptom patterns may be due to the fact that
the effects of methylmercury poisoning on health have persisted into the twenty-first century. Because
there were differences in these studies in the selection of subjects, phrasing of questions, and the
scoring methods’ choice of answers were not necessary the same, the percentages of each study, shown
below, do not necessarily represent the severity of subjects’ symptoms.
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Figure 18. Prevalence of symptoms when comparing nine questions common to all five studies.
The prevalence of all characteristic symptoms for Minamata disease was very. In this study, we used
the prevalence of “sensory numbness in both hands” instead of “numbness of hands and feet”.
Sugiura studied fishermen in Minamata City (1990) and in Izumi City (1988) and pointed out that
health problems were present not only in certified patients but also in uncertified patients and other
fishermen [12]. In our study, there were no certified patients, but most of them had similar symptoms.
Although activities of daily living (ADL) of these patients decreased from 60 years old, 9.1% still
needed assistance in eating, 11.6% in bodily hygiene and 10.6% in using the toilet [11]. The ADL
level of most subjects in this study was “Independent” so they were able to come for the examination
without serious assistance. The effects of chronic methylmercury cover a wide range, and disabilities
remain or progress slowly in many cases.
The symptoms in the questionnaire consist of those both specific and non-specific to
methylmercury poisoning. The symptoms whose percentage of the answer (always and sometimes) in
the Control Area were considerably lower, compared to those in the exposed groups (e.g., “perioral
numbness”, “difficulty in tasting”, “difficulty in buttoning”), are supposed to more specific symptoms.
Tables 2 and 4, Figures 2 and 3 show that prevalence of specific symptoms as well as that of non-specific
symptoms became higher through methylmercury exposure.
Increases in specific symptoms from methylmercury poisoning mean that those high percentages
of symptoms include the effects of methylmercury. Also increases of non-specific symptoms in exposed
people mean that methylmercury also has non-specific health effects.
The prevalence of symptoms was highly correlated among the four exposed groups. By the effects
of non-specific symptoms, there were some correlations between the control and the four exposed
groups, but the correlations were extremely high among the exposed groups (Tables 3 and 4, Figure 2).
These patterns of symptoms were supposed to reflect the characteristics of methylmercury poisonings.
That the correlation between the control and exposed groups in symptoms of “always and
sometimes” became higher than that in symptoms of “always” can be explained by effects of the
non-specific symptoms for methylmercury poisoning in the control area (Tables 5 and 6, Figure 3).
As with symptoms, positive neurological signs in the four exposed groups were highly more
prevalent than the control area (Table 7, Figure 4). Also, the correlation among the four exposed groups
was also supposed to reflect the characteristics of methylmercury poisoning (Table 8). Furthermore,
the concordance between these findings by 144 doctors with different specialties suggests that the
instructions for the examinations were successful.
Many factors may have influence on the final prevalence including possible bias in the selection of
subjects, variations in the doctors’ examination technique, judgment criteria, the subjects’ age, and other
health complications. Despite the possible influence of these factors, the high level of consistency in
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the gathered results show that there was a high degree of precision involved. Also, the collected data
suggests that the effects of methylmercury contamination are still present today.
Clinical signs were also as various as studies previously reported. According to Tatesu et al.,
269 residents in Minamata district, diagnosed with Minamata disease in 1972, showed sensory
disturbance (97.0%), ataxia (93.7%), hearing disturbance (84.0%), weakness (67.3%), speech disturbance
(62.5%), and constriction of visual field (59.5%) [9].
Fujino, in his study from 1974 to 1979, reported that those who had lived longer on Katsurajima
Island, showed a higher prevalence in all signs of Hunter Russell syndrome: somatosensory
disturbance, ataxia, constriction of visual fields, auditory disturbance, and dysarthria. The combination
of these symptoms became less as the subjects’ ages decreased [10]. In a study from 1975 to 1979,
Ninomiya et al. reported that hypoesthesia (60.3%), ataxia (20.7%), impairment of hearing (43.8%),
visual change (25.6%), and dysarthria (13.2%) were recognized in 121 residents from the polluted area
in Goshonoura [13].
In our study from 2005, subjects in the methylmercury-polluted area had dysarthria (23%),
auditory disturbance (33%), visual constriction (28%), positive finger-nose test (50%), heel-shin test
(48%), normal gait disturbance (41%), and poor one-foot standing (66%) [6].
Because these studies differed in the selection of subjects, examination method, and judgement
criteria, their positive neurological findings were not necessarily the same. However, common
abnormalities in many functions including somatosensory, visual, and hearing acuities, coordination of
upper and lower extremities were recognized, indicating that methylmercury poisoning still prevails.
4.3. Dose-Response Relationship of Chronic Methylmercury Poisoning
The severity of the subjects’ symptoms varied widely and some of them were experienced
sporadically, which means that symptoms were persistent, intermittent, or periodical in many cases.
The severity of neurological signs ranged from no finding to continual seriousness. The seriousness
generally correlated with the volume of fish ingested (Table 11, Figures 5 and 6), but even between
subjects with a low intake of fish and those with a high intake the severity of the cases varied from
no findings to findings with high severity were observed (Figure 6). This is the first study that
dose-response effects were observed in methylmercury poisoning in Japan.
According to pathological studies on Minamata disease, a spongy state, from complete loss of
neurons in the cerebral and cerebellar cortex, can occur in the severe cases, whereas in milder cases,
“scattered single cell necrosis” in the cortex is supposed to occur [14]. Nowadays, this cellular loss in
milder cases has been supposed to be caused by “apoptosis” [15]. This could explain the variability in
seriousness of this disease.
A higher percentage of intermittent or periodical signs and symptoms has been supposed be
characteristics of mild and moderate chronic methylmercury poisoning. Uchino reported that in 63
out of 77 certified Minamata disease patients (82%), changes in the range of sensory disturbance were
observed [16]. The functions of the brain cortex have plasticity and can be affected by other parts of
central nervous system, which can lead to fluctuations in signs and symptoms.
4.4. Late Onset of Methylmercury Poisoning
In this study, 65.0% of the subjects in the four exposed areas developed the first symptoms after
1968 (Table 12, Figure 7), when the dumping of polluted waste-water from the Chisso Cooperation
stopped. After the appearance of the first symptom, the order of subsequent symptoms appeared
gradually in the following order: muscle cramps, four-limb numbness, difficulty in fine finger
tasks, stumbling tendency, and limited peripheral vision (Table 12). When we consider that most
of the subjects had been exposed to methylmercury in or before 1968, there was a delay in the
appearance of symptoms. In 1991, The Central Environmental Pollution Council of the Environment
Agency (the predecessor of the present Ministry of Environment) (Japan) reported without evidence,
“the period from methylmercury exposure to the onset is ordinarily supposed to be one month,
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at least within one year” [17]. Although this opinion is held by the Japanese administration even
now, the reality is completely different. In the same year 1991, Igata, the chairman of the Council,
wrote “roughly speaking, such late onset and late progression are limited to some patients and the
peak was reached before 1975” [18], which was 7 years after the Chisso company stopped releasing
contaminated wastewater in 1968 and also a time when cases with an acute onset of Minamata disease
were rarely found. The true latency period is much longer.
Even in acute cases of maximum methylmercury exposure in Iraq, the mean latent periods ranged
from 16 to 38 days [19]. In the experiments with monkeys, a latency period of 6 years was reported [20].
Evans et al. conducted a long-term study on nonhuman primates and demonstrated that the latency
period was dose dependent [21,22]. Our data support the thesis that the latency period became longer
as the exposure became milder (Table 13, Figure 9). The longest latency from exposure to symptomatic
onset has not been determined. According to our data, the first symptom may already have been
present before 2008, one year before the survey (Figures 7 and 8), which explains that it is difficult to
determine the longest latency period.
4.5. How Far Had the Methylmercury Pollution Spread?
Many of the subjects in the Northern Area (41.6%) had not lived in the designated area, but the
pattern of signs and symptoms were almost the same as the Minamata Area (4.6%), Southern Area
(7.7%), and Other Areas (5.3%) (Table 2). The scores of signs and symptoms in the non-designated
area were almost the same as the designated area (Table 10). These data show that residents in the
non-designated area had similar health effects from methylmercury and the spread of Minamata
disease was larger than previously thought. At least, within the area where fish and shellfish can be
obtained daily, adverse health effects caused by methylmercury may have occurred.
4.6. What Is the Longest Time, After Methylmercury Exposure, That Late Developing Symptoms Can Appear?
Similar patterns of signs and symptoms were observed in BA1968 (Table 15, Figures 11–13)
as same as in the elderly subjects. The scores of signs and symptoms in BA1968 were also similar to
those of subjects in the designated area, and greater than the Control Area (Table 16). Figure 14 shows
the development of methylmercury-related symptoms. The data indicates that the detrimental effects
on health from methylmercury poisoning had continued to spread, even after the release of polluted
waste-water had been stopped in 1968.
The Central Environmental Pollution Council of the Environment Agency, without any evidence,
stated in 1991, “Since 1969, the possibilities of being exposed to levels of methylmercury that can cause
Minamata disease no longer exist”. Our study shows that this statement in 1991 was incorrect.
It is difficult to determine whether subjects of BA1968 (as displayed in Figure 14) had developed
their symptoms due to continued exposure after 1968 or if they were late developing symptoms.
What we can say is that it is difficult to determine at which time, after chronic or continuous
methylmercury exposure, that a person, not showing health problems, can be judged to be safe
from late developing Minamata Disease symptoms.
4.7. Signs and Symptoms in Subjects Whose Sensory Disturbance Was Not Recognized
In Japan, there are a lot of people who have been exposed methylmercury and who have some
neurological abnormalities. Four-limb sensory disturbance has been supposed to be the minimum
neurological abnormality in Japan [1]. Outside of Japan, epidemiological studies have not seen
such extreme neurological signs, but other more mild or latent neurocognitive and behavioral
symptoms [23,24].
This study showed that subjects without sensory disturbance had experienced many other
subjective symptoms and objective abnormalities similar to those of subjects with sensory disturbance
(Table 17, Figures 15–17). This means that there is a range of varieties of symptoms from methylmercury
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poisoning. Although sensory disturbance is important in methylmercury poisoning, the recognition of
health problems caused by methylmercury should not be limited to cases with sensory disturbance.
4.8. Other Problems
There are some limitations in this study. Firstly, this study was a cross-sectional study and
participants in this study were limited to subjects who had volunteered to be tested. Therefore,
it is obvious that our data may not concur with the data of the general population in these areas.
But our data does show the spread of methylmercury poisoning along Shiranui Seashore.
Secondly, the lifestyle and occupations were not the same among the four groups. But the high
prevalence of the specific complaints and neurological findings of Minamata disease and the similar
patterns of such prevalence of symptoms and neurological signs support our opinion.
5. Conclusions
The effects of methylmercury poisoning on human health had spread outside of the central area
and could have still been caused until recently. By using the frequency of fish ingestion as an indirect
indication of methylmercury exposure, a dose-response relationship was confirmed for methylmercury
pollution in Minamata. The latency period from exposure of mercury to the onset of symptoms
was much longer than previously thought, and the latency period increased as the exposure levels
decreased. Further investigations on the health effects of methylmercury over a wider area, covering
longer periods, and on a wider range of signs and symptoms must continue in the future.
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The authors wish to make the following corrections to this paper [1]:
1. Page 1, Abstract, lines 12–15: Period of time changed to match time between 1968 and the year
in which our data was taken:
“Our data indicates that Minamata disease had spread outside of the central area and could still
be observed recently, almost 50 years after the Chisso Company’s factory had halted the dumping of
mercury polluted waste water back in 1968.” should be changed to “Our data indicates that Minamata
disease had spread outside of the central area, and could still be observed recently, almost 40 years
after the Chisso Company’s factory had halted the dumping of mercury polluted waste water back
in 1968.”.
2. Page 3, paragraph 2, lines 5–7: Restructuring of sentence to make it clearer:
“Applicants seeking recognition were being socially discriminated against and the lack of a
comprehensive pollution survey meant that many residents with health problems had not sought
diagnosis.” should be changed to “Due to social discrimination and the lack of a comprehensive
pollution survey, residents with health problems were reluctant to seek a diagnosis.”.
3. Page 4, paragraph 2, lines 2–4: Incorrect word replaced by correct one:
“We performed this survey in order to research the prevalence of signs and symptoms as well as
the geometrical and chronological spread of health problems caused by methylmercury.” should be
changed to “We performed this survey in order to research the prevalence of signs and symptoms,
as well as the geographical and chronological spread of health problems caused by methylmercury.”.
4. Page 6, paragraph 1, lines 5–6: Missing word inserted:
“Those who had been born or had moved to the polluted on or after 1 January 1969 were classified
under the third category (BA1968: n = 30, M/F = 21/9, Age = 37.4 ± 2.3).” should be changed to “Those
who had been born or had moved to the polluted area on or after 1 January 1969 were classified under
the third category (BA1968: n = 30, M/F = 21/9, Age = 37.4 ± 2.3).”, adding the word ‘area’.
5. Page 6, paragraph 2, lines 2–5: Rearrange order at the end of the paragraph:
“To evaluate this group, we selected 88 out of 227 subjects whose age was lower than 49 from the
Control Area (M/F = 40/48, Age = 37.5 ± 6.0), and 84 out of 786 exposed subjects in the designated area
who were born after 31 December 1968 (M/F = 44/40, Age = 44.8 ± 2.3) and whose age was lower than
49 from the four exposed groups.” should be changed to “To evaluate this group, we selected 88 out
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of 227 subjects, whose age was lower than 49, from the Control Area (M/F = 40/48, Age = 37.5 ± 6.0)
and 84 out of 786 exposed subjects in the designated area, who were born after 31 December 1968 and
whose age was lower than 49, from the four exposed groups (M/F = 44/40, Age = 44.8 ± 2.3).”.
6. Page 8, 2.6.2, lines 2–3: Added missing words to clarify better:
“To evaluate the severity of the neurological signs, we added (a) mark(s) to positive signs and
symptoms, and we calculated the total score in the exposed four groups.” should be changed to
“To evaluate the severity of the neurological signs and symptoms, we added (a) mark(s) to positive
signs and symptoms, and we calculated the total score in the exposed four groups and the control
group.”, adding ‘and symptoms’, as well as ‘and the control group’.
7. Page 21, Section 3.5.2, line 1: Remove “other”:
“The frequency of fish ingestion was closely related to the onset year of other symptoms (Table 13,
Figure 9).” should be changed to “The frequency of fish ingestion was closely related to the onset year
of the symptoms (Table 13, Figure 9).”.
8. Page 23, Table 14: Table title shortened:
“Table 14. Score of signs and onset of symptoms in each area.” should be changed to “Table 14.
Score of signs and onset of symptoms.”.
9. Page 27, Figure 17: Changed “symptoms” to “signs”:
“Figure 17. Prevalence of neurological signs in subjects with and without sensory disturbance.
Except for the prevalence of sensory disturbance, that of other symptoms was lower in subjects without
sensory disturbance than in subjects with sensory disturbance but was generally higher than the Control
Area. The prevalence patterns were similar in exposed subjects with and without sensory disturbance
except for the prevalence of sensory disturbance.” should be changed to “Figure 17. Prevalence of
neurological signs in subjects with and without sensory disturbance. Except for the prevalence of
sensory disturbance, that of other signs was lower in subjects without sensory disturbance, than in
subjects with sensory disturbance, but was generally higher than the Control Area. The prevalence
patterns were similar in exposed subjects with and without sensory disturbance except for the
prevalence of sensory disturbance.”.
10. Page 32, Figure 18, Missing word inserted:
“Figure 18. Prevalence of symptoms when comparing nine questions common to all five studies.
The prevalence of all characteristic symptoms for Minamata disease was very. In this study, we used
the prevalence of “sensory numbness in both hands” instead of “numbness of hands and feet.”” should
be changed to “Figure 18. Prevalence of symptoms when comparing nine questions common to all five
studies. The prevalence of all characteristic symptoms for Minamata disease was very high. In this
study, we used the prevalence of “sensory numbness in both hands” instead of “numbness of hands
and feet.””, thus inserting ‘high’ as in ‘very high’ in the first sentence.
11. Page 32, paragraph 2, lines 1–2: The age range data used for ADL comparison was 60–69.
This resulted in a change for the value for bodily hygiene from 10.6% to 7.0%. The scientific results,
however, remain the same:
“Although activities of daily living (ADL) of these patients decreased from 60 years old, 9.1% still
needed assistance in eating, 11.6% in bodily hygiene and 10.6% in using the toilet [11].” should be
changed to “Although activities of daily living (ADL) of these patients decreased from 60 years old,
9.1% still needed assistance in eating, 11.6% in bodily hygiene, and 7.0% in using the toilet in the age
range of 60–69 [11].”, where the percentage of those using the toilet has been changed from 10.6% to
7.0%, and the words ‘in the age range of 60–69’ have also been added at the end.
12. Page 32, paragraph 3, lines 5–6: Referenced table numbers corrected:
“Tables 2 and 4, Figures 2 and 3 show that prevalence of specific symptoms as well as that of
non-specific symptoms became higher through methylmercury exposure.” should be changed to
“Tables 3 and 5, Figures 2 and 3 show that prevalence of specific symptoms as well as that of non-specific
symptoms, became higher through methylmercury exposure.”.
13. Page 33, 4.3, lines 7–8: The following sentence should be removed, as its meaning is incorrect:
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This is the first study that dose-response effects were observed in methylmercury poisoning
in Japan.
14. Page 34, 4.6, paragraph 3, lines 1–2: Reworded to clear up possible ambiguity:
“It is difficult to determine whether subjects of BA1968 (as displayed in Figure 14) had developed
their symptoms due to continued exposure after 1968 or if they were late developing symptoms.”
should be changed to “We can understand that subjects of BA1968 (as displayed in Figure 14) had
developed their symptoms due to continued exposure after 1968. But it is impossible to determine
whether subjects who were born before BA1968 and had developed their symptoms after 1968 had
developed their symptoms due to continued exposure after 1968 or if they were late developing
symptoms resulting from exposure before 1968.”.
15. Page 34, Section 4.7, lines 3–5 Added reference to some international studies:
“Outside of Japan, epidemiological studies have not seen such extreme neurological signs,
but other more mild or latent neurocognitive and behavioral symptoms [23,24].” should be changed to
“Outside of Japan, epidemiological studies with such extreme neurological signs are rare except for
Iraq, Canada, and so on, but many other more mild or latent neurocognitive and behavioral symptoms
have been reported [23,24].”.
16. Page 35, 4.8, paragraph 2, line 1: Reworded to clear up possible ambiguity:
“Secondly, the lifestyle and occupations were not the same among the four groups.” should
be changed to “Secondly, the lifestyle and occupations were not the same between exposed and
control groups.”.
17. Page 36, reference 12. Misspelling corrected:
“12. Sugiura, A. Health conditions among fisheren living in the Minamata disease prevalent area.
Jpn. J. Public Health 1994, 41, 428–440. (In Japanese)” should be changed to “12. Sugiura, A. Health
conditions among fishermen living in the Minamata disease prevalent area. Jpn. J. Public Health 1994,
41, 428–440. (In Japanese)”.
18. Page 36, reference 17. Incorrect reference to “Bristol, UK” removed:
“17. Central Council for Environmental Pollution Control. About Future Measures to Minamata
Disease; The Environmental Agency: Bristol, UK, 1991. (In Japanese)” should be changed to
“17. Central Council for Environmental Pollution Control. About Future Measures to Minamata Disease;
The Environmental Agency: Tokyo, Japan, 1991. (In Japanese)”.
None of the above changes affect the scientific results. The manuscript will be updated and the
original will remain online on the article webpage. We apologize for any inconvenience caused to
our readers.
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Abstract: The main chemical forms of mercury are elemental mercury, inorganic divalent mercury,
and methylmercury, which are metabolized in different ways and have differing toxic effects
in humans. Among the various chemical forms of mercury, methylmercury is known to be
particularly neurotoxic, and was identified as the cause of Minamata disease. It bioaccumulates
in fish and shellfish via aquatic food webs, and fish and sea mammals at high trophic levels
exhibit high mercury concentrations. Most human methylmercury exposure occurs through seafood
consumption. Methylmercury easily penetrates the blood-brain barrier and so can affect the nervous
system. Fetuses are known to be at particularly high risk of methylmercury exposure. In this
review, we summarize the health effects and exposure assessment of methylmercury as follows:
(1) methylmercury toxicity, (2) history and background of Minamata disease, (3) methylmercury
pollution in the Minamata area according to analyses of preserved umbilical cords, (4) changes in the
sex ratio in Minamata area, (5) neuropathology in fetuses, (6) kinetics of methylmercury in fetuses, (7)
exposure assessment in fetuses.
Keywords: methylmercury; kinetics; toxicity; fetus; exposure assessment
1. Methylmercury Toxicity
Mercury has been used by humans for centuries due to its unique physical and chemical properties.
However, the different chemical forms of mercury, which include elemental mercury (Hg0), inorganic
divalent mercury (Hg2+), and organic mercury (mainly methylmercury, CH3Hg+), cause a variety of
toxic effects [1,2]. Differences in exposure sources, the affected organs, toxic effects, and metabolism are
seen among the various chemical forms of mercury. For example, the general population is exposed to
small amounts of elemental mercury due to its use in dental amalgams. On the other hand, workers at
artisanal small-scale gold mining sites and gold shops in Amazon River regions can be exposed to
high levels of elemental mercury, as they often have to heat gold-mercury amalgams to evaporate
the mercury and obtain the gold [2]. In humans, minimal amounts of liquid elemental mercury are
absorbed from the digestive tract, and so liquid elemental mercury does not cause acute toxicity,
even when the liquid mercury in a thermometer is accidentally ingested. However, problems can arise
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when liquid mercury is heated and bursts into the surrounding air [2]. A large proportion of inhaled
gaseous elemental mercury (approximately 80%) is absorbed into the blood via the lungs, and, as an
uncharged and therefore lipid-soluble substance, it can easily pass through the blood-brain barrier.
With time, the gaseous elemental mercury in the patient’s brain is oxidized to inorganic divalent
mercury and causes damage to the brain, and the inorganic mercury also accumulates in the kidneys,
where it causes renal damage [2]. The amount of inorganic mercury absorbed through the digestive
tract is comparatively low (5–10%) [3]. However, the intake of a large amount of inorganic mercury
compounds, such as mercury (II) chloride, in cases of accidental ingestion or ingestion with suicidal
intent causes digestive tract and kidney disorders, which can result in death [3]. In the environment,
a part of the divalent mercury can be changed to methylmercury by some micro-organisms and sunlight.
It then bioaccumulates in fish and marine mammals which exhibit elevated, food-web dependent
methylmercury levels [4]. Most human methylmercury exposure occurs from the consumption of
fish and seafood. Methylmercury is readily absorbed by the digestive tract (>90% is absorbed) [5].
In addition, it exhibits high affinity for sulfhydryl groups [1], and some methylmercury combines with
L-type cysteine to form L-cysteine-methylmercury conjugates, which have similar chemical structures
to methionine, an essential amino acid [6]. The conjugates are then distributed to all tissues, including
the brain (via the blood brain barrier), as they are treated like L-type neutral amino acids [7,8]. In the
epidemics of marked methylmercury intoxications in Minamata [9,10], Japan and Iraq [11], the brain
was the organ that was most severely affected, particularly in that the developing brains of fetuses
were damaged [12,13].
2. History and Background of Minamata Disease
The epidemic of methylmercury intoxication that occurred in Minamata area, Kumamoto
Prefecture, Japan, is known as “Minamata disease”. It was the first experience of severe methylmercury
poisoning caused by anthropogenic environmental pollution [10]. The causative agent, methylmercury,
was produced from inorganic mercury as a byproduct of the process used to manufacture acetaldehyde
at Chisso Co., Ltd. (Kumamoto, Japan), in Minamata City, and it was directly discharged into Minamata
Bay [10]. People who consumed a large amount of fish and shellfish that had been contaminated with
methylmercury from Minamata Bay developed symptoms of methylmercury toxicity. The first patient
to suffer from neurological symptoms was reported in May 1956. Kumamoto University soon started
to investigate the cause of this outbreak, and in March 1957 they reported that they suspected that
this disease was a type of heavy metal poisoning transmitted via fish and shellfish consumption [10].
However, because this was the first case of methylmercury poisoning due to environmental pollution
it took many years for the cause and effect relationship to be fully elucidated. In the meantime,
the number of patients with Minamata disease started to rapidly increase, mainly in the fishing village
of Minamata [10]. Therefore, people were afraid that the disease was “a strange contagious disease”
with an unknown cause. In 1958, Chisso Co., Ltd., moved their effluent outlet from Minamata Bay to
the Minamata River in an effort to ameliorate the epidemic taking place in the areas near Minamata.
However, this resulted in the disease spreading to the areas surrounding Minamata City. In addition,
a second epidemic of methylmercury poisoning, so-called “Niigata Minamata disease”, occurred in
1965. This outbreak was caused by methylmercury derived from the same acetaldehyde production
process as was responsible for the epidemic in Minamata City. Chisso Co., Ltd. stopped acetaldehyde
production in May 1969. In September 1969, almost 12 years after the first case of Minamata disease
was encountered, the Japanese government officially announced that the causative agent of Minamata
disease was methylmercury, which had been discharged from the above-mentioned chemical plants.
3. Methylmercury Pollution in the Minamata Area According to Analyses of Preserved
Umbilical Cords
Unfortunately, no human or biota samples were collected from the Minamata area during the
period of severe methylmercury pollution, and so methylmercury exposure levels could not be
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determined. Therefore, the time-course and regional distribution of methylmercury pollution in the
Minamata area were unknown. However, Japanese people have an ancient custom of preserving their
children’s umbilical cords as mementos, and so it was possible to assess methylmercury exposure
levels in the Minamata area by analyzing the preserved umbilical cords of children born in the
region, which in turn provided a reliable estimate of the time-course of the changes in methylmercury
pollution [14,15]. A study by Nishigaki and Harada (1975) achieved a breakthrough in that it revealed
that the Minamata inhabitants’ methylmercury exposure levels peaked in the first five years of the
1950s, and then the methylmercury levels of the preserved umbilical cord tissue samples decreased
according to the decline of acetaldehyde production in the Minamata area. Sakamoto et al. [16]
analyzed a total of 325 umbilical cord samples, including 124 newly collected samples and the
164 samples collected during the studies published by Harada et al. [15,17,18]. Figure 1 shows
the methylmercury concentrations of individual preserved umbilical cords (μg/g dry weight) from
the Minamata area and the annual level of acetaldehyde production at the time the samples were
collected. Elevated methylmercury concentrations (≥1 μg/g) were mainly observed in the inhabitants
born from 1947 to 1968. The peak methylmercury concentrations (≥2 μg/g) were mainly observed
during the period from 1955 to 1959, when the typical fetal-type Minamata disease patients were
born [13], and a reduction in the frequency of the male sex was detected in the Minamata area by
Sakamoto et al. [16]. The residents’ methylmercury concentrations started to decrease along with the
decline in acetaldehyde production, which ceased in 1968. After 1968, no individuals with elevated
methylmercury concentrations (≥1 μg/g) were encountered. These unique retrospective studies of the
methylmercury concentrations of preserved umbilical cord samples revealed not only the historical
time-course of methylmercury pollution, but also its regional distribution, in the Minamata area.
Sakamoto et al. [19] also calculated a conversion factor for converting methylmercury concentrations
in dry weight of cord tissue to the equivalent maternal hair (0–1 cm from the scalp) level (conversion
factor: 24.09). Preserved umbilical cord tissue would also be useful for retrospective dose-response
studies of methylmercury exposure and the occurrence of fetal-type Minamata disease in Japan.
Figure 1. Individual methylmercury concentrations of preserved umbilical cords (μg/g dry weight)
from the Minamata area and the amount of annual acetaldehyde production.
4. Changes in the Sex Ratio in Minamata City
Several decades ago, skewed sex ratios at birth due to hazardous chemicals became a matter
of international concern, especially the skewed sex ratio caused by dioxin contamination in Seveso,
Italy [20]. As mentioned above, prenatal methylmercury exposure has much stronger effects on fetuses
than on their mothers. Therefore, Sakamoto et al. examined the sex ratio at birth in Minamata area to
evaluate the effects of severe methylmercury exposure [16]. In four of the five years from 1955 to 1959,
unexpectedly low numbers of males were born in Minamata City. Furthermore, a dose-dependent
(based on the estimated environmental level of methylmercury) reduction in the frequency of the male
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sex was observed in that period (male sex:total population ratio; 0.515 for Kumamoto City (the control),
>0.492 for Minamata City, >0.459 for the area in which Minamata disease was most prevalent, and
>0.382 among the families of fishermen). The lowest male:total population ratio (0.393) was observed
among the offspring of mothers with Minamata disease [16]. However, no reduction in the frequency
of the male sex was observed in the cases in which only the father was affected by Minamata disease.
This phenomenon was suspected to have been caused by maternal methylmercury exposure leading to
methylmercury having direct effects on fetuses. In addition, the proportion of male stillbirths in the city
increased to 173 males/100 females (male proportion: 0.634) when the methylmercury pollution was
at its most severe, indicating that more males were lost at the fetal stage. The increased proportion of
stillborn males in Minamata City partly explains the lower proportion of males in the abovementioned
study. However, little is known about the sex-related differences in the susceptibility of fetuses against
the lethal effects of methylmercury.
5. Neuropathology in Fetuses
Among the adults with Minamata disease that were exposed to high levels of methylmercury,
neuronal degeneration was observed from medical autopsies, predominantly in certain areas of the
cerebral cortex (the parietal, occipital, and temporal lobes), cerebellum, and peripheral nerves [9].
Figure 2a shows the lesion distribution among adult cases of Minamata disease. The main symptoms
exhibited by these patients included sensory disturbances in the distal parts of the extremities followed
by ataxia, concentric contraction of the visual field, impairment of gait and/or speech, muscle weakness,
tremors, abnormal eye movement, and hearing impairment [21], which mainly reflected the areas of
the brain that suffered nerve damage [9]. In Iraq, a large-scale epidemic of methylmercury poisoning
occurred in 1972–1973 after wheat seeds were disinfected with methylmercury [11]. This outbreak
affected more than 6000 people and resulted in 400 deaths. The main symptoms were similar to those
of Minamata disease. A study conducted in Iraq [11] showed that in adult cases of methylmercury
poisoning the estimated mercury body burden thresholds (mg) at diagnosis for various symptoms were
as follows: abnormal sensory perception, about 25 mg (equivalent to a mercury blood concentration of
250 μg/L); ataxia, about 50 mg; articulation disorders, about 90 mg; hearing loss, about 180 mg; death,
>200 mg.
In Minamata City, a high incidence of cerebral palsy was observed from 1955 to 1959, when the
most severe cases of Minamata disease occurred. The incidence rate was 5.8%, which was much higher
than the normal incidence rate (0.2–0.64%) in Japan [10]. The study group of Kumamoto University
concluded that they were fetal-type Minamata disease patients, who were exposed to methylmercury
via placenta [10]. The symptoms observed in fetal-type Minamata disease patients (22 typical severe
cases) were mental retardation, inability of walking by oneself, disturbances of coordination, speech,
chewing and swallowing, and increased muscle tone, which are similar to the symptoms of cerebral
palsy [10]. Histopathological examinations of Japanese fetal-type Minamata disease patients revealed
widespread and severe neuronal degeneration in the central nervous system [18]. Figure 1b shows the
lesion distribution fetal-type cases of Minamata disease. On the other hand, their mothers had mild
or no manifestations of methylmercury poisoning [13]. In Iraq, the children that were most severely
affected by methylmercury poisoning manifested with severe sensory impairments, general paralysis,
hyperactive reflexes, and/or impaired mental development [11]. The world Health Organization
suggested that Iraqi data implied that a peak maternal hair mercury level of 10–20 μg/g is associated
with a 5% risk of neurological disorders [5].
In an animal experiment using rats, distinct patterns of neuronal degeneration were observed [22]
by methylmercury administration at various stages of brain development. For example, neonatal
rats administered methylmercury for 10 days from postnatal day (PD) 2 showed minimal damage
in the hippocampus and brainstem nuclei, young rats administered 10 days from PD 15 showed
neuronal degeneration in the cerebral cortex, striatum, and red nucleus, while adult rats from PD 60
showed severe lesions in the cerebellum and dorsal root ganglia. Moreover, neonatal rats exposed
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to methylmercury for prolonged period (>30 days) from PD 2 showed the widespread neuronal
degeneration in the cerebral neocortex and spinal sensory ganglia [23]. These rat experiments indicated
that the distribution pattern of methylmercury-induced brain lesions changes depending on the
stage of brain development at which methylmercury exposure occurs, and the widespread neuronal
degeneration in human fetal-type Minamata disease could be caused by prolonged methylmercury
exposure during brain growth.
Figure 2. Comparisons of the distributions of lesions among adult and fetal-type cases of Minamata
disease. Note: The distributions of degenerated neurons in adult (a) and fetal patients (b) are shown.
(Modified from Reference [9] with permission).
6. Kinetics of Methylmercury in Fetuses
Fetuses depend on their mothers for nutrients, including amino acids, fatty acids, and vitamins.
However, they can also be exposed to methylmercury through the maternal consumption of fish and
shellfish. Furthermore, some animal studies have shown suggested that methylmercury is actively
transferred from mother to fetus via placental amino acid transport systems [24–26]. In humans, it was
reported that cord blood contains higher concentrations of methylmercury than maternal blood [27–31].
Especially, Stern and Smith [31] summarized the data of the cord blood/maternal blood methylmercury
ratio from 10 reports published from 1975 to 2000. Table 1 shows the total maternal and cord blood
mercury concentrations recorded in various study populations from the recent papers which were
published after 2016. Although the cord blood/maternal ratio varied from 1.03 to 2.04, all the data
indicated that cord blood mercury levels were higher than those of maternal blood as summarized by
Stern and Smith [31].
Table 1. Total maternal and cord blood mercury concentrations in various study populations.







Ten cites, Canada T-Hg μg/L 0.562 (n = 1673) 0.802 (n = 1419) 1.43 2008–2011 (2016) [32]
Laizhou By, China T-Hg μg/L 0.72 (n = 410) 1.20 (n = 410) 1.67 2010–2012 (2016) [33]
Busan, Korea T-Hg μg/L 3.12 (n = 127) 5.46 (n = 127) 1.75 2009–2010 (2016) [34]
Tong Gang, Taiwan T-Hg μg/L 2.24 (n = 145) 2.30 (n = 145) 1.03 2010–2011 (2017) [35]
Tokyo, Japan T-Hg μg/L 4.97 (n = 334) 10.15 (n = 334) 2.04 2010–2012 (2018) [36]
Kumamoto, Japan T-Hg ng/g 3.79 (n = 54) 7.26 (n = 54) 1.92 2006–2007 (2018) [37]
In developing fetuses, the brain is sensitive to methylmercury exposure [5]. Both the high
sensitivity of the developing brain to methylmercury [38] and the increased methylmercury
accumulation in the blood and brain [26] of fetuses are recognized toxicological features of
methylmercury. Consequently, the effects of dietary seafood intake in pregnant women remain
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an important public health issue, especially in populations that consume large quantities of fish and
sea mammals, such as toothed whales and seals. Mercury levels in pregnant women can be affected by
fish consumption patterns such as the amount, species, frequency, and seasons of the fish consumption
during pregnancy. Consequently, the comparison among studies is not always easy [39].
7. Exposure Assessment in Fetuses
Since the brain is the organ that is most at risk from methylmercury, the biomarkers used to
determine human methylmercury exposure levels should reflect the methylmercury concentration
in the brain. In humans, methylmercury has an average biological half-life of approximately 70 days
(whole body) [5]. Generally, the amount retained in the body reaches an equilibrium during constant
methylmercury intake, e.g., from seafood consumption. Animal experiments have indicated that the
ratio of the blood mercury concentration to the brain mercury concentration remains constant under
steady state conditions. Therefore, the mercury concentration in the blood/red blood cells is a good
biomarker for assessing methylmercury exposure [5]. The mercury concentration in hair reflects the
blood methylmercury concentration during hair formation and is frequently used as a biomarker
for evaluating methylmercury exposure [5]. Although analyses of hair mercury concentrations are
affected by a number of variables, such as the hair’s growth rate, density, color, waving, external
contamination, and any permanent treatments [5], segmental analysis of maternal hair is able to provide
time-course information because the average hair growth rate is commonly assumed to be about 1 cm
per month [40,41]. On the other hand, cord blood circulates in the fetal body and can directly reflect
the methylmercury concentrations in fetal organs, including the fetal brain, at birth [41]. In addition,
a number of studies have employed toenail and/or fingernail mercury concentrations as biomarkers
for assessing methylmercury exposure [42–45]. In most of these studies, toenails rather than fingernails
were preferred, because toenails are often less contaminated than fingernails, especially among dental
personnel and gold miners, who handle mercury amalgams [2].
The organ that is most affected by methylmercury exposure during gestation is the fetal brain.
For this reason, biomarkers that reflect fetal methylmercury exposure during gestation are very
important for predicting the effects of methylmercury on child development. In a study conducted in
the Faroe Islands, the cord blood mercury concentration was the preferred biomarker for evaluating
methylmercury exposure, whereas in a study carried out in the Seychelles, the maternal hair mercury
concentration was used as the only biomarker of fetal exposure. Umbilical cord tissue has also
been used to determine fetal methylmercury exposure levels in some studies [14,46]. In addition,
maternal mercury levels in fingernails and toenails at parturition showed strong correlations with
those in cord blood [45]. Figure 3 shows the correlation coefficients (r) for the relationships among
various biomarkers of methylmercury exposure at parturition, which were obtained from our
previous studies [30,45]. All of the biomarkers, including maternal blood, maternal hair, cord blood,
maternal nails, the placenta, and cord tissue showed strong correlations with each other (r: >0.70).
This suggests that all of the examined biomarkers are useful for assessing the prenatal exposure of
fetuses to methylmercury.
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Figure 3. Correlation coefficients (r) for the relationships among biomarkers of methylmercury exposure
at parturition. Note: Red blood cells were used to calculate the correlations between the levels of
methylmercury in blood, the placenta, and cord tissue (- - -) [30]. Whale blood was used to calculate the
correlations between the methylmercury levels of blood, hair, and nails (—) [45].
8. Summary
The United Nations Environment Programme (UNEP) agreed to develop a global legally-binding
instrument on Hg in 2013 as the Minamata Convention on Mercury [4], and the treaty entered into
force in August of 2017. UNEP concluded that the rapid increase in historical environmental Hg levels
began during the industrial revolution in the 19th century. The impact of increased Hg will appear as
increased methylmercury levels in the marine environment, especially in fish and marine mammals,
and finally in humans who consume marine products. Among the human populations, fetuses who
bear the next generation are at the highest risk to the methylmercury exposure. Therefore, we need an
effort to reduce the anthropogenic emissions/releases of mercury into the environment, “recognizing
to reflect the lessons learned from Minamata disease”.
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Abstract: Seafood is an important component in a healthy diet and may contain methylmercury
or other contaminants. It is important to recognize the risks and benefits of consuming seafood.
A longitudinal prospective birth cohort study has been conducted to clarify the effects of
neurotoxicants on child development—the Tohoku Study of Child Development (TSCD) in Japan.
TSCD comprises two cohorts; a polychlorinated biphenyls (PCB) cohort (urban area) and a
methylmercury cohort (coastal area). Our previous results from the coastal area showed prenatal
methylmercury exposure affected psychomotor development in 18-month-olds, and boys appear to
be more vulnerable to the exposure than girls. In this report, we have added the urban area cohort
and we reanalyzed the impact of prenatal exposure to methylmercury, which gave the same results
as before. These findings suggest prenatal exposure to low levels methylmercury may have adverse
effects on child development, especially in boys.
Keywords: methylmercury; prenatal exposure; child development
1. Introduction
Seafood is a good source of protein and various essential nutrients including n-3 polyunsaturated
fatty acids (n-3 PUFAs), selenium, iodine, and vitamin D, whereas it is low in fatty acids. Among
the nutrients, n-3 PUFAs, such as docosahexaenoic acid (DHA), are important because these fats are
difficult to get in sufficient amounts from other food items but are highly beneficial for maternal and
fetal health because of their critical role in proper brain development and function [1,2]. However,
seafood also contains several toxic chemicals like methylmercury and polychlorinated biphenyls (PCB)
due to bioaccumulation in the aquatic food chain [3,4]. Human exposure to methylmercury and PCB
occurs mainly from the intake of seafood [5]. Indeed, mercury exposure level is related to the amount
of seafood intake [6], and several studies have confirmed a relationship between seafood intake and
mercury blood/hair levels in humans [6–8]. Importantly, because methylmercury readily crosses
the placenta, fetuses are at a high risk to exposure [9]. Many previous studies found an association
between prenatal exposure to methylmercury and adverse effects on child neurodevelopment [10–17].
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Because the Japanese are one of the world’s largest seafood consumers, we initiated the Tohoku
Study of Child Development (TSCD) in 2001 [18]. TSCD is a prospective birth cohort study that
investigates the effects of neurotoxicants on child development in Japan with the objective to determine
the potential risks and benefits of seafood eating during pregnancy. TSCD consists of two birth
cohorts, an urban area and a coastal area cohort, in northeastern Japan [19–24]. The purpose of
the urban area cohort is to examine the effect of PCB exposure, and that of the coastal area cohort
is to examine the effect of prenatal methylmercury exposure on child development. The chemical
substances being measured are different, but the protocols are almost the same. We previously
reported that the psychomotor development in 18-month-old children of the coastal area was
significantly correlated with cord-blood total mercury (THg) only in the boys, and that this association
remained significant after adjustment for possible confounders, including maternal-plasma DHA and
cord-plasma selenium [22]. This result suggests that boys are more vulnerable to methylmercury
exposure than girls, which is consistent with a few other studies [22,23,25–27]; although most
other studies on this subject did not include gender-specific analyses [28]. Even if the gender was
considered, most birth cohort studies in children included it as a confounding variable, which needed
to be controlled and generalized the chemotoxic effects without accounting for possible gender
discrepancies [29].
In this report, we introduce the exposure status of methylmercury in Japanese pregnant women,
and the protocol of TSCD. Then, we also measured methylmercury exposure levels in an urban
area cohort, therefore, we investigated the impact of prenatal methylmercury exposure on the
developmental scores using the Bayley scales of infant development second edition (BSID-II) [30] in
the urban and coastal areas for 18-month-old children, with an emphasis on the potential impact of the
child gender.
2. Materials and Methods
2.1. TSCD Outline
The TSCD protocols have been described in a previous report [18]. TSCD comprises two birth
cohorts from northeastern Japan, an urban area and a coastal area cohort. The first birth cohort study
had been conducted in an urban area to examine the effects of perinatal low-level PCB exposure on
child developmental outcomes. The second birth cohort study is being conducted to examine the effects
of prenatal methylmercury exposure to child development outcomes. To decide the research field,
we investigated an area with a high methylmercury exposure level. We conducted a preliminary
survey to select the research area from four candidate areas in the Tohoku region. To identify
the area with the highest hair THg concentration, we recruited women who visited their regional
obstetrical-gynecological clinics to provide their hair samples for THg analysis. Written informed
consent was obtained from each participant prior to collecting the hair samples. In addition, we referred
to a study by Yasutake et al. [31], who reported hair THg concentration data from five districts in
Japan. Based on all these results, we had finally decided to conduct the coastal area for our research
(Candidate area A of Table 1).
To establish an optimal study population, the eligibility criteria included a singleton pregnancy,
Japanese as the mother tongue, and neonates born at term (36–42 weeks of gestation) with a birth weight
of more than 2400 g and no congenital anomalies or diseases. We referred to the Dutch PCB/Dioxin
study before starting our cohort study [32]. One of the inclusion criteria of the Dutch study is child born
at term (37–42 weeks). This is because the reason for preterm birth is thought to be affected by factors
other than prenatal PCB exposure. Therefore, in our study, low birth weight children and preterm birth
children were excluded. Outcome measurements of age-appropriate neurobehavioral assessments and
parent report questionnaires were selected to examine the effect of prenatal methylmercury exposure.
The details of the follow-up neurobehavioral assessments and questionnaires are shown in Table 2.
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The study protocol was approved by the Medical Ethics Committee of the Tohoku University Graduate
School of Medicine.
Table 1. Geometric mean and min/max of hair THg * in candidate areas of our research area (μg/g).
Candidate Area n Geometric Mean Min Max
Candidate area A 100 3.27 1.00 13.3
Candidate area B 94 1.99 0.66 10.3
Candidate area C 99 1.80 0.55 5.35
Candidate area D 100 2.01 0.67 8.15
Yasutake et al. Tohoku J. Exp. Med. 2003, 199(3), 161–169
Minamata 594 1.23 0.09 7.33
Kumamoto 327 1.33 0.14 6.20
Tottori 209 1.40 0.26 12.5
Wakayama 303 1.40 0.00 8.09
Chiba 233 2.30 0.14 25.8
* Total mercury.
Table 2. Follow-up and outcome measures of TSCD *.
Child Age Neurobehavioral Development Assessment
3 days Neonatal Behavioral Assessment Scale
7 months Kyoto Scale of Psychological Development (KSPD)
Bayley Scales of Infant Development second edition (BSID-II)
Fagan Test of Infant Intelligence
18 months (1.5 years) KSPD, BSID-II, Evaluation of Environmental Stimulation (EES)
Raven standard progressive matrices
30 months (2.5 years) Child Behavior Checklist age for 2–3, EES
42 months (3.5 years) Kaufman Assessment Battery for Children
66 months (5.5 years) Social-Maturity Skill Scale (S-M scale)
84 months (7 years) Wechsler Intelligence Scale for Children Third edition
120 months (10 years) S-M scale
144 months (12 years) Wechsler Intelligence Scale for Children Forth edition
* Tohoku Study of Child Development.
2.1.1. Urban Area Cohort (PCB Cohort)
For the urban area cohort, we recruited 1500 of 22-week-pregnant women from January 2001 to
September 2003. Of these, 687 pregnant women agreed to participate (participation rate, 45.8%) and
provided written informed consent to provisionally register for this study. After birth, 88 provisional
registrants withdrew from the study due to various reasons in accordance with the eligibility criteria,
for example, premature birth, and being transferred to another hospital. A total of 599 mother–child
pairs were finally registered. The flowchart of how the study participants were determined is shown
in Figure 1a.
2.1.2. Coastal Area Cohort (Methylmercury Cohort)
For the coastal area cohort, we recruited 1312 of 22-week-pregnant women from December 2002 to
March 2006; 879 pregnant women agreed to participate (participation rate, 67.0%) and provided written
informed consent to provisionally register for this study. While the initial registration procedure was
the same as that for the urban area cohort, a screening step for identifying participants with high hair
THg levels was added. Immediately after the recruitment, hair samples were obtained and analyzed
for THg content. Potential participants with a high THg level were registered together with a matching
number of participants with a low THg level. These low THg participants were selected with adjusting
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the age, sex, amount of seafood consumption, and the tendency to consume certain fish species. At this
step, 102 participants were excluded from the study, because participants had lower hair THg. Finally,
749 mother–child pairs were registered. The flowchart of how the study participants were determined
is shown in Figure 1b.
Figure 1. Flowchart of study population. Flowchart indicating the number of mother–child pairs
included and excluded from the study population.
2.2. Exposure Markers
THg concentrations in whole cord blood, hair, and breast milk were analyzed using cold vapor atomic
absorption spectrometry [19,20]. The analytical method for THg has been described elsewhere [20,33].
Cord blood and breast milk PCB were analyzed by high-resolution gas chromatography and
high-resolution mass spectrometry using the isotope dilution method. Laboratory analytical methods
and quality control procedures were described elsewhere [19,34]. Cord blood lead concentrations
in whole cord blood were determined by inductively coupled plasma mass spectrometry (ICP-MS,
SRL Inc., Tokyo, Japan) [19,22,23]. Cord blood selenium was analyzed by ICP-MS, and cord plasma
selenium was analyzed by Watkinson method [22,23]. Maternal plasma DHA was analyzed by using
gas chromatography [22].
2.3. Outcome
The BSID-II score was one of the study outcomes used for 18-month-old children. The raw scores
were standardized for the child’s age in days at the time of test administration. The raw scores of each
scale were converted into the mental developmental index (MDI) and psychomotor developmental
index (PDI), based on age-appropriate norms. These scores are derived from the total raw scores of
each test and normalized on a score scale with a mean of 100 and a standard deviation (SD) of 15. Since
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there was no standardized version of the BSID-II for Japan, we prepared a Japanese version ourselves.
The reliability of administration of the BSID-II has been described elsewhere [35].
2.4. Confounding Variables
Information about pregnancy, delivery, and the characteristics of infants at birth such as child
gender, birth weight, and birth order were obtained from medical records. We obtained information
about demographics and smoking/drinking habits during pregnancy (presence/absence) from a
questionnaire four days after delivery.
Maternal seafood intake during pregnancy was assessed using a food frequency questionnaire
(FFQ) that was administered by trained interviewers immediately after delivery. Methylmercury
intake was estimated from seafood intake and methylmercury concentrations in each type of seafood.
The calculation method has been described elsewhere [36].
The maternal intellectual ability was evaluated using the Raven standard progressive matrices [37].
We used the raw score for analysis because it has not been standardized in Japan. Home environment
was assessed using the Evaluation of Environmental Stimulation (EES) questionnaire [38], which had
been established in Japan modified after home observation for measurement of the environment
score [39]. The mother was asked to fill out the Raven standard progressive matrices and the EES
when her child was 18 months of age.
2.5. Statistics
The THg in cord blood and maternal hair were logarithmically transformed (log10) because of
skewed distributions. Sex differences in basal characteristics, exposure levels, and scores of the BSID-II
were analyzed using the Student t-test, Mann–Whitney U test, or Fisher exact test. Multiple regression
analysis was used to adjust for possible confounders. Independent variables in the analysis were
child gender, birth weight, birth order, drinking and smoking habits, the Raven scores, EES score,
and testers of the BSID-II (for which dummy variables were used). All analyses using two-sided
p-values, were performed using SPSS Ver. 23.0 (SPSS Inc., Tokyo, Japan, 2016) and the statistical
significance was set at p < 0.05.
3. Results
In the urban area cohort (PCB cohort) with 599 registered mothers, cord blood samples were
collected from 562 participants (93.8%), maternal hair samples at parturition were collected from
595 participants (99.3%), and the FFQ was administered to 598 participants (99.9%). In the coastal area
cohort (methylmercury cohort) with 749 registered mothers, cord blood samples were collected from
731 participants (97.6%), maternal hair samples at parturition were collected from 748 participants
(99.9%), and the FFQ was administered to all participants (100.0%). In Japan, the tolerable weekly
intake (TWI) for methylmercury of 2.0 μg/kg body weight per week for pregnant and potentially
pregnant women was proposed by the Japan Food Safety Commission [40]. However, 12.4% of the
urban area participants and 18.2% of the coastal area participants exceeded the TWI [22,36].
In this study, we excluded children who did not have cord blood samples for methylmercury
biomarker, did not participate in the 18-months BSID-II examination, or lacked a confounder for this
analysis. Thus, for the final analysis, 416 mother–child pairs from the urban area and 600 mother–child
pairs from coastal area were included (Figure 1). The mean age of the participating children was
18 months (range, 17 to 24 months). Table 3 shows the basal characteristics of the mother–child pairs.
By comparing the urban and coastal area cohorts, differences were found in many variables, such as
maternal age at parturition, BMI before pregnancy, and drinking/smoking habits during pregnancy.
The distributions of the biomarkers are shown in Table 4. Although the methylmercury biomarkers
were significantly higher in coastal area participants than in urban ones, there was no difference in total
seafood intake during pregnancy. Since the amount and species of seafood consumed were expected
to be different among the districts in Japan, we examined the differences in intake of each kind of
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seafood (Table 5). Coastal area participants consumed more bonito, salmon, shellfish, some other kind
of fish, and shellfish than the urban area participants, who consumed more whale, yellowtail, and eel.
The type of seafood eaten by coastal area participants had high concentrations of methylmercury such
as bonito.
Table 3. Background characteristics of TSCD * mother–child pairs.
Basal Characterisctics
Urban Area Coastal Area
p-Value **Mean ± SD * Mean ± SD *
(or %) (or %)
Maternal characteristics
Maternal age at parturition (years) 31.3 ± 4.4 29.5 ± 4.9 p < 0.001
Body mass index before pregnancy (kg/m2) 21.0 ± 2.8 21.5 ± 3.3 0.002
Drinkers during pregnancy (%, yes) 31.7 16.6 p < 0.001
Smokers during pregnancy (%, yes) 7.8 12.5 p < 0.001
Maternal education level (%, >12 y) 74.9 41.5 p < 0.001
Raven score *** 51.5 ± 6.3 49.9 ± 6.0 p < 0.001
EES score at 18 months *** 28.2 ± 3.4 26.6 ± 3.8 p < 0.001
Child characteristics
Child gender (%, boys) 52.6 50.9 0.547
Birth order (%, first child) 51.4 42.1 0.001
Gestational duration (weeks) 39.5 ± 1.3 39.7 ± 1.2 0.038
Birth weight (g) 3073 ± 338 3141 ± 365 p < 0.001
Delivery type (%, vaginal delivery) 83.6 84.4 0.765
Apgar score (1 min) 8.2 ± 0.8 8.4 ± 0.8 p < 0.001
* TSCD, Tohoku Study of Child Development; SD, standard deviation. ** Student t-test or χ2 test. *** Raven,
Raven standard progressive matrices; EES, Evaluation of Environmental Stimulation.
Table 4. Exposures indices in urban and coastal area participants.
Exposures
Urban Area Coastal Area
p-Value *
n, Median, 5–95 Percentiles n, Median, 5–95 Percentiles
Exposure biomarkers:
Cord-blood THg (ng/g) ** 562, 10.0, 4.2–22.4 731, 16.0, 5.6–39.3 p < 0.001
Maternal hair THg (μg/g) ** 595, 2.0, 0.9–4.4 748, 2.6, 0.9–6.0 p < 0.001
Breast milk THg (ng/g) ** - 27, 0.8, 0.1–1.8 -
Cord-blood PCB (ng/g-lipid) ** 518, 45.8, 18.4–112.2 - -
Breast milk PCB (ng/g-lipid) ** 544, 93.1, 42.4–185.9 - -
Cord-blood lead (ng/dL) 555, 1.0, 0.6–1.8 664, 0.7, 0.4–1.4 p < 0.001
Cord-blood selenium (ng/mL) 555, 192.7 (130.3–271.9) - -
Cord-plasma selenium (ng/g) - 709, 66.3, 51.0–271.9 -
Maternal-plasma DHA ** - 742, 169.7, 101.1–256.9 -
Seafood intake during pregnancy (kg/y) 598, 44.4, 12.6–110.8 749, 47.7, 10.5–140.6 0.089
* Mann–Whitney U test. ** THg, total mercury; PCB, polychlorinated biphenyls; DHA, docosahexaenoic acid.
The participation rate of each examination is shown in Table 6. The urban area cohort was closed
after the examination at the age of 84 months due to the lack of research funds. However, while we
were examining the 84-month-old children of the coastal area cohort, the Great East Japan Earthquake
hit, causing severe damage. Because of this disaster, the participants were compulsorily divided into
predisaster and postdisaster groups [21]. The follow-up rate for the 84-months-old examination of the
predisaster group was 78.1%, but for the postdisaster group, it was 65.6%. Therefore, the follow-up
rate for the 84-months-old examination was lower than the other examination.
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Table 5. Comparison of the amount of intake of seafood determined by the FFQ * (g/day).
Fish Species
Urban Area (n = 598) Coastal Area (n = 749)
p-Value **
Median (Min-Max) Median (Min-Max)
Tuna 4.1 (0.0–123.7) 4.4 (0.0–105.0) 0.161
Bonito 2.1 (0.0–41.8) 2.7 (0.0–108.3) p < 0.001
Whale 0.0 (0.0–17.5) 0.0 (0.0–2.3) 0.004
Salmon 3.1 (0.0–34.7) 3.1 (0.0–92.5) 0.037
Eel 0.3 (0.0–32.1) 0.0 (0.0–12.5) p < 0.001
Yellowtail 0.6 (0.0–70.0) 0.0) (0.0–70.0) p < 0.001
Silvery blue fish 5.8 (0.0–55.0) 5.8 (0.0–70.0) 0.546
White-meat fish 7.2 (0.0–87.0) 7.2 (0.0–87.0) 0.918
Other fish 0.0 (0.0–57.9) 3.0 (0.0–90.0) p < 0.001
Squid/Octopus 2.0 (0.0–30.0) 2.0 (0.0–60.0) 0.264
Shellfish 1.7 (0.0–39.3) 2.3 (0.0–50.0) p < 0.001
Salmon roe 0.0 (0.0–37.5) 0.0 (0.0–37.5) 0.162
Canned tuna 1.7 (0.0–60.0) 2.0 (0.0–60.0) 0.524
* FFQ, food frequency questionnaire. ** Mann–Whitney U test.
Table 6. Follow-up rates of each examination.
Time of Each Examination
Urban Area Coastal Area
Registrants Participants % Registrants Participants %
3 days 599 587 98.0 749 709 94.7
7 months 594 516 86.9 749 653 87.2
18 months (1.5 years) 589 477 81.0 747 617 82.6
30 months (2.5 years) 595 499 83.9 739 649 87.8
42 months (3.5 years) 566 472 83.4 733 597 81.3
66 months (5.5 years) 580 456 78.6 727 614 84.5
84 months (7 years) 546 457 83.7 720 498 69.2
120 months (10 years) 711 569 80.0
144 months (12 years) 699 385 55.0
The scores of the BSID-II are provided in Table 7. The MDI of the BSID-II was significantly higher
in the urban area children than that in the coastal area children, whereas there was no difference in
the PDI of the BSID-II between these two groups. Table 8 shows the results of the multiple regression
analysis. Cord-blood THg was not significantly correlated with any BSID-II scores. However, there was
a relationship between child gender and BSID-II scores. Therefore, the following analysis was carried
out separately for boys and girls. As shown in Table 9, it was only in boys that the cord-blood THg
was significantly associated with lower PDI of the BSID-II. As we focused on the PDI score of BSID-II
and stratified the participants by research area, the association between cord-blood THg and PDI was
found only in the coastal area boy group (Table 10).
Table 7. Scores of the BSID-II (Mean ± SD *) at 18 months of age (n = 1016).
BSID-II Scores
Urban Area (n = 416) Coastal Area (n = 600)
p-Value **
Mean ± SD * Mean ± SD *
MDI *** 89.8 ± 11.9 86.9 ± 10.6 <0.001
PDI *** 84.6 ± 10.6 84.4 ± 10.6 0.793
* SD, standard deviation. ** Student t-test. *** MDI, mental developmental index; PDI, psychomotor developmental index.
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Table 8. Relations of cord-blood THg * and possible confounders to the scores of BSID-II: Standardized
regression coefficients (β) of multiple regression analysis (n = 1016).
Major Independent Variables
MDI ** PDI **
β p-Value β p-Value
Cord-blood THg * −0.028 0.380 −0.053 0.104
Child gender −0.230 <0.001 −0.111 <0.001
Birth weight 0.034 0.261 −0.012 0.696
Birth order −0.031 0.312 0.049 0.113
Drinking habit during pregnancy 0.035 0.253 −0.044 0.164
Smoking habit during pregnancy 0.000 0.997 0.040 0.197
Raven score *** 0.036 0.238 0.063 0.044
EES score at 18 months *** 0.134 <0.001 0.071 0.025
Contribution rate, R2 0.101 <0.001 0.080 <0.001
Other independent variables: Testers of the BSID-II and research area. Cord-blood THg was logarithmically
transformed. * THg, total mercury. ** MDI, mental developmental index; PDI, psychomotor developmental index.
*** Raven, Raven standard progressive matrices; EES, Evaluation of Environmental Stimulation.
Table 9. Relations of cord-blood THg ** and possible confounders to the scores of BSID-II: Standardized
regression coefficients (β) of multiple regression analysis.
Major Independent Variables
Boys (n = 523) Girls (n = 493)
MDI * PDI * MDI * PDI *
β p-Value β p-Value β p-Value β p-Value
Cord-blood THg ** −0.036 0.437 −0.122 0.008 −0.017 0.729 0.024 0.616
Birth weight 0.093 0.036 0.045 0.307 −0.051 0.262 −0.085 0.057
Birth order 0.007 0.873 0.026 0.554 −0.085 0.061 0.066 0.142
Drinking habit during pregnancy −0.021 0.639 −0.039 0.379 0.085 0.062 −0.053 0.236
Smoking habit during pregnancy 0.000 0.999 0.033 0.440 0.012 0.782 0.057 0.203
Raven score *** 0.052 0.239 0.036 0.407 0.006 0.888 0.090 0.045
EES score at 18 months *** 0.092 0.038 0.086 0.052 0.204 <0.001 0.068 0.137
Contribution rate, R2 0.058 <0.001 0.078 <0.001 0.061 <0.001 0.082 <0.001
Other independent variables: testers of the BSID-II and research area. Cord-blood THg was logarithmically
transformed. * MDI, mental developmental index; PDI, psychomotor developmental index. ** THg, total mercury.
*** Raven, Raven standard progressive matrices; EES, Evaluation of Environmental Stimulation.
Table 10. Relations of cord-blood THg * and possible confounders to the PDI ** of BSID-II: Standardized
regression coefficients (β) of multiple regression analysis only in boys.
Major Independent Variables
Urban Area (n = 220) Coastal Area (n = 303)
β p-Value β p-Value
Cord-blood THg * −0.033 0.606 −0.18 0.002
Birth weight −0.045 0.477 0.091 0.128
Birth order −0.081 0.202 0.091 0.124
Drinking habit during pregnancy −0.058 0.362 −0.044 0.450
Smoking habit during pregnancy −0.016 0.806 0.062 0.282
Raven score *** −0.098 0.126 0.124 0.033
EES score at 18 months *** 0.039 0.543 0.116 0.048
Contribution rate, R2 0.148 <0.001 0.052 0.007
Other independent variables: testers of the BSID-II and research area. Cord-blood THg was logarithmically
transformed. * THg, total mercury. ** PDI, psychomotor developmental index. *** Raven, Raven standard
progressive matrices; EES, Evaluation of Environmental Stimulation.
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4. Discussion
4.1. Outline of the TSCD
In this report, we summarized the protocol and state of progress of the TSCD. The TSCD consists
of participants in an urban area and coastal area, and both areas are in northeastern Japan; various
differences were found in the basal characteristics as in Table 3. When clarifying the health effects of
prenatal methylmercury exposure, the importance of collecting information of basal characteristics
and confounding factors was shown. Although there was no difference in fish intake between the
two cohorts, hair/cord-blood THg was significantly higher in the coastal participants. For this reason,
it was shown that the coastal participants consume fish containing higher mercury levels than urban
participants. Most fish samples contain methylmercury, but the concentrations vary greatly according
to the fish species. In fact, the coastal participants consume seafood with higher methylmercury
concentration such as bonito (Table 5).
In our cohort, follow-up rates of the coastal area have decreased to 69.2% in 84-month-old
examination and 55.0% in 144-month-old examination, respectively as in Table 6. A possible reason
why the follow-up rate of 84-month-old examination was decreased in the coastal area would be the
effects of the Great East Japan Earthquake. The disaster also had several significant impacts on our
participants and cohort. For instance, hair THg of the children was decreased by approximately 30%
after the disaster. In these areas, the consumption of seafood was decreased after the disaster because
of destructive damage to the fishery [24]. The disaster induced subtle deficits in verbal intelligence
quotient (IQ) of 84-month-old children, probably due to a temporal blank in their education [21].
However, the follow-up rate improved at next examination at 120-month-old. In the 144-month-old
examination follow-up rate was down to 55% as in Table 6. Reasons for not being able to participate
in the examination include children being busy with study and sports club activities, and parents
working, so their schedules do not match. Other than that, we thought that we were able to maintain a
function as a cohort.
4.2. Exposure Levels
The median THg levels of maternal hair at parturition were 2.0 μg/g and 2.5 μg/g in the urban
and coastal areas, respectively, which were lower than the levels reported in other studies in the
Faroe Islands [41,42], the Seychelles [43], Canada [44], Brazil [6,45], and France [46], but higher than
those in Italy [47], the Philippines [48], China [49], Austria [50], and the United States (US) [51].
These suggest that the level of exposure to methylmercury in our study participants was definitely not
high compared with other studies. However, 93.6% of the urban area participants and 94.5% of the
coastal area participants of our cohort had hair THg concentrations higher than the US Environmental
Protection Agency (EPA) recommended levels (1.0 μg/g for hair THg) for optimal health. Yasutake et
al. [31] reported that it would not be adequate to employ the reference dose (RfD) of the US EPA in
Japan. We think that it is necessary to examine the effect of prenatal methylmercury on Japanese.
As described in the Results section, the Japan Food Safety Commission proposed TWI for THg at
2.0 μg/BW-kg/week in 2005. To apply the TWI for THg, 12.4% of pregnant women in the urban area
and 18.2% of pregnant women in the coastal area exceeded it [22,36]. In Japan, the Ministry of Health,
Labour, and Welfare advises that pregnant women limit consumption of certain species. However,
according to the results of another of our studies, 25.5% (14/55) of women who have never been
pregnant did not know about this advice, and even 47.7% (336/705) of women who had been pregnant
did not know about it.
Since fish are rich in n-3 PUFAs, fish consumption is the primary source of n-3 PUFAs intake,
and Saito et al. [52] reported the determinants of n-3 PUFAs status in maternal and cord blood were
examined, and maternal seafood consumption was a potent factor. To avoid the adverse health effects
of prenatal methylmercury while retaining the benefits provided by fish consumption, it is important
to select suitable fish species and to pay attention to the amount of fish intake. For that purpose,
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the information and knowledge about seafood intake, including advice from the Ministry of Health,
Labour, and Welfare, must be known thoroughly by pregnant women and women who may become
pregnant. It is necessary to transmit correct information to next generation who become parents.
4.3. Gender-Specific Analyses
Compared to studies on other heavy metals (cadmium, manganese, and arsenic), studies on
methylmercury and lead that were analyzed by based on child gender are more abundant. However,
child gender-specific susceptibility to prenatal methylmercury exposure has not received sufficient
attention [28]. When we look at just prenatal exposure to methylmercury, boys seem more susceptible
to adverse effects than girls. Indeed, studies of human prenatal methylmercury poisoning in Iraq
found that male newborns suffered worse complications from methylmercury exposure than female
newborns [53]. In Minamata, Japan, it was reported that the male/female birth ratio decreased in the
overall city population as well as in the fishing villages during 1955–1959, when the pollution degree
of methylmercury was very high. Additionally, a decrease in maternal Minamata disease patients was
observed, but this was due to the high number of stillborn male fetuses [26]. The adverse effects of
methylmercury on child neurodevelopment were reported by cohort studies in northern Quebec [54],
Seychelles [25,55], Faroe Islands [56,57], Massachusetts [58], Guiana [47], and the city of Zhoushan [50].
On the other hand, two studies reported the negative impact on girls [59,60]. According to our previous
studies, the birth weight and psychomotor development of the boys were affected by cord-blood
THg level [23]. The mechanism underlying gender differences in exposure related neurotoxicity is
unknown, and information regarding gender differences in susceptibility of methylmercury is still too
limited to draw any definite conclusions.
Understanding gender differences is useful for elucidating the pathways from exposure to
manifestation, and may also provide new insights into prevention strategies [28]. In order to clarify
this, further studies are required to clarify the mechanism of effects of prenatal exposure on gender
difference in experimental studies. Also, sample size is an important factor that must be considered
carefully. There are several large prospective birth cohort studies on environmental contaminants and
child health, such as the Danish National Birth Cohort in Denmark [61], the Norwegian Mother and
Child Cohort Study in Norway [62], the Newborns and Genotoxic exposure risks project in EU [63],
and the Japan Environment and Children’s Study in Japan [64]. Each of these studies is made up of
more than 100,000 parent–child pairs. Such large cohorts may solve this issue in the near future.
4.4. Regional Difference
In the current study, we found that increasing cord blood THg was associated with lower PDI
of the BSID-II at 18 months of age in the coastal area boys but not in the urban area boys. We can
postulate several reasons for this discrepancy. One of these reasons might be that the coastal area
pregnant women in our study had a higher and wider range of cord-blood and hair THg than the
urban area pregnant women. The maternal hair THg at parturition in the coastal area participants of
this study ranged from 0.31 μg/g to 11.0 μg/g and in the urban area participants from 0.29 μg/g to
9.34 μg/g, respectively. The extremely low and narrow range of methylmercury concentration in the
urban area participants of the present study may be the reason why we obtained insignificant results.
Exposure level and range of the study population may be important for detecting a significant result.
As confounders for the BSID-II scores, birth weight, score of the maternal Raven standard
progressive matrices, and score of the EES were chosen in multiple regression analysis (Tables 8–10),
and there were significant differences in them between the urban area cohort and the coastal area cohort
(Table 3). It is common knowledge that these variables are closely related to child development. For
instance, a consistent association between birth weight and child development has been established [65].
The Port Pirie Cohort Study reported that the higher the occupational prestige and maternal IQ and
the better the home environment, the higher the children’s cognitive function [66]. To clarify the
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effect of prenatal methylmercury exposure, these crucial confounders should be collected properly in
future studies.
4.5. Future Vision
The Faroe cohort study showed that prenatal methylmercury related neuropsychological
dysfunctions were most pronounced in the domains of language, attention, and memory, and to a
lesser extent in visuospatial and motor functions at 7 and 14 years [10,40,67]. After that, they examined
whether negative associations are still detectable eight years later, at age 22. The results at age 22
suggest that cognitive deficits associated with prenatal methylmercury exposure remain through
young adulthood. They concluded that prenatal exposure to this marine contaminant appears to cause
permanent adverse effects on cognition [68]. At the present stage, even in our cohort, the negative
effect of prenatal methylmercury exposure has been observed, follow-up data are needed to determine
if adverse effects occur at older ages and if such effects are determined to be related to methylmercury.
We have collected data on the development at different age of our children so we are planning to
analyze the effect of prenatal exposure to methylmercury on child development. As our participants
are turning 12-year-old, 10 years later, we would like to reconfirm Faroe study’s results in Japan.
We are also measuring toxic chemicals other than THg, for instance PCB and lead in cord-blood
and blood as in Table 4, due to estimation of the combined risks of the mixture effects is required.
Exposure to a mixture of chemicals is ubiquitous in real life and all children are exposed to multiple
toxic chemicals [69]. Recently, gradually the number of such studies is increasing [19,70–74], however,
the results pattern was not so clear. A research model with concomitant exposures is necessary for
evaluating subtle effects on child development. In addition, n-3 PUFAs is essential for normal brain
development. Three studies reported that the negative association between prenatal methylmercury
exposure and cognitive development became apparent only after adjustment with n-3 PUFAs
intake [75–77]. These studies indicated the essential nutrients such as n-3 PUFAs masked the effects of
methylmercury. Future studies need to indicate the exposure levels of both beneficial nutrients and
toxic substances such as methylmercury and PCB. Moreover, we are planning to identify high-risk
groups with genetic susceptibilities to methylmercury.
5. Conclusions
The TSCD examined both the potential risks and benefits of eating fish during pregnancy.
Our participants are turning 12-year-old, and till now, we thought that we were able to maintain
a function as a cohort. Results of the TSCD suggest that even relatively low levels of exposure to
methylmercury may have adverse effects on child development especially in boys. Thus, a long-term
follow-up study should be conducted to obtain further information about the effects of methylmercury
exposure on child development.
In Japan, the TWI for methylmercury of 2.0 μg/kg body weight per week for pregnant and
potentially pregnant women was decided by the Japan Food Safety Commission (2005). 12.4% of the
urban area participants and 18.2% of the coastal area participants exceeded the TWI [22,36]. However,
a lot of Japanese people do not know about the TWI. Seafood is an important part of a healthy diet
and contains good nutritional properties for pregnant women and fetuses. Therefore, we need to
present correct information about how to eat seafood. It is necessary to transmit correct information to
next generation who become parents. We want to clarify an information providing method of more
efficiently and effectively providing required information to pregnant women to protect our children’s
lives and futures.
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Abstract: There is growing evidence of immunotoxicity related to exposure to toxic trace metals,
and an examination of gene expression patterns in peripheral blood samples may provide insights
into the potential development of these outcomes. This pilot study aimed to correlate the blood
levels of three heavy metals (mercury, cadmium, and lead) with differences in gene expression in
24 participants from the Long Island Study of Seafood Consumption. We measured the peripheral
blood mRNA expression of 98 genes that are implicated in stress, toxicity, inflammation, and
autoimmunity. We fit multiple linear regression models with multiple testing correction to correlate
exposure biomarkers with mRNA abundance. The mean blood Hg in this cohort was 16.1 μg/L,
which was nearly three times the Environmental Protection Agency (EPA) reference dose (5.8 μg/L).
The levels of the other metals were consistent with those in the general population: the mean Pb
was 26.8 μg/L, and the mean Cd was 0.43 μg/L. The expression of three genes was associated with
mercury, four were associated with cadmium, and five were associated with lead, although none were
significant after multiple testing correction. Little evidence was found to associate metal exposure
with mRNA abundance for the tested genes that were associated with stress, toxicity, inflammation,
or autoimmunity. Future work should provide a more complete picture of physiological reactions to
heavy metal exposure.
Keywords: Hg; Cd; Pb; mRNA; Fish
1. Introduction
Three toxic metals to which humans are commonly exposed include mercury, cadmium, and
lead [1]. Hg, Cd, and Pb are known to influence many diseases and conditions, including but
not limited to cancer and neurologic, renal, and bone diseases [2–4]. Exposure to these metals
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may affect human health due to varied mechanisms of action, including their possible alteration
of gene expression [5,6]. Despite most of the population having only moderate exposure to these
metals, which is the equivalent of approximately 1 μg/kg/day for Pb, 0.30–0.35 μg/kg/day for Cd,
and approximately 0.12 μg/kg/day for total Hg [2–4,7–9], it is important to characterize how the
human body reacts upon exposure. At levels of exposure that are common in the general population,
the associations of some of these metals with disease states including coronary heart disease, kidney
disease, various autoimmune diseases, neurological and neurodegenerative disorders, and myocardial
infarction have been observed [10–12]. Specifically, methylmercury (MeHg) exposure has been most
strongly associated with neurotoxicity, including neurodevelopmental delays in children and decreased
manual dexterity and fine motor speed in adults, as well as impaired verbal skills, memory, and
visual motor functions in both children and adults. Cd has been associated with kidney disease in
industrially-exposed populations, and gastrointestinal complications and bone fragility in those with
low-level oral exposure. Pb has been associated with neuropathy, reproductive toxicity, renal disease,
and hypertension in adults, and loss of IQ in children [2,3,13]. Importantly, over the past century,
exposure to these heavy metals has been on the rise in the developing population, resulting from
increases in heavy metal use in agriculture, technology, and industry [14]. The frequent exposures to
these metals and their health implications emphasize the necessity for evaluating the risks of these
toxicants not only clinically, but at the molecular level as well, for a better understanding of the
human body’s biochemical reactions to these environmental pollutants and providing potential early
biomarkers of exposure.
These heavy metals may induce their systemic effects through changes in gene expression,
as the abundance of gene transcripts (mRNA) is often altered in toxic, immune, and autoimmune
responses. A limited number of in vitro studies reported correlations between metal exposure and
mRNAs encoding genes related to stress, toxicity, and autoimmunity/immunity. Kawata et al.
(2007) investigated alterations in gene expression in human HepG2 cells upon heavy metal exposure
compared to known chemical responses, and they found that large numbers of the chemically-inducible
genes were also responsive to Cd and Hg [15]. In human fibroblasts, Li et al. (2008) identified
35 genes that were responsive to Cd, most of which were associated with cell cycle, immunity/defense,
nucleoside metabolism, and signal transduction [16]. Lee et al. (2013) also investigated altered RNA
expression due to Cd, and they found the upregulated expression of 30 genes in HK-2 human proximal
tubular cells, including genes that were involved in transcription and heat shock [17].
Animal studies, specifically murine models, have provided additional insight into the
physiological response to heavy metals, although these efforts have also been limited in number
and primarily investigated the effects of Cd. Murine models of metal exposure and gene expression
in various organs (including intestine, kidney, liver, and testes) have demonstrated Cd-modulated
and Hg-modulated expression of genes encoding functions related to transport, oxidative stress,
and inflammation: the modulation genes related to heat shock, acute phase, metallothionein,
and antioxidants due to Cd and Hg, and the modulation of genes related to angiogenesis, hypoxia,
toxicity, and carcinogenesis due to Cd [18–21]. However, these animal studies primarily involved
high-dose exposures to heavy metals measured in organs, which must be considered when comparing
results to lower-level human dietary or occupational metal exposures assessed in peripheral blood.
There is currently a dearth of epidemiologic studies investigating how heavy metals correlate with
gene expression in humans at more population-relevant exposure levels. Changes in expression are
often linked to disease initiation and progression, and environmental exposures to toxins can modulate
this genetic predisposition in the human system [22]. A limited number of epidemiologic studies
have noted the effect of long-term Hg, Cd, or Pb exposure, as measured in blood and urine, on the
modulated expression in blood of mRNA involved in a variety of oxidative stress, toxicity, and DNA
repair pathways, suggesting an effect of these metals on the human body’s response to stress [23,24].
For experimental short-term, gaseous metal fume exposure, Wang et al. (2005) similarly observed
decreases in oxidative stress response transcripts in blood, in addition to decreases in apoptosis-related
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and inflammatory response-related transcripts [25]. A recent study by Korashy et al. (2017) also noted
the modulation of mRNA abundance in blood in response to blood Hg, Cd, or Pb, in this case with
a large number of genes upregulated, and a smaller number of genes downregulated in response to
the metal exposure [26]. Despite these limited studies suggesting varied stress responses correlated
with metal exposure, studies have not looked at transcript abundance across a number of genes,
necessitating work in this area to better understand how physiological pathways are modulated in
response to metal exposure, rather than only individual genes. Furthermore, the correlations reported
to date are not consistent for genes in related pathways, and merit additional scrutiny.
In this pilot study, we investigated gene expression associations with metal exposure in humans,
testing the hypothesis that increased peripheral blood levels of total Hg, Cd, and Pb are correlated
with increased expression of 98 genes known to be involved with response processes for inflammation,
autoimmunity, oxidative stress, and toxicity.
2. Methods
2.1. Participant Recruitment
The study was approved by Stony Brook University’s Committee on Research Involving Human
Subjects (CORIHS) (IRB #2010-1179). Between 2011–2012, 290 avid seafood consumers were recruited
from the general Long Island population. Participants were recruited in-person and through flyers
posted at fishing piers, seafood restaurants, markets, gyms, libraries, university bulletin boards, and
three advertisements and an article about the study that ran in a newspaper (Newsday).
Interested participants (996 individuals) were informed that the study was being conducted to
evaluate the risks and benefits of seafood consumption. Interested participants filled out surveys of
self-reported seafood consumption to evaluate their approximate expected blood Hg levels based on
seafood Hg concentrations reported in Karimi et al. (2012) [27]. The estimated blood Hg cutoff that
was used to determine eligibility for this study to ensure adequate power was an estimated whole
blood concentration of 5.8 μg/L, which corresponds to the United States (US) EPA reference dose
of 0.1 μg/kg/day. This cutoff yielded 746 eligible participants, of which 290 enrolled in our study.
Eligible participants completed questionnaires to collect demographics, among other factors.
For this study, 24 individuals were selected for analysis of both metals and mRNA expression.
These individuals were selected because they were among those with the highest and lowest levels
of each metal type, thereby ensuring a range of exposure levels for each metal. Age, gender, current
smoking status, and levels of omega-3 fatty acids in plasma (for laboratory methods, see Karimi et al.
2014) were extracted from the database for use in regression analyses [28].
2.2. Blood Biomarkers: Collection and Analysis of Blood Hg, Cd, and Pb
Blood biomarkers were collected and used for analysis due to their low variability, long half-life,
and reflection of body burden resulting from representation of organ metal uptake [29]. Whole blood
was collected by venipuncture for the measurement of heavy metals (Hg, Cd, and Pb) in trace metal
tubes containing K2EDTA. Blood specimens were stored at 4 ◦C and sent to RTI International’s
Trace Inorganics Laboratory (Research Triangle Park, NC, USA) for analysis of Hg, Cd, and Pb by
ICP-MS (Thermo-X Series II). A 1000 μg/mL gold solution (High Purity Standards) was added to
samples for heavy metal stability. Samples were microwave-digested with nitric acid and hydrogen
peroxide (J.T. Baker, Ultrex Grade), and diluted with deionized water. Standard reference materials,
including bovine and caprine blood (NIST SRM955c caprine blood, NIST SRM966 bovine blood, and
UTAK human blood), were also digested and analyzed for quality control, with an average recovery
percentage of 110 ± 14% (n = 9). Sample blanks and method blanks showed negligible Hg, Cd, and Pb,
confirming a lack of background contamination due to the sample collection method and digestion
method, respectively. Three samples were found to be below the detection limit (LOD) (0.3 μg/L) for
Hg, and all of the samples were above the LOD for Pb (0.1 μg/L) and for Cd (0.04 μg/L).
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2.3. Gene Expression by Reverse Transcription-Polymerase Chain Reaction PCR (RT-PCR)
Whole blood was collected via venipuncture from 13 females and 11 males (n = 24) for analysis of
gene expression. Participants were selected to ensure a range of blood metal levels that was consistent
with the entire study population. Whole blood samples were stored in PAXgene Blood RNA tubes
at −80 ◦C (BD Diagnostics, Franklin Lakes, NJ, USA), following instructions from the manufacturer.
Samples were thawed at room temperature before further processing for at least two hours to ensure the
digestion of cellular debris and stability of RNA. The PAXgene Blood miRNA kit (Qiagen, Valencia, CA,
USA) was used to isolate total RNA in 80 μL of supplied elution buffer. Mean RNA Integrity Number
(RIN) was 7.91 (min 7.0, max 8.7), as measured via a Bioanalyzer RNA chip (Agilent, Santa Clara, CA,
USA). The average ratio of absorbance at 260 nm and 280 nm was 2.04 (min 1.94, max 2.13), which was
measured via Nanodrop 2000 (Nanodrop, Wilmington, DE, USA).
Isolated RNA (300 ng) was reverse transcribed to cDNA using an RT2 First Strand Kit (Qiagen,
CA), as per the manufacturer’s instruction. For each sample, 102 μL of cDNA were loaded onto RT2
Profiler PCR Array Human Stress & Toxicity (PAHS-003ZA) and Human Inflammatory Response and
Autoimmunity (PAHS-077ZA) 96-well plates, along with 1248 μL of RNAse-free water and 1350 μL
of 2X SYBR Green ROX qPCR Mastermix (Qiagen, CA; Tables S1 and S2). Plates were sealed using
optical adhesive film and run on an Applied Biosystems 7300 Real-Time PCR System using standard
run settings.
Ct detection threshold was set at 0.2 for each sample to compare results across the dataset.
Ct values were then extracted for each gene and normalized against the geometric mean of β-actin
and GAPDH housekeeping (HK) genes to obtain ΔCt values. ΔCt values were then unlogged (2−ΔCt),
obtaining a value proportional to the relative abundance level in the sample. Probes with Ct values
above 30 (set LOD) were excluded, and any gene with one or more missing values across the sample’s
set was excluded. Out of the 168 measured genes, 98 genes were consistently detected in the blood of
all 24 test subjects, and were carried forward in the analysis.
2.4. Data and Statistical Analysis
Linear regression models were constructed to investigate the correlations between gene expression
and each measured metal (Hg, Cd, Pb), with each gene as an individual dependent variable. All of
the models were adjusted by age and gender. Metal levels were not associated with smoking status
or with omega-3 fatty acids; therefore, in order to maintain parsimony given the small sample size,
these variables were not included in the model. Adjusted R square, beta coefficient, p-value, and corrected
p-value were reported to be significantly associated with one or more metals for each gene. To address
multiple testing, the false discovery rate q-value (Benjamini–Hochberg) was calculated, and is reported
for those genes that were significantly associated with a metal prior to multiple testing correction [30].
3. Results
Control (“housekeeping”) genes represented in the arrays were detected at similar levels across
the individual plates. Probes did not detect matching DNA strands (HGDC), indicating effective RNA
isolation. The average blood Hg in participants was 16.1 μg/L, which was approximately three times
higher than the RfD. Average blood Cd and Pb were 0.42 μg/L and 26.8 μg/L, respectively (Table 1).
There was no significant difference between males and females for the measured markers.
Table 1. Characteristics of the study cohort (n = 24), 13 females, 11 males.
Variable Average SD Min. Max. T Test Average Difference p by Sex
Age (years) 58 13 19 78 0.82
Hg (μg/L) 16.1 14.5 0.30 44.6 0.32
Pb (μg/L) 26.8 12.6 11.4 60.1 0.29
Cd (μg/L) 0.43 0.36 0.01 1.47 0.85
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Three genes were significantly associated (p < 0.05) with Hg, four were significantly associated
with Cd, and five were significantly associated with lead (Table 2). Without multiple testing correction,
Hg was significantly associated with IL1RAP, CXCR1, and ITGB2, Cd was significantly associated
with ITGB2, C3AR1, TLR9, and TNFRSF10A, and Pb was significantly associated with TNFRSF1A,
VEGFA, MMP9, ULK1, and SQSTM1. However, no genes were significantly correlated with metals
after accounting for multiple testing.







B p Value BH-Corrected
p
IL1RAP Hg 0.36 −0.34 0.03 0.95
CXCR1 Hg 0.19 −2.26 0.04 0.95
ITGB2 Hg 0.11 −1.95 0.05 0.95
ITGB2 Cd 0.18 89.13 0.02 0.87
C3AR1 Cd 0.34 14.22 0.01 0.87
TLR9 Cd 0.16 −1.61 0.04 0.96
TNFRSF10A Cd 0.12 −2.75 0.04 0.96
VEGFA Pb 0.37 0.04 0.01 0.50
TNFRSF1A Pb 0.19 1.29 0.01 0.50
ULK1 Pb 0.22 0.14 0.02 0.50
SQSTM1 Pb 0.14 1.41 0.02 0.50
MMP9 Pb 0.11 1.32 0.03 0.59
All models adjusted by age and sex.
4. Discussion
After multiple testing correction, our results show no significant associations between peripheral
blood Hg, Cd, and Pb and mRNA levels that are indicative of stress, toxicity, immune response,
or autoimmunity. However, given that this is a small pilot study, the significant associations that are
present between these metals and certain genes without adjustment for multiple testing may help
direct a searchlight for future studies with larger sample sizes and potentially higher exposures to
heavy metals. Therefore, even though the results were not significant after multiple testing correction,
we feel that it is important to consider the biologic plausibility of those genes that were associated
prior to multiple testing correction.
The expression of each of the three genes that were associated with total blood Hg prior to multiple
testing correction—IL1RAP, CXCR1, and ITGB2—decreased as Hg levels increased. These three
genes are markers for inflammatory responses, as indicated by the Inflammatory Response and
Autoimmunity PCR Assay we employed, suggesting that the inflammatory response induced by these
three gene products may be dampened at higher levels of Hg. In a sensitivity analysis, we repeated
the multiple regression analyses additionally adjusting for omega-3s as a percentage of fatty acids in
phospholipid fraction of plasma, and for the self-reported frequency of total fish intake. Beta coefficients
and directions of association were consistent, suggesting that confounding by fish intake is not
influencing our findings. However, biologic plausibility must be considered, as in previous work,
relatively toxic doses of heavy metals were required to achieve significant changes in gene expression
in animal models, suggesting that higher exposure levels would provide a more considerable effect
upon expression of these genes in humans as well [19]. Nonetheless, all three gene products are known
to be involved in neutrophil-dependent pathways and pathways downstream of neutrophil activation,
as they are activated largely through NF-κB pathways, and subsequently activate effector pathways
or provide negative feedback to neutrophils. This suggests that their similar associations with Hg
in this study may be due to the gene products’ functional relationships in stimulation of immune
actors. IL-8, which is a ligand for the gene product of CXCR1, and the integrin β-2, are both known to
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be involved in stimulating neutrophil activation and migration, which in turn stimulates the release
of a variety of cytokines and chemokines through an NF-κB pathway in both murine and human
models [31–34]. Cytokines released by neutrophils include IL-1β and IL-1α; these are ligands for
the receptor that is associated with the gene product of IL-1RAP, which, similar to IL-8, also serve
to both stimulate neutrophil activation and migration [34–36]. Therefore, the gene products of our
Hg-associated genes play a role in regulation of the inflammatory response through release by NF-κB
pathways or the promotion of those pathways, suggesting a common modulation by Hg that may
become more apparent in a study with a larger sample size.
C3AR1, similar to ITGB2, was positively associated with Cd, whereas TLR9 and TNFRSF10A were
negatively associated with Cd prior to multiple testing correction. MMP9, VEGFA, ULK1, SQSTM1,
and TNFRSF1A were all positively associated with Pb prior to multiple testing correction. Studies
have not been conducted epidemiologically nor at the level of toxicity to evaluate the modulation of
expression of these genes by these metals, and therefore, no data-driven hypotheses can be developed.
Dose-response curves have not been established for Cd with respect to gene expression, and therefore,
biologic plausibility is unable to be evaluated primarily due to a lack of data at relevant doses.
One challenge in this area of study that impacts the interpretation of the metal-associated
genes is the dual immunosuppressive and immunostimulatory effects of heavy metals, which are
currently not well-characterized [5]. Unlike some immunotoxins, both effects due to metals have been
found in animal and human studies, highlighting the difficult task of identifying which pathways in
particular are affected and interacting. Metals as immunotoxins do not act in immunosuppressive
ways specifically, but also may play a role in stimulating allergic responses, autoimmunity, or infection
susceptibility [8]. This differential effect of metals on humans characterizes metals more accurately as
immunomodulators rather than immunotoxins, and suggests that future work be focused more on
distinguishing these effects at different doses. Such pathway modulations must be studied in more
depth through studies of entire pathways, rather than individual protein products; i.e. examining
multiple protein products in a pathway, in order to better understand exactly which products are being
upregulated and downregulated to result in an outcome pathway modulation.
A limitation that should be considered is the potential for metal toxicity to be affected by a variety
of factors that can alter how inflammatory/stress/autoimmune/toxicity markers are modulated.
Factors affecting metal toxicity include the form of the metal, level of exposure, duration of exposure,
mode of exposure, and toxicokinetics/toxicodynamics of the compound [6]. We measured total Hg
in the blood among a population of seafood consumers; therefore, this is likely to reflect methylHg
exposure, which is the dominant form of Hg in fish. Certain populations are also more susceptible to
metal toxicity, including those with glutathione deficiencies, thalassemia, or cystinuria, and adolescents
or older individuals; however, we were able to control only for age in this study. Blood measures of
metals may be associated with potential confounding variables, such as cigarette smoking, although
we did not observe associations between smoking and metal levels in this study. Nonetheless,
the possibility of a confounding factor influencing the metal levels and gene expression cannot
be ruled out. Gene expression can also appear to be modulated, particularly in one-time mRNA
measurements, due to a lack of stability of mRNA transcripts over time. The half-lives of mRNA
transcripts vary widely, and can depend on a number of extracellular signals and factors that regulate
transcript degradation at different levels for the modulation of gene expression [37]. Due to such
extensive variation in mRNA half-life and stability, one-time measurements of mRNA are not ideal for
representing gene expression. Future work may look at particular metal compounds at varying levels,
durations, and routes of exposure in a wider variety of individuals to obtain a more complete picture
of their effects on particular gene markers measured over time.
Another important limitation of this study involves the difficulty of evaluating graded
transcript abundance as a measure of gene upregulation or downregulation. The upregulation and
downregulation of genes may be evident in only a small transcript abundance modulation, whereas
the modulation of other genes may present as large a difference in transcript abundance. To account
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for this variation in expression response, our analysis focused only on positive or negative changes,
sans gradient. Future work may seek to examine graded transcript abundance modulations for
an improved understanding of dosage-dependence and relative contributions/interactions of gene
products in the discussed pathways.
To conclude, in this small pilot study of 24 individuals, we report no association between Hg,
Cd, or Pb and any of 98 mRNA markers of stress, toxicity, inflammation, or autoimmunity in seafood
consumers with elevated blood Hg. However, the associations that were present prior to multiple
testing adjustment may point toward genetic pathways for future work in larger populations with
multiple measurements across time in order to better understand how the human body responds to
heavy metal exposure.
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